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(adapted from Lawrence, Lai, and Clements 2010 and Prassas et al. 2015). .........14 
Figure 3 – Schematic representation of KLK genes in different species. The arrows 
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Abstract  
 
The advances in sequencing technologies have greatly contributed to the 
increasing number of available genomes for different species, as well as to the 
development of detailed catalogs of human genetic variation. Likewise, these represent 
important tools for detecting footprints of natural selection acting on different timescales 
and help providing a better understanding of the molecular basis of current patterns of 
human disease susceptibility. Among the myriad of targets of natural selection, genes 
involved in reproductive functions are particularly relevant since they are at the frontline of 
the individual fitness. 
The kallikrein (KLK) gene family encodes 15 serine proteases, often co-expressed 
in a wide variety of tissues and in many biological fluids, including in the seminal plasma. 
In this sense, KLKs are known to modulate key physiological processes through complex 
proteolytic cascades, in which family members act at different hierarchical levels. In the 
particular case of the semen liquefaction cascade, KLKs are involved in the hydrolysis of 
the major seminal structural proteins, the semenogelins (SEMGs), resulting in sperm 
release in the vaginal cavity. Previous studies provided evidence of KLKs substrates 
being preferred targets of natural selection through mechanisms linked to male fertility and 
sperm competition. Also, the loss of KLK2 in some primate species was found to correlate 
to different semen physiologies. In addition, aberrant expression of most human KLK 
members was reported in individuals with abnormal semen parameters. 
The three independent studies presented in the present work were all based on the 
central hypothesis that KLK genes might have been targeted by natural selection and that 
their genetic variation may underlie both beneficial and disease phenotypes. The analysis 
of the selective pressures acting on the KLK cluster was performed in two stages. The first 
was based on comparative and phylogenetic approaches, centered in KLK2 and KLK3, for 
a total of 22 primate species. The second enclosed a comprehensive evaluation of the 
1000 Genomes phase I data, in order to characterize a potential signature of natural 
selection among KLK genes in Asian populations. At the interspecific level, this study 
supported the origin of KLK3 in Catarrhini through an event of KLK2 duplication and 
functional divergence of KLK3 towards a different substrate specificity and it unraveled an 
intricate evolutionary dynamics of KLK2 and KLK3 correlated to semenogelin gene 
structure, primate mating system and semen coagulation rates. On the other hand, in 
human populations, a complex signature of recent positive selection in East Asians was 
disclosed and characterized by a high frequency haplotype defined by three variants 
(rs1654456_G, rs198968_T and rs17800874_A) acting synergistically to promote KLK4 
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downregulation, which may be connected to tooth and epidermal features typical of these 
populations rather than with reproductive functions. 
In the last part of this work, the variation of KLK genes, their substrates 
(semenogelins) and potential inhibitors of the whey acidic protein four-disulfide core 
domain (WFDC) locus was assessed in the scope of male infertility. This analysis 
revealed a higher burden of functional low-frequency variants in cases than in controls, 
independently of the considered infertility phenotype, but solely for the KLK cluster. 
Furthermore, it was possible to identify a significantly increased risk of semen 
hyperviscosity and asthenozoospermia associated with the variants rs61742847 (KLK12, 
p.P34L) and rs147894843 (SEMG1, p.G400D), respectively. In addition, other 12 
nucleotide variants were also overrepresented in cases but, due to the still limited number 
of samples used in the genotype surveying, those were not statistically significant. 
Conversely, a decreased risk of hyperviscosity and oligozoospermia was observed for 
rs1654526 in KLK7 and for a copy number variation in SEMG1, correspondingly. 
Altogether, this work further supports that genes involved in proteolysis and 
reproductive biology, such as KLK genes, were targets of natural selection in the short 
and the larger timescales of human and primate evolution, respectively, and that KLK 
genetic variation may also underlie deleterious variants possible contributing to a lower 
reproductive fitness in humans. 
  
 3 
Resumo  
 
Os progressos nas tecnologias de sequenciação têm sido um forte contributo para 
o aumento do número de genomas disponíveis para diferentes espécies, bem como para 
o desenvolvimento de catálogos detalhados da variação genética humana. Deste modo, 
estes representam importantes ferramentas para a deteção de evidências de seleção 
natural em diferentes escalas temporais e ajudam ainda a obter um maior conhecimento 
das bases moleculares dos atuais padrões de suscetibilidade a doenças humanas. Entre 
os vastos alvos de seleção natural, os genes envolvidos em funções reprodutivas são 
particularmente relevantes, uma vez que estão na vanguarda da aptidão de um indivíduo. 
A família de genes das calicreínas (KLK) codifica 15 proteases de serina, 
frequentemente co-expressas numa grande variedade de tecidos e em muitos fluidos 
biológicos, incluindo no plasma seminal. Neste sentido, as KLKs são conhecidas por 
modular importantes processos fisiológicos através de cascatas proteolíticas complexas, 
em que membros desta família atuam em diferentes níveis hierárquicos. No caso 
particular da cascata de liquefação do sémen, as KLKs estão envolvidas na hidrólise das 
principais proteínas estruturais, as semenogelinas (SEMGs), resultando na libertação dos 
espermatozóides dentro da cavidade vaginal. Estudos anteriores mostraram que os 
substratos das KLKs foram alvos de seleção natural através de mecanismos relacionados 
com a fertilidade masculina e competição espérmica. Também a perda da KLK2 em 
algumas espécies de primatas está correlacionada com diferentes fisiologias do sémen. 
Além disso, foi reportada uma expressão aberrante de KLKs humanas em indivíduos com 
parâmetros seminais anormais.  
Os três estudos independentes apresentados no presente trabalho foram baseados 
na hipótese central de que genes das KLKs podem ter sido alvo de seleção natural e que 
a sua variação genética pode contribuir para fenótipos benéficos e de doença. A análise 
das pressões seletivas no agrupamento das KLKs foi realizada em duas etapas. A 
primeira baseou-se em abordagens comparativas e filogenéticas, centradas na KLK2 e 
na KLK3, para um total de 22 espécies de primatas. A segunda compreendeu uma 
avaliação abrangente dos dados da fase I dos 1000 genomas, com a finalidade de 
caracterizar uma potencial assinatura de seleção natural entre genes das KLKs em 
populações asiáticas. A nível interespecífico, este estudo suporta a origem da KLK3 nos 
Catarríneos através de um evento de duplicação da KLK2 e divergência funcional da 
KLK3 para uma diferente especificidade de substrato e desvenda uma intrincada 
dinâmica evolutiva da KLK2 e da KLK3 correlacionada com a estrutura génica das 
semenogelinas, sistemas de acasalamento nos primatas e rácios de coagulação do 
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sémen. Por outro lado, nas populações humanas, foi revelada uma complexa assinatura 
de seleção positiva recente nos asiáticos de leste, caracterizada por um haplótipo de 
elevada frequência, definido por três variantes (rs1654456_G, rs198968_T e 
rs17800874_A) que atuam sinergicamente para promover uma redução nos níveis de 
KLK4, o que pode estar relacionado com características dentárias e epidérmicas típicas 
dessas populações e não com funções reprodutivas. 
Na última parte deste trabalho, foi avaliada no âmbito da infertilidade masculina a 
variação dos genes das KLKs, dos seus substratos (semenogelinas) e potenciais 
inibidores do locus whey acidic protein four-disulfide core domain (WFDC). Esta análise 
revelou uma maior carga de variantes funcionais de baixa frequência nos casos do que 
nos controlos, exclusivamente no agrupamento das KLK e independentemente do 
fenótipo de infertilidade considerado. Além disso, foi possível identificar um maior risco 
significativo de hiperviscosidade do sémen e de astenozoospermia associado com os 
variantes rs61742847 (KLK12, p.P34L) e rs147894843 (SEMG1, p.G400D), 
respetivamente. Adicionalmente, outros 12 variantes nucleotídicos encontravam-se 
também sobre-representados em casos mas, devido ao limitado número de amostras 
utilizadas na genótipagem, estes não atingiram significância estatística. Por outro lado, foi 
observada uma diminuição do risco de hiperviscosidade e de oligozoospermia para o 
variante rs1654526 na KLK7 e para uma variação do número de cópias (CNV) na 
SEMG1, correspondentemente. 
De um modo geral, este trabalho suporta que genes envolvidos na proteólise e na 
biologia reprodutiva, tais como os genes das KLKs, foram alvos de seleção natural ao 
longo da escala evolutiva dos humanos e dos primatas. Este estudo suporta ainda que a 
variação genética das KLKs pode também conter variantes deletérios que poderão 
contribuir para um menor fitness reprodutivo nos humanos. 
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1. Genetic variation and natural selection 
Curiosity is part of the human nature and, like a child in the “why” stage, we always 
seek more knowledge about ourselves and our origins: “Where do we come from?”, “Why 
are we so different from one another?”, “Why are some individuals predisposed to certain 
diseases while others are not?”. Answering these questions has been a major challenge 
in the scientific community for several decades and these have been the main focus of a 
considerable number of studies of human genetic diversity. In the last decades, a few 
milestones marked the field of human genetics. First, the Human Genome Project 
generated a human reference sequence, which provided improved knowledge about the 
location and organization of genes but bestowed little information on the genetic variation 
at a population level (Lander et al. 2001; Venter et al. 2001). This issue was later 
addressed in other initiatives such as The International HapMap Project, which genotyped 
millions of common single nucleotide polymorphisms (SNP) and assessed their allele 
frequencies and linkage disequilibrium (LD) patterns in three major human groups: 
Africans, Europeans and Asians (International HapMap 2005; International HapMap et al. 
2007). More recently, the 1000 Genomes Project extended the characterization of the 
human genetic variation to a total of 26 human populations using high-throughput 
sequencing approaches, thus allowing not only the identification of common single 
nucleotide variants (SNVs), but also rare SNVs as well as small and large insertions and 
deletions (Genomes Project et al. 2010; Genomes Project et al. 2012; Genomes Project et 
al. 2015; Sudmant et al. 2015). Altogether, these projects have provided a detailed 
catalogue of the human genetic diversity, which to this date represents a fundamental tool 
to address how different genes and variants influence current human traits and 
susceptibility to disease. 
Importantly, the complex patterns of genetic diversity in present-day humans are 
the endpoint result of random mutation and recombination, demographic history and other 
evolutionary processes acting in different timescales, which may span from millions or 
thousands of years ago to more recent events occurred only a few generations ago. The 
patterns of human genetic variation, together with some archeological evidence, support 
the “out-of-Africa” model, proposing the origin of modern humans in East Africa followed 
by a series of expansions, bottlenecks and migrations between populations. The recent 
increment in genome-wide datasets of human genetic variation and the current 
sequencing efforts of archaic hominins have allowed researchers to confirm and refine 
this model. Moreover, these efforts have uncovered additional levels of complexity, such 
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as those associated to the dispersal of modern humans and their admixture with 
Neanderthals and Denisovans (Quintana-Murci et al. 1999; Voight et al. 2005; Gutenkunst 
et al. 2009; Green et al. 2010; Laval et al. 2010; Reich et al. 2010; Gravel et al. 2011; 
Harris and Nielsen 2013).  
However, as humans spread out of Africa to other continents, they have been 
exposed to a novel set of environments, which included different climate variables 
(temperature, humidity, precipitation and short wave radiation flux), dietary components 
(roots, cereals and milk) and pathogen burden, consequently, humans had to adapt and 
survive under different selective pressures (Coop et al. 2009; Barreiro and Quintana-Murci 
2010; Hancock et al. 2010b; Luca et al. 2010; Cagliani and Sironi 2013; Fumagalli and 
Sironi 2014; Karlsson et al. 2014). Natural selection is the evolutionary process by which 
heritable beneficial traits become more frequent in a population over time, as an outcome 
of a higher reproductive fitness of their carriers (Darwin 1859; Luca et al. 2010). Hence, a 
genetic variant associated with an advantageous phenotype will increase in frequency and 
it may eventually reach fixation by positive selection, whereas a deleterious variant will 
most likely be eliminated by purifying selection (Figure 1A) (Nielsen 2005; Sabeti et al. 
2006; Luca et al. 2010; Scheinfeldt and Tishkoff 2013). Conversely, the balancing 
selection scenario favors diversity by maintaining two or more beneficial alleles in the 
population, thus none of the selected variants might reach fixation (Figure 1B) 
(Charlesworth 2006; Andres et al. 2009; Fumagalli et al. 2009; Andres et al. 2010; 
Ferreira et al. 2011; Ferreira et al. 2013b; Key et al. 2014; Teixeira et al. 2015). 
Most approaches used to detect positive selection are based on distinctive 
signatures affecting the patterns of genetic variation, which may be identified individually 
by the analysis of the site frequency spectrum (SFS), patterns of LD decay, population 
differentiation or even using a combination of these metrics in the so-called composite 
methods (Table 1).  
In a classical scenario of positive selection (or hard-sweep), the advantageous 
variant arises de novo in a population and is quickly swept to high frequencies, leaving in 
the genome a footprint of low diversity around the selected locus that fades over with 
genetic distance (Figure 1C). As this phenomenon occurs soon after the arising of the 
new variant, recombination will not have time to break down the haplotypic structure of the 
beneficial allele, generating unusual LD patterns and homogenous long-ranged 
haplotypes. Subsequently, many linked neutral sites will also be found at high frequencies 
as a result of hitchhiking. During the selective sweep, novel mutations may accumulate 
within  the  selected  chromosomes,  however,  due  to  the  rapid increase in frequency of  
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Figure 1 – Different scenarios of natural selection. Each panel depicts changes in variant frequencies over 
time. Horizontal blocks represent chromosomes, neutral variants are shown as circles on the chromosomes 
and advantageous or deleterious variants are represented with a 12-point star. (A) Purifying selection - in 
which deleterious variants are removed from the population. (B) Balancing selection - in which the two alleles 
are maintained in the population as a result of heterozygote advantage over homozygous individuals. (C) 
Classic selective sweep - in which a novel advantageous variant arises in a population and increases in 
frequency over time until it approaches fixation. (D) Selection from standing variation - in which a variant that 
is already present in the population becomes advantageous in a new environment and increases in frequency 
over time until it approaches fixation. (E) Polygenic selection - involves multiple loci in different chromosomes 
(represented by different colors), when a complex trait becomes advantageous, it increases in frequency as 
do the set of variants contributing to it (adapted from Scheinfeldt and Tishkoff 2013). 
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these chromosomes, most mutations will tend to be rare, causing an excess of rare 
variants (Luca et al. 2010; Scheinfeldt and Tishkoff 2013; Vitti et al. 2013). Furthermore, a 
selective advantage allele may be dependent on the specific environment in which it 
segregates and, since separated populations are likely to be subject to distinct selective 
pressures and local adaptation to different environments and cultural lifestyles, a 
particular allele may be beneficial in one population but not in others, generating 
frequency differences across populations (Excoffier 2002; Vitti et al. 2013). Examples of 
classical selective sweeps are related to lactose tolerance (LCT), skin pigmentation 
(SLC24A5) and tooth and hair morphology (EDAR) (Bersaglieri et al. 2004; Coelho et al. 
2005; Lamason et al. 2005; McEvoy et al. 2006; Verrelli et al. 2006; Sabeti et al. 2007; 
Fujimoto et al. 2008; Basu Mallick et al. 2013). 
Recent lines of evidence suggest that classic selective sweeps may have been rare 
in human evolution, whereas other mechanisms of selection are more likely to have been 
shaping current patterns of genetic diversity (Pritchard and Di Rienzo 2010; Pritchard et 
al. 2010; Hernandez et al. 2011; Crisci and Jensen 2012; Granka et al. 2012). One of 
such models proposes that selection may act on pre-existing variation that only becomes 
advantageous with sudden shifts in the environment (selection on standing variation or 
soft sweeps). In this scenario, the variant may already be linked to different haplotype 
backgrounds (Figure 1D) and, thus, the signature of selection may be more difficult to 
detect using conventional approaches designed to identify classic selective sweeps 
(Hermisson and Pennings 2005; Przeworski et al. 2005; Pennings and Hermisson 2006b; 
Pennings and Hermisson 2006a; Peter et al. 2012; Seixas et al. 2012; Turchin et al. 2012; 
Messer and Petrov 2013). In addition, such signals may be even harder to perceive when 
an adaptive trait is influenced by multiple loci, each one contributing with small effects 
(Figure 1E) (Pritchard et al. 2010). Regardless, some examples of polygenic adaptation 
(stature and pathogen immunity) and selection on standing variation associated with 
immunity (SERPINB11), climate (ME3, ME2 and RPTOR) and dietary (MTRR, PLRP2, 
GBA3) adaptations are already described in the literature (Hancock et al. 2008; Hancock 
et al. 2010b; Lango Allen et al. 2010; Sun et al. 2010; Seixas et al. 2012; Daub et al. 
2013). 
Additional insights into the action of natural selection can be obtained by 
comparative genomic approaches, specifically in the case of ancient selective events, 
such as those underlying human speciation. Over a long timescale, positive selection can 
increase the fixation rate of beneficial alleles, which can be detected by comparing the 
rate of nonsynonymous substitutions (dN) with the rate of synonymous substitutions (dS) 
(Table 1). If  there  is no  positive  selection,  synonymous  and  nonsynonymous  changes  
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Table 1 - Common approaches used to detect selection (adapted from Vitti et al. 2013). 
Approach Intuition Statistical tests 
Comparative 
genomic methods 
Synonymous substitutions are assumed to be 
selectively neutral. Thus, they can be used to 
assess the background rate of evolution. If 
the rate of nonsynonymous substitutions 
differs significantly, it is suggestive of 
selection. 
dN/dS ratio (Yang 2007) 
Levels of polymorphism and divergence 
should be correlated (because both are 
primarily functions of the mutation rate) 
unless selection causes one to exceed the 
other. 
McDonald-Kreitman (MK) 
(McDonald and Kreitman 
1991) 
Hudson-Kreitman-Aguadé 
(HKA) (Hudson et al. 1987; 
Wright and Charlesworth 
2004) 
Frequency-based 
methods 
In a selective sweep, a genetic variant 
reaches high prevalence together with nearby 
linked variants (high-frequency derived 
alleles). From this homogeneous background, 
new alleles arise but are initially at low 
frequency (excess of rare variants). 
Tajima’s D (Tajima 1989) 
 
Fu and Li D* (Fu 1997) 
Fay and Wu’s H (Fay and Wu 
2000; Zeng et al. 2006) 
Linkage 
disequilibrium-
based methods 
Selective sweeps bring a genetic region to 
high frequency in a population, including the 
causal variant and its neighbors. The 
associations between these alleles define a 
haplotype, which persists in the population 
until recombination breaks these associations 
down. 
Long-range haplotype (LRH) 
(Sabeti et al. 2002) 
Integrated haplotype score 
(iHS) (Voight et al. 2006) 
Cross-population extended 
haplotype homozygosity (XP-
EHH) (Sabeti et al. 2007) 
Population 
differentiation-
based methods 
Selection acting on an allele in one population 
but not in another creates a marked 
difference in the frequency of that allele 
between the two populations. This effect of 
differentiation stands out against the 
differentiation with respect to neutral alleles. 
FST (Excoffier et al. 2009) 
Composite 
methods 
Combining test scores for multiple sites 
across a contiguous region can reduce the 
rate of false positives. 
Composite likelihood ratio 
(CLR) (Williamson et al. 
2007) 
Cross-population composite 
likelihood ratio (XP-CLR) 
(Chen et al. 2010) 
Combining multiple independent tests at one 
site can improve resolution and distinguish 
causal variants. Different tests can provide 
complementary information. 
Composite of multiple signals 
(CMS) (Grossman et al. 
2010) 
should occur at the same rate (dN/dS = 1), while under selection, might be an excess of 
nonsynonymous substitutions relative to the number of synonymous changes (dN/dS > 1). 
Other sophisticated methods may take into account the variation of dN/dS ratio among 
codons and evolutionary lineages, allowing to infer if specific sites have been targeted by 
positive selection or if selective pressures are acting on particular groups on the 
phylogeny or both (Nielsen and Yang 1998; Yang 1998; Yang et al. 2000; Yang and 
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Nielsen 2002; Bielawski and Yang 2003; Yang et al. 2005). These tools have been used 
in a wide variety of cases, for example, to reveal the presence of positive selection on 
genes involved in language and speech (FOXP2), reproduction (ZP2, ZP3 and ADAM2) 
and immunity (SIGLEC5, SIGLEC6, SERPINB3 and SERPINB4) (Swanson et al. 2001; 
Enard et al. 2002; Zhang et al. 2002; Kosiol et al. 2008; Gomes et al. 2014). 
Recently, there is a growing body of evidence that regions of the human genome 
targeted by positive selection may also be associated with human disease. One possible 
explanation for this correlation is a change in the selective forces acting on human 
populations; alleles which were once beneficial may now be deleterious because the 
present environmental conditions are not the same as in the past (“thrifty genotype” 
hypothesis) (Neel 1962; Neel et al. 1998). This principle is well illustrated by variants 
predisposing to type-II diabetes. Several generations ago, fat accumulation was 
advantageous because it would largely raise the chances of survival in times of famine 
and, therefore, variants associated with this trait were positively selected. However, in 
modern societies, the current settled lifestyle and the ample food availability no longer 
render this characteristic beneficial and variants that were once valuable become 
maladaptive by increasing the risk of their carrier developing type-II diabetes (Di Rienzo 
and Hudson 2005; Di Rienzo 2006; Helgason et al. 2007; Crespi 2010; Vasseur and 
Quintana-Murci 2013). On the other hand, selective events could end in an antagonist 
pleiotropy, a phenomenon in which selection results in adaptation in one trait, or early in 
life, and in deleterious effects in other contexts or later in the lifespan (Clark and Swanson 
2005; Nielsen et al. 2005; Corbo et al. 2008; Crespi 2010; Vasseur and Quintana-Murci 
2013). Furthermore, when an advantageous variant rises in frequency during the selective 
sweep, the hitchhiking effect can drive disease-causing alleles to high frequency as well 
(Shiina et al. 2006; Huff et al. 2012). Therefore, there may be a close link between 
selection and disease. Thus, the combination of comparative and population genetic tools 
with functional information can be useful to exploit such disease candidate loci. 
Overall, comparative genomics, human genome-wide scans (GWS) and candidate 
gene approaches have identified many potential examples of selection targets and verified 
that certain gene ontology categories, including sensory perception, dietary changes, 
immunity and host-pathogen interactions, reproduction and proteolysis, were enriched in 
genes under selection (Bustamante et al. 2005; Sabeti et al. 2006; Kosiol et al. 2008; 
Akey 2009; Bustamante and Ramachandran 2009; Grossman et al. 2013). In this context, 
the kallikrein (KLK) gene family represents a remarkable case for the study of evolution of 
proteolytic genes with implications in different biological processes including in 
reproductive biology and in human health and disease.   
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2. The Kallikrein (KLK) locus 
The first kallikrein was identified in the 1930s as an abundant protease in the 
pancreas and, therefore, was named tissue kallikrein, based on the Greek word for 
pancreas “kallikreas”. Later work from independent groups led to the identification and 
characterization of 14 additional genes that now comprise the KLK gene family (Lilja 1985; 
Riegman et al. 1992; Gan et al. 2000; Yousef et al. 2000; Clements et al. 2001). As the 
members KLK1, KLK2 and KLK3 were the first ones described, they became known as 
“classical kallikreins” and KLK1 remained as the prototypical kallikrein gene. In order to 
avoid confusion and harmonize the terminology of these genes, an official nomenclature 
system was proposed by the Human Genome Organization (HUGO). According to this 
nomenclature, KLK1 is called kallikrein-1, whereas every other member of the family is 
termed kallikrein-related peptidase (Lundwall et al. 2006a). However, all these molecules 
are often simply named as kallikreins. Since their discovery, it became evident that KLKs 
are involved in many physiological processes and in several pathophysiologic conditions, 
as described below.  
2.1. Structure and organization 
The human KLK cluster, located at chromosome 19q13.3-13.4, spans over 265 kb 
and includes 15 paralogue genes coding for trypsin- or chymotrypsin-like serine proteases 
(KLK1 to KLK15) and a transcribed pseudogene (KLKP1) (Yousef et al. 2004; Lu et al. 
2006; Kaushal et al. 2008; Lundwall and Brattsand 2008; Prassas et al. 2015). The 
intergenic spacing between KLK genes is variable and ranges from approximately 1.5 to 
32.5 kb, in which the smaller intergenic region is located between KLK1 and KLK15 and 
the largest one between KLK4 and KLK5. Typically, genes extend from 4.4 to 10.5 kb, 
depending mainly on intron sizing, and, except for KLK2 and KLK3, all of them are 
transcribed in the reverse chromosome strand. Moreover, all KLK genes display a 
common organization in five coding exons with variable 5’ and 3’ untranslated region 
(UTR) structures (Figure 2A) (Obiezu and Diamandis 2005; Lawrence et al. 2010). 
Furthermore, all KLK genes have at least one additional transcript resulting from 
alternative splicing, which in most instances are non-coding RNAs or result in shorter 
proteins with no protease activity (Kurlender et al. 2005; Koumandou and Scorilas 2013). 
Nonetheless, the function of these transcripts remains poorly understood and it has been 
suggested that they may mediate the signaling either at mRNA or at protein level 
(Koumandou and Scorilas 2013). The only exception to these structural features is KLKP1 
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which, in spite of having five transcribed exons, the in silico translation of the four mRNA 
transcripts indicate that none of them encode a serine protease and the two largest 
putative proteins are generated from a single exon (Yousef et al. 2004; Lu et al. 2006; 
Kaushal et al. 2008). 
 
 
Figure 2 – Genomic and proteomic structure of KLK proteases. (A) The human KLK gene cluster is 
located at chromosome 19q13.3-13.4. Arrows show the relative position and the transcription orientation for 
the 15 coding genes and expressed pseudogene. In the mRNA scheme, the boxes and lines represent exons 
and introns, respectively. KLK proteins are expressed as pre-pro-enzymes, in which the pre-domain is 
required for intracellular trafficking and the pro-domain must be cleaved in order to generate a mature KLK. 
(B) The structure of a mature KLK based on the crystal structure of KLK1. The catalytic triad residues are 
shown in green. The position of the kallikrein loop is also shown. The amino acids that are identical among all 
kallikreins are in red, whereas those that are conserved in at least eight kallikreins are in purple. Non-
conserved amino acids are in blue (adapted from Lawrence, Lai, and Clements 2010 and Prassas et al. 2015). 
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Kallikreins are encoded as single-chain pre-pro-enzymes (Figure 2A) of 244 to 293 
residues long, sharing about 40-80% of protein identity, as well as a conserved catalytic 
triad of histidine (H57), aspartic acid (D102) and serine (S195) residues (standard 
chymotrypsin numbering) (Lundwall and Brattsand 2008). Besides the catalytic triad, 
amino acids involved in protein folding are also highly conserved among KLKs, whereas 
residues associated with substrate specificity are generally more divergent (Figure 2B). 
Once synthesized KLKs are directed to the endoplasmic reticulum by the signal peptide 
(the pre-domain), which is composed by 16 to 33 N-terminal amino acids, this pre-peptide 
is later cleaved in the secretory pathway yielding an enzymatically inactive pro-KLK. 
These molecules (zymogens) only become active upon the proteolytical removal of the 
pro-domain, which allows a conformational rearrangement of the protein three-
dimensional structure by opening the KLK catalytic fissure. In most cases, the KLK pro-
domain is cleaved after an arginine or lysine residue, indicating that they are activated by 
proteases with trypsin-like specificity including other KLKs, or in some instances by 
themselves (auto-activation) (Vaisanen et al. 1999; Brattsand et al. 2005; Michael et al. 
2005; Memari et al. 2007; Yoon et al. 2007; Yoon et al. 2009; Lawrence et al. 2010). The 
exception to this rule is KLK4, which is cleaved after a glutamine residue and instead is 
activated by matrix metalloproteinase-20 (MMP20) and dipeptidyl peptidase 1 (DPP1) 
(Ryu et al. 2002; Tye et al. 2009; Yamakoshi et al. 2013).  
So far, six human KLK structures have been solved (KLK1 and KLK3 to KLK7) and, 
according to those crystallographic models, KLKs are folded into two hydrophobic 
interacting sub-domains, each one comprising a six-stranded β-barrel and a α-helix, with 
the catalytic triad located at the interface between the two sub-domains (Figure 2B) 
(Bernett et al. 2002; Gomis-Ruth et al. 2002; Laxmikanthan et al. 2005; Debela et al. 
2006; Debela et al. 2007a; Debela et al. 2007b; Debela et al. 2008; Menez et al. 2008). 
KLK substrate specificity depends on the residue that lies at the base of the substrate 
binding pocket, and it is further refined by the composition of the eight loops that surround 
the active site (Debela et al. 2008; Lawrence et al. 2010). In addition, KLK1, KLK2 and 
KLK3 structures also contain an 11-amino acid insertion known as the “kallikrein loop”, 
which is believed to play an important role in the substrate and inhibitor specificity (Yousef 
and Diamandis 2001; Borgono and Diamandis 2004; Laxmikanthan et al. 2005; Lundwall 
and Brattsand 2008).  
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2.2. Phylogenetic evolution 
The structure of KLK genes and their organization within a single syntenic locus 
suggest that all members of this family have evolved from a common ancestor by a series 
of gene duplication events that occurred at different moments of vertebrate evolution 
(Figure 3). First, it was suggested that the origin of the KLK family arose before the 
marsupial-placental split, approximately 125-175 million years ago (mya) (Elliott et al. 
2006). However, the growing number of genomes available in public databases have 
enabled a better resolution of the KLK cluster evolutionary history, tracing its origins to a 
tetrapod lineage approximately 330 mya (Pavlopoulou et al. 2010; Koumandou and 
Scorilas 2013; Kawasaki et al. 2014). Moreover, the identification of 11 marsupial 
orthologs (KLK5 to KLK15) places the majority of duplication events prior to the separation 
of marsupial (Metatheria) and placental mammals (Eutheria) (Pavlopoulou et al. 2010; 
Koumandou and Scorilas 2013; Kawasaki et al. 2014). Consistently, several KLK 
orthologs were described for the platypus genome (Ornithorhynchus anatinus), but their 
tandem organization in a single syntenic cluster could not be assessed due to the lack of 
contiguous genomic segments and a still incomplete genome assembly (Pavlopoulou et 
al. 2010; Koumandou and Scorilas 2013; Lundwall 2013) (Figure 3).  
Although the phylogenetic relationships among KLK5 to KLK15 genes are not yet 
well resolved, most studies done so far seem to agree that a single duplication 
encompassing KLK9 and KLK10 yielded KLK11 and KLK12, or vice-versa (Olsson et al. 
2004; Elliott et al. 2006; Lundwall et al. 2006b; Pavlopoulou et al. 2010; Lundwall 2013). 
Conversely, the events that generated KLK2, KLK3 and KLK4 are thought to have 
happened only after the placental mammals split (Elliott et al. 2006; Pavlopoulou et al. 
2010; Koumandou and Scorilas 2013; Lundwall 2013). Initially, the absence of KLK4 in 
elephant, hyrax, tenrec and armadillo genomes, together with phylogenetic data, 
suggested that this gene had arisen by a duplication of KLK5 in the Boreoeutheria lineage 
(Elliott et al. 2006; Pavlopoulou et al. 2010; Koumandou and Scorilas 2013; Lundwall 
2013). Still, the recent identification of a fragmented KLK4 pseudogene in the genome of 
cape golden mole (Chrysochloris asiatica; Afrotheria) points to an earlier duplication event 
that most likely occurred in a common ancestor of placental mammals (Kawasaki et al. 
2014). Further comparative analyses show even more complex histories for the classical 
KLKs, which display several events of gene gain and loss. For instance, both the dog 
(Canis lupus familiaris) and horse (Equus caballus) genomes present an additional KLK1 
homolog but, while in the horse this gene remained functional (KLK1E2), in the dog it 
degenerated  into  a pseudogene  (KLK1P).  On the  other hand, in rodents,  a remarkable 
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Figure 3 – Schematic representation of KLK genes in different species. The arrows specify the direction 
of transcription and known pseudogenes are indicated in red. Loci are not drawn to scale and bars do not 
represent chromosomes, as for many species the genomes are not yet fully assembled. On the left, a NCBI 
taxonomy-based dendrogram shows the taxonomic classes and the evolutionary relationship among taxa. 
Data compiled from Pavlopoulou et al. 2010, Koumandou and Scorilas 2013 and Lundwall 2013.  
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number of gene duplications generated an expanded locus with 13 and 10 Klk1 paralogs 
in mouse (Mus musculus) and rat (Rattus norvegicus), respectively, as well as several 
pseudogenes in mouse (Puente et al. 2003; Puente and López-Otín 2004; Pavlopoulou et 
al. 2010; Koumandou and Scorilas 2013; Lundwall 2013). Moreover, a KLK1 duplication 
leading to KLK2 seems to have occurred early in the mammal tree (Boreoeutheria), 
however, this appears to have been deleted or silenced into a pseudogene in many 
species.  Finally, in the primate lineage, in a common ancestor of Old Word Monkeys 
(Catarrhini), a recent duplication of KLK2 generated KLK3 (Elliott et al. 2006; Pavlopoulou 
et al. 2010) (Figure 3). 
2.3. Biological importance in human health and disease 
Kallikreins are often co-expressed in a wide variety of tissues (Figure 4) and found 
in many biological fluids. Accordingly, KLKs have been implicated in a broad range of 
physiological functions and proteolytic cascades, including semen liquefaction, skin 
desquamation, tooth enamel formation, neural plasticity and regulation of blood pressure 
(Klokk et al. 2006; Shaw and Diamandis 2007; Lundwall and Brattsand 2008; Lawrence et 
al. 2010; Prassas et al. 2015). Moreover, the activity of KLKs is generally regulated by 
fine-tuned processes and spatial-temporal modifications of KLK activity have been 
associated with pathological conditions such as psoriasis, atopic dermatitis, hypertension, 
diabetes, neurodegenerative disorders (Alzheimer’s and Parkinson’s disease) and several 
types of cancer (Bhoola et al. 1992; Jaffa et al. 1992; Ogawa et al. 2000; Shimizu-Okabe 
et al. 2001; Sharma 2003; Diamandis et al. 2004; Kontos and Scorilas 2012; Fischer and 
Meyer-Hoffert 2013; Fuhrman-Luck et al. 2014; Prassas et al. 2015). In this scope, KLK3, 
also known as the prostate-specific antigen (PSA), is by far the most studied member of 
the KLK family, given its relevance as a tumor marker for prostate cancer. However, 
recent studies have shown that other KLKs have been proposed as potential biomarkers 
mainly because of their deregulation in different types of cancer (Clements et al. 2004; 
Kontos and Scorilas 2012; Fuhrman-Luck et al. 2014).  
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Figure 4 –KLKs expression patterns in adult tissues. mRNA concentration for each KLK  (as indicated in 
top row) and tissue. The color code at the bottom shows the levels of expression (from Shaw and Diamandis 
2007). 
 
2.3.1. Functions in reproductive biology 
 
Semen, also known as seminal fluid, is a complex organic medium produced by 
male reproductive organs and sex accessory glands. It is composed by a wide range of 
substances that are essential for proper spermatozoa function and fundamental for semen 
coagulation and liquefaction processes (Jequier 2000). The epididymal fluid that contains 
the spermatozoa represents only a small fraction of the total ejaculated volume (<5%), 
whereas the seminal vesicles secretions, including major structural proteins, account for 
the largest semen fraction (approximately 65%). The remaining portion of semen volume 
comes mostly from prostate secretions, in a fluid enriched in proteases and Zn2+ 
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(approximately 30%) (Lundwall and Brattsand 2008). At the moment of ejaculation, in 
normal physiological conditions, prostate and seminal vesicle secretions are mixed with 
the epididymal fluid to form a coagulum in the vaginal cavity (Michael et al. 2006; Malm et 
al. 2007). This gelatinous mass results from the cross-linking of semenogelin 1 (SEMG1), 
semenogelin 2 (SEMG2) and fibronectin (FN), which are the predominant structural 
proteins of the seminal plasma, and has the role of entrapping and protecting the 
spermatozoa. Later, the liquefaction of the coagulum (5-20 minutes after ejaculation) 
allows a progressive release of the motile spermatozoa together with small peptides that 
protect sperm cells with their antibacterial, antiviral and antifungal properties (Lilja and 
Laurell 1985; Lilja et al. 1989; Malm et al. 1996; Peter et al. 1998; de Lamirande et al. 
2001; Michael et al. 2006; Edstrom et al. 2008; Lundwall and Brattsand 2008; Zhao et al. 
2008).  
The liquefaction process (Figure 5), involving a stepwise cleavage of SEMG1, 
SEMG2 and FN, is essentially driven by KLK3 and KLK2 (Lilja 1985; Lilja et al. 1987; 
Deperthes et al. 1996). In the prostate, the high concentration of Zn2+ regulates the KLK 
activity with a reversible and allosteric inhibition (Jonsson et al. 2005). Upon ejaculation, 
the Zn2+ is redistributed through the SEMGs, which consequently activates KLK3 and 
KLK2 allowing the liquefaction of the semen coagulum. However, as SEMGs are 
hydrolyzed, Zn2+ is gradually released and the KLKs activity is downregulated again. This 
mechanism of negative feedback, controlled by the availability of Zn2+, is fundamental to 
prevent excessive proteolysis which may damage spermatozoa integrity (Robert and 
Gagnon 1999; Emami and Diamandis 2007). At this stage, a number of endogenous 
inhibitors and regulatory feedback loops tightly control the cleaving process. For instance, 
protein C inhibitor (SERPINA5) and eppin (SPINLW1) are two serine protease inhibitors 
that are known to form complexes with SEMGs, preventing a premature proteolytic 
cleavage of the semen coagulum by KLK3 (Suzuki et al. 2007; Wang et al. 2007; 
McCrudden et al. 2008).  
Importantly, recent studies are proposing that other members of the KLK family 
beside KLK3 might also play a role in the cascade of semen liquefaction. For example, 
KLK2, KLK4, KLK5, KLK14 and KLK15 were shown to activate pro-KLK3 in vitro 
(Deperthes et al. 1996; Takayama et al. 2001a; Takayama et al. 2001b; Michael et al. 
2006; Emami and Diamandis 2008) and KLK5 and KLK14 were also reported to cleave 
SEMGs and FN in vitro (Michael et al. 2005; Michael et al. 2006; Emami et al. 2008). 
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Despite the recent progress in the understanding of KLKs physiological functions in 
semen liquefaction, their pathological relevance in male infertility remains largely 
unknown. Currently, it is estimated that in Western countries approximately 15-20% of 
couples within reproductive age experience difficulties in achieving pregnancy after one 
year of regular sexual intercourse. Furthermore, among these couples the male factor 
Figure 5 - Schematic representation of the semen liquefaction proteolytic cascade. (A) In normal 
physiologic conditions, KLKs are activated in the prostate through a zymogen activation cascade. KLK 
activation by other KLK is represented by straight arrows and auto-activation ability is illustrated by curved 
arrows. The pro-peptide is represented by the yellow rectangle. (B) Upon ejaculation, the sperm-rich 
epididymal fluid is mixed with prostatic fluids (including KLKs) along with secretions of the seminal vesicles 
(including SEMG1, SEMG2 and FN), forming the semen coagulum. SEMGs chelate Zn2+ ions, which leads 
to KLK reactivation and subsequent proteolysis of the SEMGs and FN, resulting in seminal coagulum 
liquefaction (adapted from Michael et al. 2006 and Prassas et al. 2015). 
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contributes with approximately 50% and in about 20% of cases it may inclusively be the 
single cause of infertility (Organization 1992; Cedenho 2007; Practice Committee of 
American Society for Reproductive 2012). The male infertility factor is mainly assessed by 
a semen analysis (spermiogram), where both macro- and microscopic parameters are 
examined, such as coagulation and liquefaction, viscosity, pH, sperm concentration, 
morphology and motility (Table 2). Given the importance of KLKs in semen liquefaction 
and the previous findings of an association between abnormal semen parameters and 
prostate dysfunction, a possible role of KLKs in infertility was advanced (Andrade-Rocha 
2003; Emami et al. 2009; Du Plessis et al. 2013). Supporting this hypothesis is the 
evidence of aberrant KLK expression found in individuals with abnormal semen 
liquefaction/viscosity. While a delayed liquefaction was associated with a lower expression 
of KLK2, KLK3, KLK13 and KLK14, a hyperviscosity phenotype was correlated not only to 
the down-regulation of KLK2, KLK13 and KLK14 but also KLK1, KLK5-KLK8 and KLK10 
(Emami et al. 2009). Moreover, KLK14 expression was found to be significantly reduced in 
asthenozoospermic patients and, in a recent proteomics study of seminal plasma, KLK3 
was found to be upregulated in patients with oligoteratozoospermia (Emami et al. 2009; 
Sharma et al. 2013).  
 
Table 2 – Semen quality nomenclature according to WHO 1999. 
Phenotype Description 
Normozoospermia Normal ejaculate as defined by reference values 
Oligozoospermia Sperm concentration < 20 x 106 spermatozoa/mL 
Asthenozoospermia Percentage of spermatozoa with rapid progressive motility < 25% 
Teratozoospermia* Percentage of morphologically normal spermatozoa < 4% 
Oligoasthenozoospermia 
Sperm concentration < 20 x 106 spermatozoa/mL and percentage of 
spermatozoa with rapid progressive motility < 25% 
Oligoteratozoospermia 
Sperm concentration < 20 x 106 spermatozoa/mL and percentage of 
morphologically normal spermatozoa < 4% 
Asthenoteratozoospermia 
Percentage of spermatozoa with rapid progressive motility < 25% and 
percentage of morphologically normal spermatozoa < 4% 
Oligoasthenoteratozoospermia 
Sperm concentration < 20 x 106 spermatozoa/mL, percentage of 
spermatozoa with rapid progressive motility < 25% and percentage of 
morphologically normal spermatozoa < 4% 
Delayed liquefaction Complete liquefaction does not occur in 60 minutes at 37ºC 
Hiperviscosity Semen forms a thread larger than 2 cm long 
* The morphology parameter is defined according to WHO 2010. 
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2.3.2. Functions in skin physiology 
 
 The skin is a multifunctional organ that maintains the body temperature, protects 
from water loss, mechanical stress, UV-light and also works as a first barrier against 
infectious agents (bacteria and virus). All these functions of the skin are essentially 
attributed to the epidermis, the outermost layer which histologically is mainly composed by 
keratinocytes. These cells are formed in a basal layer (stratum basale, SB) and undergo 
differentiation throughout their migration towards the skin surface, the stratum corneum 
(SC). By the time keratinocytes reach the SC, they have already completed their 
differentiation into corneocytes and are filled with keratin and are metabolically dead 
(Figure 6A).  
A fine balance between cell proliferation and shedding is crucial to maintain the skin 
barrier integrity, which is mainly achieved by an active renewal process called skin 
desquamation (Lundwall and Brattsand 2008; Ishida-Yamamoto et al. 2011; Nishifuji and 
Yoon 2013; Ishida-Yamamoto and Igawa 2014). In this process, KLK5 and KLK7 play an 
important role through the proteolytic cleavage of corneodesmosomes, the cell-cell 
junction structures that mediate corneocyte cohesion. Whereas KLK5 cleaves 
corneodesmosin (CDSN), desmocollin 1 (DSC1) and desmoglein 1 (DSG1), KLK7 is only 
able to digest the first two molecules (Caubet et al. 2004).  
The majority of the studies regarding KLKs and skin physiology have focused on 
the importance of KLK5 and KLK7 in skin desquamation but recent findings suggest that 
other KLKs might also be involved in epidermal pathways. For instance, different levels of 
KLK1, KLK6, KLK8 and KLK14 were reported in the SC and, except for KLK8, all of them 
were shown to degrade DSG1 in vitro (Borgono et al. 2007; Kishibe 2014; Prassas et al. 
2015). Furthermore, KLK5, KLK6, KLK7 and KLK14 were all described as regulated in the 
skin by the serine protease inhibitor Kazal-type 5 (SPINK5, also known as 
lymphoepithelial kazal type inhibitor or LEKTI) and by alterations in the physiological pH 
(Caubet et al. 2004; Brattsand et al. 2005; Egelrud et al. 2005; Deraison et al. 2007; 
Fortugno et al. 2011). In this regard, a complex proteolytic cascade has been proposed to 
regulate the process of skin desquamation (Figure 6B). 
Apart from the functions reported above, KLKs might also be involved in epidermal 
inflammation, modulation of the lipid-permeability barrier and melanosome transfer, all 
mediated through the activation of the protease-activated receptor-2 (PAR-2), a 
transmebrane G-protein-coupled receptor present in keratinocytes. Indeed, PAR-2 
receptors were found to be overexpressed in different skin disorders characterized by 
epidermal  barrier defects and  inflammation, such as atopic dermatitis (AD), psoriasis and  
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Figure 6 – Schematic representation of epidermis architecture and KLK proteolytic cascade in the 
skin. (A) The epidermis is organized in different layers mainly arranged by keratinocytes in different stages of 
differentiation. Keratinocytes are formed in the basal layer (stratum basale, SB) and begin to differentiate in 
the stratum spinosum (SS). This differentiation process occurs as keratinocytes migrate towards the skin 
surface. By the time these cells reach the stratum corneum (SC) they have already differentiated into 
corneocytes, cells filled with keratin and metabolically dead. (B) Pro-KLKs are secreted at the SG by lamellar 
granules (LG) of keratinocytes into SC interstices, where activation occurs by removal of the pro-peptide 
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Figure 6 (cont.) - (yellow rectangle). Once active, KLKs cleave the corneodesmosome proteins, desmoglein 1 
(DSG1), desmocollin 1 (DSC1) and corneodesmosin (CDSN), resulting in corneocyte shedding (skin 
desquamation). Several KLKs (KLK4, KLK5, KLK6 and KLK14) may also activate the protease-activated 
receptor-2 (PAR-2), leading to inflammation, modulation of lipid-permeability barrier or melanosome transfer. 
The KLK activity in the skin is regulated by protease inhibitors, such as serine protease inhibitor Kazal-type 5 
(SPINK5 or LEKTI), and by the epidermal pH gradient (adapted from Ovaere et al. 2009 and Prassas et al. 
2015).  
 
Netherton syndrome (NS) (Buddenkotte et al. 2005; Descargues et al. 2006; Eissa and 
Diamandis 2008; Lee et al. 2010). Furthermore, the similar localization pattern of PAR-2 
and several KLKs (KLK1, KLK4-KLK7, KLK9-KLK11, KLK13-KLK14) in skin lesions of AD 
and NS patients, together with the in vitro activation of PAR-2 by KLK4, KLK5, KLK6 and 
KLK14, seems to support the existence of a KLK-PAR-2 activation mechanism (Steinhoff 
et al. 2003; Komatsu et al. 2005; Descargues et al. 2006; Komatsu et al. 2007a). In 
addition, the deregulation of KLK activity has been thought to be one of the triggering 
causes of AD, NS and psoriasis, moreover, several clinical studies have already 
demonstrated the upregulation of multiple KLKs in these pathologies (Komatsu et al. 
2002; Komatsu et al. 2005; Komatsu et al. 2007a; Komatsu et al. 2007b; Komatsu et al. 
2008). In the NS, SPINK5 disruptive mutations have been reported, so far, as the single 
genetic cause underlying abnormal KLK activity (Chavanas et al. 2000; Walley et al. 2001; 
Bitoun et al. 2002; Komatsu et al. 2002; Komatsu et al. 2008). Consistently, Spink5 
knockout mouse model was found to display an uncontrolled Klk activity, as observed in 
patients with NS (Descargues et al. 2005).  
 
2.3.3. Functions in tooth enamel formation 
 
Dental enamel is the most highly mineralized tissue in the human body and its 
developmental stage (amelogenesis) is tightly controlled by two major proteases, MMP20 
and KLK4 (Bartlett and Simmer 1999; Simmer and Hu 2002; Lu et al. 2008). These two 
proteases are responsible for the hydrolysis of the dental extracellular matrix proteins: 
amelogenin, ameloblastin and enamelin, which account for about 90%, 5% and 2% of the 
total of the enamel protein, respectively (do Espirito Santo and Line 2005). Briefly, 
amelogenesis can be divided into three major stages: the secretory, the transitional and 
the maturation stage. In the first two stages, MMP20 is the predominantly expressed 
protease and it is responsible for the early processing of amelogenin and ameloblastin, 
allowing enamel crystallites to grow in length (Ryu et al. 1999; Iwata et al. 2007; Lu et al. 
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2008; Nagano et al. 2009). On the other hand, KLK4 expression is only initiated in the 
transitional stage and continues throughout the maturation phase, further contributing to 
the degradation of matrix proteins. Specifically, KLK4 favors crystal growth in width and 
thickness, thus promoting enamel hardening (Figure 7) (Hu et al. 2002; Ryu et al. 2002; 
Simmer and Hu 2002; Yamakoshi et al. 2006; Lu et al. 2008; Zhu et al. 2014).  
The characterization of MMP20 and KLK4 activities in the different stages of 
amelogenesis was only possible through the use of knockout mouse models lacking either 
Klk4 or Mmp20 (Yamakoshi et al. 2011). While non-cleaved amelogenin and ameloblastin 
were only observed in the Mmp20 null mice in the secretory stage, in the Klk4 null mice 
only enamel proteins were accumulated in late maturation phase (Yamakoshi et al. 2011). 
Furthermore, whereas mice lacking Klk4 produced enamel of normal thickness but with 
softer inner regions, the Mmp20 null mice presented thin and structurally abnormal 
enamel (Simmer et al. 2009; Smith et al. 2011). Importantly, KLK4 was described as a 
pro-enzyme activated by MMP20 and DPPI based on in vitro experiments (Ryu et al. 
2002; Tye et al. 2009; Yamakoshi et al. 2013). However, KLK4 and MMP20 expression 
overlap only during a short time period in the transitional stage, on the contrary, DPP1 
expression is maintained throughout enamel formation, suggesting this as the 
predominant activator of KLK4 (Hu et al. 2002; Tye et al. 2009). 
 
 
Figure 7 – KLK4 in tooth enamel formation. The ameloblasts secrete a protein-rich matrix composed by 
amelogenin, enamelin and ameloblastin, as well as KLK4, MMP20 and DPP1 proteases. During the 
transitional and maturation stages, pro-KLK4 is secreted and activated by MMP20 and DPP1. Upon activation, 
KLK4 degrades the dental extracellular matrix proteins, allowing crystal growth in width and thickness, thus 
promoting enamel hardening (adapted from Prassas et al. 2015). 
In the amelogenesis framework, the importance of KLK4 is further highlighted by 
disruptive mutations in the human KLK4 gene (W153X and G82Afs*87), which cause 
specific tooth malformations, such as enamel hypomaturation, tooth hyper-pigmentation 
and hyper-sensitivity to hot and cold stimuli (Hart et al. 2004; Wright et al. 2006; Wright et 
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al. 2011; Wang et al. 2013). This genetic condition, known as hypomaturation-type 
amelogenesis imperfecta (AI2A1), has been reported in three unrelated families, two 
carrying the W153X mutation and one carrying the G82Afs*87. In all cases, the affected 
patients were homozygous for the loss-of-function mutations (Hart et al. 2004; Wright et 
al. 2011; Wang et al. 2013). 
2.4. Primate adaptive evolution 
Primate mating behavior was found to drive the intensity of sperm competition and, 
concomitantly, the evolution of genes involved in reproduction. Specifically, promiscuous 
species in which females are known to mate with more than one male per periovular 
period (polyandrous or multimale/multifemale) exhibit physiological traits better adapted 
for fertilization, like larger testis and larger seminal vesicles relative to body size (Harcourt 
et al. 1981; Dixson and Anderson 2002). Another feature that was shown to correlate to 
mating system and promiscuity was the thickness of the seminal coagulum or the 
presence of a copulatory plug (Dixson and Anderson 2002). Broadly speaking, a thicker 
coagulum is more efficient in preventing the fertilization, by rival males, of a recently 
inseminated female in succeeding copulations than a gelatinous one (Jensen-Seaman 
and Li 2003). In this context, SEMGs represent one of the best known examples of 
evolution driven by post-copulatory selection, in which higher dN/dS ratio values observed 
in chimpanzees (Pan troglodytes) were correlated to larger numbers of male partners per 
periovular period and increased thickness of the semen coagulum. In contrast, in 
monoandrous taxa, the semen coagulum is fluid and SEMGs seem to have undergone a 
more relaxed evolution, accumulating of several inactivating mutations (Jensen-Seaman 
and Li 2003; Dorus et al. 2004; Hurle et al. 2007). 
Considering the role of KLKs in the hydrolysis of SEMGs, it is likely that KLKs 
evolution might also correlate to sperm competition. In fact, loss of KLK2, either by gene 
deletion or inactivating mutations, has already been reported in several species with 
different outcomes in reproductive biology (Clark and Swanson 2005). On one hand, the 
absence of KLK2 was described in gorillas (Gorilla gorilla) and gibbons (Hylobates sp.), 
two examples of monoandrous species, in which SEMG1 and SEMG2 have been 
inactivated due to the accumulation of premature stop codons. In these species, the loss 
of SEMGs are thought to diminish the semen viscosity, impairing the formation of the 
semen coagulum and possibly rendering KLK2 activity redundant (Clark and Swanson 
2005). On the other hand, in the rhesus monkey (Macaca mulatta), the presence of a 
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KLK2 mutation affecting the catalytic triad (D102A) and, consequently, enzyme activity 
was proposed to contribute to the different semen physiology of this species, in which the 
semen does not liquefy but forms a copulatory plug instead (Clark and Swanson 2005). 
Given that the rhesus monkey is a polygamous species in nature, the presence of a 
copulatory plug is important for sperm competition and mate guarding. However, taking 
into account that SEMG1 has been inactivated by a frameshift mutation in this species 
too, KLK2 loss-of-function could result in a reduced ability to dissolve the semen 
coagulum, thus allowing the formation of a copulatory plug. Still, the role of KLKs in the 
reproductive system and the dynamical implications of mating behavior remain poorly 
characterized. 
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The importance of KLKs in the cascade of semen liquefaction together with the 
evidence that proteolytic and reproductive genes might have been targeted by natural 
selection, at inter- and intraspecific level, has motivated the characterization of KLK 
sequence variation in different primate species, and in healthy and diseased human 
populations.  
 
Specific aims of this work: 
 
1. Unravel the evolutionary history of the most recent KLK duplicates, KLK2 
and KLK3, and address a possible correlation to primate mating systems and 
sperm competition. In a systematic analysis of KLK2 and KLK3, using comparative and 
phylogenetic procedures, a total of 22 primate species with diverse mating systems and 
different patterns of semen coagulation were investigated.  
 
2. Characterize a signature of natural selection shaping KLK cluster diversity 
in Asian populations. The hypothesis of a potential signature of natural selection among 
KLK genes in Asians, as previously highlighted by independent genome-wide scans of 
positive selection, was accomplished by undertaking a comprehensive  survey of 1000 
Genomes (phase I) data and combining it with in vitro functional assays for the most likely 
candidate variants. Furthermore, a possible ascertainment bias of the 1000 Genomes 
data was evaluated by Sanger sequencing of several genomic segments across the KLK 
cluster in a subsample of individuals screened by the 1000 Genomes project. 
 
3. Assess the impact of KLK sequence variation in different infertility 
phenotypes. An association study of male infertility centered in the genetic screening of 
the KLK cluster, along with their targets, SEMG1 and SEMG2, and their potential 
inhibitors of the whey acidic protein four-disulfide core domain (WFDC) locus was 
performed in a cohort of Portuguese infertility cases and controls. The survey for potential 
candidate variants for male infertility was achieved through a combination of pooled 
sample high-throughput sequencing, Sanger sequencing and other genotype screening 
methods.  
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Abstract 
The human kallikrein (KLK) and whey acidic protein four-disulfide core domain 
(WFDC) gene families, located at chromosomes 19q13.3-13.4 and 20q13, respectively, 
encode molecules with key roles in the cascade of semen coagulation and liquefaction. 
Semenogelins 1 and 2 (SEMGs), the main components of the semen coagulum, establish 
a cross-linked matrix that entraps spermatozoa. In contrast, KLK3 and KLK2, further 
assisted by other KLKs, hydrolyze the coagulum in a process crucial for spermatozoa 
motility. Here, we examined the contribution of KLK and WFDC variation into human 
infertility, by performing a pilot screening of coding and non-coding regions, covering 
approximately 93 kb of genomic sequence, by means of a pooled sample high-throughput 
approach, later, followed by a genotyping survey for most promising candidates in a 
cohort of cases (N=238) and controls and (N=217). Among the 456 variants identified in 
the pooled sequencing, 296 were low-frequency for which a higher burden of deleterious 
alleles was detected in cases for KLKs. Eleven variants were confirmed to be 
overrepresented in cases and likely affecting KLK4 and KLK12 structure, KLK3 activity or 
KLK3, KLK14 and KLK15 gene expression. In SEMGs we identified 3 rare variants 
expected to modify the profile of cleaved peptides with potential effects in spermatozoa 
interactions. A common nucleotide substitution in KLK7 (rs1654526) and a copy number 
variation in SEMG1, were on the other hand associated to a reduced risk for different 
infertility phenotypes. Overall, the results support the importance of KLKs and SEMGs in 
male reproduction and provide evidence for a contribution of their genetic variation into 
semen hyperviscosity and asthenozoospermia.  
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Introduction 
Infertility is a major reproductive disorder characterized as the inability to achieve a 
viable pregnancy after one year of regular sexual intercourse, which affects up to 20% of 
couples within reproductive age in Western countries (Rowe et al. 1993; Cedenho 2007). 
In the disease pathogenesis, male and females are thought to have nearly equivalent 
contributions, as many physiological processes are required to achieve a successful 
fertilization. Indeed, in most couples, the two partners are often subfertile and only in a 
smaller percentage of cases the male factor is considered as the primary cause for a 
reproductive failure (Thonneau et al. 1991; Practice Committee of American Society for 
Reproductive 2012). So far, the recognized causes for male infertility are congenital 
defects leading to reproductive malformations, endocrine and immunologic dysfunction, 
mechanic trauma, urogenital infections causing post-testicular obstruction, impaired 
spermatogenesis and also major and minor genetic abnormalities, such as aneuploidies, 
translocations and deletions in Y and other chromosomes, as well as point mutations in 
genes like CFTR, AR, DAZL, and SRY (Jungwirth et al. 2012; Tahmasbpour et al. 2014). 
Although, infertility has been proposed as a complex disease with a strong genetic 
component, it continues mostly unexplained, as the large proportion of disease cases are 
frequently defined as idiopathic or have an unknown etiological cause (Carrell and Aston 
2011; Aston 2014). 
In the clinical practice, abnormal semen parameters as determined by reference 
threshold values of the World Health Organization (WHO), are regarded as evidence for 
male infertility and accordingly, infertility patients are classified into different non-mutually 
exclusive phenotypes. These include hyperviscosity, for a persistence of semen viscosity; 
oligozoospermia or azoospermia, for lower spermatozoa counts; asthenozoospermia, for 
reduced spermatozoa motility and teratozoospermia, for altered spermatozoa morphology 
(WHO 1999; WHO 2010). 
Semen is a body fluid that results from an assorted mixture of the spermatozoa-rich 
secretions of testis and epididymis, with the products from the seminal vesicles, prostate, 
and bulbourethral glands. Upon ejaculation, the semen forms a gelatinous mass – the 
semen coagulum – that entraps the spermatozoa in a matrix of linked seminal proteins. 
Over a short period of time (5 to 20 minutes), the semen coagulum starts to be liquefied 
through the activity of several enzymes, allowing a progressive release of the 
spermatozoa and the regain of their motility (Lilja 1985; Deperthes et al. 1996; Robert et 
al. 1997). 
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Several proteins known to play key roles in the cascade of semen coagulation and 
liquefaction belong to the kallikrein (KLK) gene family, found in chromosome 19q13.3-13.4 
region, and to the whey acidic protein four-disulfide core domain (WFDC) family, located 
at chromosome 20q13. Specifically, the two major structural seminal proteins enrolled in 
the semen coagulation and spermatozoa immobilization, semenogelin 1 (SEMG1) and 
semenogelin 2 (SEMG2), belong both to the WFDC locus (Lundwall and Brattsand 2008; 
Clauss et al. 2011). On the other hand, the core enzymes involved in the semen 
liquefaction and SEMGs hydrolysis into multiple shorter peptides are KLK3 (also known as 
prostate-specific antigen – PSA) and KLK2 (Lilja 1985; Lilja et al. 1987; Deperthes et al. 
1996). Moreover, the WFDC cluster also encompasses 17 small serine protease inhibitor 
genes, which include SLPI and PI3, two ubiquitous molecules with antimicrobial activities 
at reproductive mucosal surfaces, and EPPIN, a molecule that coats the spermatozoa in a 
protein complex with fibronectin and SEMGs, modulates KLK3 activity and coagulum 
proteolysis, and also protects spermatozoa form bacterial attacks (Yenugu et al. 2004; 
Wang et al. 2005; Williams et al. 2006; Wang et al. 2007; Weldon et al. 2007; McCrudden 
et al. 2008; Zhao et al. 2008; Zhang et al. 2013). Less is known about other WFDC 
molecules, but most genes were found to be mainly expressed in male reproductive 
tissues and several were detected in the human seminal plasma by proteomic profiling 
(Clauss et al. 2002; Thimon et al. 2008; Batruch et al. 2012; Chhikara et al. 2012). 
Conversely, the KLK locus includes a total of 15 trypsin- or chymotrypsin-like serine 
protease genes (KLK1-KLK15) with pervasive activities in diverse proteolytic cascades, 
including semen liquefaction. As example, KLK4, KLK5, KLK14 and KLK15 were all 
shown to regulate the activity of KLK3, and KLK5 and KLK14 were reported to overlap 
with KLK3 in the hydrolysis SEMGs and fibronectin (Takayama et al. 2001a; Takayama et 
al. 2001b; Michael et al. 2006; Emami et al. 2008; Emami and Diamandis 2008). 
In the latest years, the evidence supporting a possible contribution of KLK and 
WFDC families into different male infertility phenotypes has been consolidating. In the 
study by Emami et al., most KLKs were correlated to a downregulation of protein 
expression and a hyperviscosity phenotype, whereas the delay of semen liquefaction was 
associated to a restricted set of proteins (KLK2-3 and KLK13-14) displaying reduced 
protein expression (Emami et al. 2009). Furthermore, in the same study a link between 
KLK14 expression levels and asthezoospermia was established, and more recently KLK3 
was found to be significantly upregulated in patients combining oligo and 
teratozoospermia phenotypes (Emami et al. 2009; Sharma et al. 2013). On the other 
hand, SEMG1 has been recently shown to be upregulated in infertile patients with and 
without asthenozoospermia, but no correlation could be observed between the patterns of 
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SEMG degradation and hyperviscosity (Martinez-Heredia et al. 2008; Esfandiari et al. 
2014; Legare et al. 2014; Yu et al. 2014). Moreover, in the EPPIN gene two single 
nucleotide variants (SNV) were shown to correlate with semen quality in the Han-Chinese 
population, one presenting a decreased risk to low sperm number and the other an 
increased risk to abnormal motility (Ding et al. 2010a; Ding et al. 2010b). 
In this study, we sought to investigate in which extent the genetic variation within 
KLK and WFDC families affects the regular process of semen coagulum liquefaction, and 
underlies hyperviscosity and other infertility phenotypes. By performing a comprehensive 
survey of KLK and WFDC coding and non-coding regions using a high-throughput 
sequencing strategy, we demonstrated that KLKs have an excess of low-frequency 
variants among infertility cases and we validated a total of 12 candidate variants of male 
infertility in KLKs but also in WFDCs, with expected impact in the proteolytic processing of 
the semen coagulum. 
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Material and methods 
Infertility cases and control samples 
Biological samples (blood or buccal swabs and semen) from infertile men (n = 238) 
and controls (n=91) of Portuguese origin (2 generations at least) were collected from 
individuals undergoing routine spermiogram analysis at two fertility centers. All samples 
were classified regarding sperm count, motility and viscosity state according to the World 
Health Organization guidelines (WHO, 1999). Cases were classified into different infertility 
phenotypes and regarded as oligozoospermic, for sperm counts below 20 million/mL, as 
asthenozoospemic, for rapid progressive motility less than 25% and as hyperviscous, if 
semen drops form a thread more than 2 cm long (WHO, 1999). Patients with known 
causes of infertility, including chromosome anomalies and Yq microdeletions were 
excluded from this study. Individuals with sperm counts, motility and viscosity parameters 
above the mentioned thresholds were considered as normal and included in the control 
group. In addition, 32 individuals with at least one offspring and 94 random males with 
unknown spermiogram parameters, born in Portugal were included in the controls. 
Genomic DNA was extracted from peripheral blood leukocytes using the Citogene 
Blood Kit (Citomed) or Generation Capture Column Kit (Qiagen), and from buccal swabs 
using BuccalAmp DNA Extraction Kit (Epicentre) according to the manufacturer’s 
instructions. Semen samples were collected by masturbation after 3 days of sexual 
abstinence, centrifuged at 7000 g for 10 min to separate the spermatozoa from the 
seminal plasma and stored at -80 ºC. 
Variant screening by pooled next-generation sequencing (NGS) 
Initially, we carried out a pilot survey using the Somatic Mutation Identification in 
Pooled Samples (SMIPS) technique (Puente et al. 2011), a modified method for the 
analysis of pooled samples (Druley et al. 2009). In this approach (phase I), a subset of 
222 samples were subdivided into three major groups, according to their phenotypes 
(Supplementary Fig. S1). First, as a proxy for a fertile group we included 57 individuals 
with normal sperm counts, motility and viscosity parameters and 22 men with at least one 
offspring. Then, the other 143 samples were further subdivided in two groups according to 
the presence or absence of a hyperviscosity phenotype (HV and NV, respectively), and 
whereas the HV group was composed by 75 cases, all showing abnormal viscosity alone 
or in combination with other phenotypes, the NV group consisted of the remaining 68 
cases with oligozoospemia, asthenozoospermia or both, but without hyperviscosity. For 
Chapter 3 | Papers 
 
71 
each group, we pooled equal amounts of genomic DNA per sample (>600 ng per 
individual, per group). 
Multiple primer pairs (Supplementary Table S1) were designed based on the 
human genome reference sequence (GRCh37) in order to amplify 220 amplicons (119 
from the KLK cluster and 101 from the WFDC cluster), covering 159 exons and 53 
putative regulatory regions, according to ENCODE data for DNase hypersensivity sites, 
H3K4Me1 Mark and transcription factor CHIP-seq, in a total of ~ 93 kb of genomic 
sequence. Amplification was performed separately for each primer pair using Platinum 
DNA polymerase or Platinum Pfx DNA polymerase (Invitrogen/Thermo Fisher Scientific), 
200 μM dNTPs (Invitrogen/Thermo Fisher Scientific), 600 nM of each primer, 1 mM 
MgCl2, and 100 ng of pooled DNA. PCR cycling conditions were: 5 min at 94 °C, followed 
by 35 cycles of 30 sec at 94 °C, 30 sec at 60 °C, and 40 sec at 72 °C, and a final 
extension of 5 min at 72 °C. All PCR products were then purified using QIAquick PCR 
Purification Kit (Qiagen). 
For each group, equimolecular amounts (4 x 1011 molecules) of each amplicon 
were pooled, and a random amplicon ligation reaction was performed as previously 
described (Druley et al. 2009). The concatenated products were precipitated with a 10 mM 
MgCl2 solution, resuspended in Tris-EDTA buffer (10mM Tris; 1 mM EDTA; pH 8.0) and 
then fragmented in a Covaris S2 sonicator (200 Cycles, Duty Cycle 10%, intensity 5 and 
360 sec) (Covaris). DNA libraries were prepared according to the Illumina protocol for 
paired-end sequencing, and the three libraries were run in Illumina HiSeq 2000 in a single 
lane (Macrogen, Inc). 
All reads were initially mapped to the human reference genome (GRCh37) using 
the Burrows-Wheeler Alignment (BWA) tool (Li and Durbin 2009). Next, a pileup file was 
generated in SAMtools (Li et al. 2009) and the variant calling was performed with an in-
house script and filtered based on the following criteria: i) Phred base quality score ≥ 20; 
ii) a minimum coverage of 10.000 reads per pool; and iii) a minimum base call count per 
variant corresponding to at least 0.8 expected chromosomes ((N allele-specific base calls 
* 2 * N individuals in pool) / N total base calls). Variant calls surpassing the filtering were 
normalized to allele frequencies for each pool and these were compared with publically 
available databases of human variation (1000 Genomes phase III) for the European 
population (average of the frequencies for Iberian, British, Finnish, Toscani and CEU 
populations - Utah residents with Northern and Western European ancestry). 
Functional consequences of the identified variants were inferred using Variant 
Effect Predictor (VEP) tool from Ensembl, which incorporates variant location and SIFT 
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and Polyphen scores for changes to protein sequence (Kumar et al. 2009; Adzhubei et al. 
2010; McLaren et al. 2010). The effect of synonymous substitutions in mRNA secondary 
structure and the outcome of non-coding variants in mRNA splicing and in the binding of 
transcription factors was predicted in silico using the online tools RNAsnp, Human 
Splicing Finder v.2.4.1 and MatInspector, included in the Genomatix software suite 
(Genomatix Software GmbH), respectively (Desmet et al. 2009; Sabarinathan et al. 2013). 
Structural analysis of protein sequences was done through ClustalO alignments mapped 
onto the three-dimensional structure of KLK4 bound to benzamidine, a competitive 
inhibitor (PDB ID 2BDG) (Sievers et al. 2011). The structure with the mapped residues 
was rendered with PyMol version 0.99rc6 (DeLano Scientific). 
Genotyping validation and extension study 
From the SMIPS analysis we selected several regions for variant calling validation 
based on the following criteria: 1) regions from genes with known implications in male 
reproduction, containing at least two low-frequency variants (minor allele frequency (MAF) 
< 0.05) with predicted functional repercussions (splice region, nonsynonymous or located 
in transcription factor binding regions) and displaying discrepancies between cases and 
controls; 2) private non-singleton low-frequency variants located in genes with possible 
implications in male reproduction and showing predicted functional consequences, as well 
as higher allele counts in cases than in controls; and 3) common SNVs (MAF ≥ 0.05) with 
predicted functional consequences and significant frequency differences between case 
and control groups. In total, 7 regions and 4 SNVs were chosen to be analyzed by Sanger 
sequencing or SNaPShot genotyping (phase II), respectively, in the 143 cases and 79 
controls screened in phase I. All samples were PCR-amplified and whereas amplicons for 
KLK3 (exon III-IV), KLK4 (exon II), KLK6 (exon V), KLK12 (exons II and IV) and KLK14 
(exons I and III) were sequenced with BigDye Terminator v3.1 Cycle Sequencing Kit 
(Thermo Fisher Scientific) and run on an ABI 3130 automated sequencer, the SNVs 
rs1654526 (KLK7), rs74705037 (KLK8), rs3212852 (KLK15) and rs75681320 (EPPIN) 
were genotyped using the ABI PRISM SNaPshot Multiplex Kit (Thermo Fisher Scientific) 
and run on an ABI 3130 automated sequencer. All Sanger sequences were assembled 
and analyzed using Geneious version 5.5.8 software (http://www.geneious.com, Kearse et 
al. 2012) and all putative polymorphisms were manually curated to minimize sequencing 
errors. SNaPShot peak calling was obtained and analyzed using the GeneMaper software 
(Thermo Fisher Scientific). Further information regarding PCR, sequencing and SNaPShot 
conditions are available from authors upon request. In the end, 8 SNVs were selected for 
an extended genotyping study (phase III) carried out in the remaining 95 infertility cases 
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(36 HV and 59 NV), 44 fertile controls (34 individuals with semen parameters above the 
threshold and 10 fertile men) and in 94 random Portuguese controls. 
SEMG1 and SEMG2 genetic screening 
A pilot study covering the regions encoding the repeat units of SEMG1 and SEMG2 
was performed by Sanger sequencing in the same subset of 222 samples used in phase I. 
Functional consequences of identified variants were inferred as described above. The 
CNV and the nonsynonymous variants predicted as damaging were further genotyped in 
the remaining samples by Sanger sequencing, length fragment analysis or SNaPshot 
genotyping. Further information regarding PCR, sequencing and SNaPShot conditions are 
available from authors upon request. 
Statistical analyses 
For the SNVs with a MAF ≥ 0.05 in the European population (1000 Genomes data 
phase III), statistical significant differences between cases and controls were estimated 
using Fisher’s exact test. To control the significance levels under multiple test 
comparisons we performed the Bonferroni correction (α = 0.05/n, where n is the total 
number of SNVs tested). Furthermore, to test for the hypothesis of a possible enrichment 
of low-frequency variants with predicted functional repercussions in KLK and WFDC 
clusters, we calculated C-alpha statistic as implemented in the AssotesteR package with 
100,000 permutations (Sanchez 2013). For the statistical analysis of pooled sequenced 
data we performed two independent tests: one considering the nonsynonymous 
substitutions and splice region SNVs together, and the other one taking only into account 
variants located in untranslated regions (UTRs). In the analysis of SEMG data we carried 
out again two independent tests using either all nonsynonymous substitutions or only 
those nonsynonymous substitutions predicted as damaging. Three sets of comparisons 
were done throughout the study: the control group was tested against HV and NV cases 
separately, and a third comparison was done for the control group against all infertility 
cases (HV+NV). Statistical analyses were carried out using RStudio application for 
statistical computing (http://www.rstudio.com). 
Proteomic analysis 
The possible effects of KLK3 variants p.E131K and p.S210W were assessed by 
proteomic analysis of the seminal plasma for individuals bearing these mutations. For 
p.S210W the results were extracted from a seminal proteome profiling study (unpublished 
data). For the analysis of p.E131K, the seminal plasma was mixed with 4x Laemmli 
Sample Buffer (BioRad), heated at 95ºC for 5 min and separated by SDS-PAGE (12% 
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poly-acrylamide). The resulting gels were either stained with PageBlue, (Thermo Fisher 
Scientific) or transferred onto a nitrocellulose membrane (GE Healthcare) for KLK3 
immunodetection. The membrane was then blocked with 5% non-fat milk and probed with 
the KLK3 primary antibody (SantaCruz Antibodies) at a 1:5000 dilution. Immunoblots were 
visualized using ECL detection kit (GE Healthcare). Protein staining band corresponding 
to KLK3, as assessed by immunoblotting, were manually excised from the gel, placed in 
0.5 mL microcentrifuge tubes and stored at 4 °C until tryptic digestion following an already 
published procedures of mass spectrometry (MS) (Osorio and Reis 2013).  
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Results 
Sequence variability of KLK and WFDC gene clusters 
In order to identify potential candidate variants for male infertility among KLK and 
WFDC clusters, we used a pooled sample approach and a high-throughput sequencing 
strategy to survey a subset of 143 cases (75 HV and 68 NV) and 79 controls for 220 
amplicons (119 and 101 spread over KLK and WFDC clusters, respectively) 
(Supplementary Fig. S1 and S2). Overall, the sequenced regions covered approximately 
93 kb and included both coding and non-coding genomic segments, comprising UTRs and 
putative regulatory regions defined according to ENCODE data for DNase hypersensivity 
sites, transcription factor binding sites and histone marks. 
In the data analysis, strict filtering methods were used to reduce the number of 
false-positives caused by sequencing errors, even so, we found an excess of novel 
variants in genomic segments encompassing ALUs, satellites and low complexity and 
simple tandem repeats. Moreover, in these regions we found large discrepancies to 
described SNVs frequencies for Europeans, pointing out to the existence of errors in the 
sequence assembling caused by the reads misalignment (Supplementary Fig. S3 and 
S4). These findings agreed with previous recommendations by others authors for a 
cautionary analysis of SNVs located in copy number variations (CNVs) and repetitive 
regions, due to the poor alignment of the short sequence reads (100 bp) produced by 
NGS methods (Alkan et al. 2011; Treangen and Salzberg 2012).  
Similar concerns were also raised in our study for SEMGs (Supplementary Fig. S3), 
more precisely, in the region encoding the repeat units of 60 amino acids (180 bp) length. 
Here, the high levels of sequence similarity within the variable SEMG1 units (5 or 6 units) 
and between the fixed units of SEMG2 (8 units) seem to have hampered the correct 
assembling of short reads to the human reference sequence. Therefore, taking into 
account the limitations of NGS methods in evaluating the genetic variation of repetitive 
elements, we decided to remove from our high-throughput analysis all SNVs identified 
within those regions, which included all SEMG amplicons.  
In a further step, to assess the accuracy of our pooled sequencing approach, we 
compared the estimated SNVs frequencies for the control group (without novel variants) to 
those described for Europeans as a whole (average frequencies of populations with 
European ancestry from the 1000 Genomes phase III data). A strong linear correlation (r2 
= 0.826) was observed between MAFs of analyzed SNVs (Fig. 1), emphasizing the 
qualitative (low-frequency and common variant calling) and quantitative (allele frequency 
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inference) nature of the method implemented for the screening of KLK and WFDC gene 
variability. 
Globally, in this phase of the study (phase I), a total of 456 SNVs were identified 
(Supplementary Table S2), in which 296 (64.9%) were low-frequency (MAF < 0.05) and 
104 (22.8%) were novel variants. In addition, 98 (21.5%) SNVs were located in coding 
exons (58 nonsynonymous and 40 synonymous), 72 (15.8%) in UTRs and 16 (3.5%) in 
splice regions. 
Analysis of common variants association to male infertility 
To test the association to male infertility of the 160 identified common SNVs (MAF  
0.05), we performed a series of comparisons between controls and different groups of 
cases: all infertility phenotypes (HV+NV), hyperviscosity cases (HV), or astheno- and 
oligozoopermic phenotypes without hyperviscosity (NV). Precisely, 29 SNVs, 23 in KLKs 
and 6 in WFDCs, were found to have significant associations in at least one of the 
comparisons (Supplementary Table S3). However, only 2 variants in the HV group 
maintained their statistical association after controlling for multiple test comparisons (P < 
0.0003125). The SNV showing the strongest value (P = 0.0002) was a synonymous 
substitution in WFDC6 (rs41304411, ENST00000372665.3:c.366C>A, p.I122I), with no 
obvious functional effect. The other associated SNV, rs1654526 
(ENST00000595820.5:c.606+585C>T) (P = 0.0003), was located in KLK7, within a 
enhancer region that harbors several binding sites for transcription factors (FOS, FOSL2 
and JUND) and repressors (CTCF) as indicated by chromatin segmentation and Chip-seq 
data from ENCODE, respectively (Supplementary Fig. S5). Interestingly, both SNVs 
showed higher frequencies in controls than in cases, which suggest an undirected link or 
a possible protective role of these SNVs to male infertility. 
Burden tests of low-frequency variants 
The vast majority of SNVs identified in our study were low-frequency variants (MAF 
< 0.05), for which standard statistic tests have low power to detect associations, especially 
in relative small sample sizes (few hundred individuals). To circumvent this limitation and 
to investigate whether there is a higher burden of low-frequency deleterious variants 
(nonsynonymous and splice region SNVs) in cases than in controls, we applied the C-
alpha statistic under several gene combined analysis (Neale et al. 2011) (Table 1). We 
started by analyzing KLK and WFDC genes altogether in a single group, for which a 
significant enrichment of low-frequency variants in infertility cases was detected 
independently of the considered disease phenotype (HV, NV and HV+NV). In two other 
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tests, to address if KLK and WFDC clusters were differentially enriched in low-frequency 
SNVs, we calculated the statistic for each gene family, separately. This analysis confirmed 
a higher burden of low-frequency variants for all phenotypes, but solely for KLK genes. An 
equivalent approach was used to inquiry if cases had a higher burden of regulatory SNVs 
(5’ and 3’ UTR variants) than controls, nevertheless, none of the analysis yielded 
significant results (Table 1). 
Candidate variant genotyping 
To confirm variant calling and allele frequency estimates obtained in the first phase 
of the study (phase I), we performed a genotyping screening by Sanger sequencing for 
the most promising candidate genes of male infertility (phase II; Supplementary Fig. S1). 
Here, we prioritized the analysis of several gene regions based in the following criteria: 1) 
previous evidence of deregulated activity in infertility cases and/or recognized role in male 
reproduction; 2) gene contains at least 2 low-frequency variants with potential deleterious 
effects; and 3) SNV is absent in controls or displays major frequency differences between 
cases and controls (two or more times higher). Specifically, we selected for the Sanger 
sequencing study segments of KLK3, KLK4, KLK6, KLK12 and KLK14 genes. The 
function of KLK12 has not been fully elucidated yet, but according to its mRNA expression 
in male genital tissues and protein identification in seminal plasma, it is likely to have an 
important function in male reproductive biology (Shaw and Diamandis 2007). 
As a whole, the results of the Sanger sequencing screening provided a good fit to 
the estimated MAFs in pooled samples, as demonstrated by the strong correlations 
between SNVs for the three sample groups considered (HV: r2 = 0.9725; NV: r2 = 0.9695; 
controls: r2 = 0.9509) (Fig. 2). Noticeably, in these segments the estimates of allele 
frequency derived from the pooled sequencing had similar levels of accuracy for both 
common (MAF ≥ 0.05) and low-frequency (MAF < 0.05) variants (Fig. 2). 
In the category of low-frequency variants, several SNVs emerged as promising 
candidates for male infertility (Table 2 and Supplementary Fig. S6). In KLK3, we 
confirmed for the HV group the segregation of rs111901464 (ENST00000593997.5: 
c.658G>A, p.E220K), a SNV located in the intron IV of KLK3 also predicted to have a 
negative impact in a shorter KLK3 isoform; an increased incidence in HV cases of a 
nonsynonymous substitution (rs61729813, ENST00000326003.6: c.629C>T, p.S210W); 
and we identified in a single asthenozoospermic patient, a variant previously uncovered 
by the pooled sequencing (rs182759459, ENST00000326003.6: c.391G>A, p.E131K). 
While both p.E220K and p.E131K entailed a substitution of two amphipathic residues with 
opposite side chain charges that are frequently involved in salt-bridges and in interactions 
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with non-protein atoms, the p.S210W involved the change of a small polar amino acid to a 
large hydrophobic aromatic residue. In KLK14, we confirmed an increased prevalence 
among infertility cases of 2 deleterious SNVs, a splice donor site (rs117229324, 
ENST00000391802.1: c.26+1G>A) likely affecting normal splice processing (HSF and 
MaxEnt scores changes from 93.16 to 66.33 and 10.24 to 2.06, respectively) and a 
nonsynonymous variant (rs112658494, ENST00000391802.1: c.412C>T, p.R138W) 
replacing a positively charged amino acid by a large hydrophobic aromatic residue rarely 
engaged in non-protein atom binding. Furthermore, in KLK12, we found 2 SNVs confined 
to infertility cases, one identified in a single patient and causing a loss of a disulfide bond 
(rs140609488, ENST00000319590.8:c.587G>A, p.C196Y) and the other detected in a few 
cases leading to a substitution of an extremely conserved proline (rs61742847, 
ENST00000319590.8: c.101C>T, p.P34L) across KLK family (Supplementary Fig. S6). 
Finally, in KLK4 and KLK6, we validated the presence of two rare deleterious variants 
found in isolated cases. Whereas, for KLK4, we uncovered in an asthenozoospermia case 
a novel p.Q42L replacement affecting a highly conserved amino acid among KLKs 
(Supplementary Fig. S6), in KLK6, we disclosed for a combined phenotype of 
asthenozoospermia and hyperviscosity a p.T234M (rs77760094, ENST00000310157.6: 
c.701C>T) mutation located in the C-terminal region. Noticeably, for KLK6 we also found 
in two controls a novel variant p.I216N with predicted functional consequences. The 
p.I216N replaces a hydrophobic amino acid with an aliphatic side chain by a polar residue 
frequently involved in protein activity and binding sites, such as the catalytic triad of 
several cysteine proteases. 
To investigate the putative structural consequences of the candidate variants, we 
mapped the affected residues onto the solved three-dimensional (3D) structure of KLK4 
bound to a competitive inhibitor. Notably, the alignment of kallikrein sequences showed 
that several variants cluster at close or even equivalent positions in the primary structure 
(Fig. 3A). Moreover, the threading of the alignment onto a 3D structure revealed further 
clustering of positions 196 of KLK12 and 210 of KLK3 to position 215 in KLK6 (Fig. 3B). 
Interestingly, this cluster is located in the inhibitor-binding pocket of the structure, which 
suggests that these variants may directly affect the binding of the corresponding 
kallikreins to their substrates. In fact, the C196Y variant in KLK12 is expected to destroy a 
disulfide bond, termed SS6, necessary for the catalytic activity of kallikreins (Oka et al. 
2002). The remaining variants map to different parts of the structure, and still show a 
tendency to cluster. Thus, variants E131K in KLK3 and R138W in KLK14 map to the same 
position in the structure (Fig. 3B). In the absence of further functional information, this 
suggests that variants in this position are selected for in infertile patients. Similarly, 
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variants Q42L in KLK4 and P34L in KLK12 cluster in consecutive positions in the 
structure. Both positions are well conserved among kallikreins (Fig. 3A and 
Supplementary Fig. S6) and appear about ten residues downstream from the activation 
site, suggesting that these variants might affect protein folding and the activation process. 
Finally, the T234M variant in KLK6 is located in a -helix close to the C-terminus of the 
protein. 
Beside the validation of candidate genes by Sanger sequencing 3 more dispersed 
variants were selected for genotyping using a SNaPShot multiplex reaction approach. 
These included a SNV located in the KLK8 5’UTR (rs74705037, ENST00000600767.5: c.-
29C>T), within a region recognized by ENCODE chromatin segmentation data as an 
enhancer and predicted by MatInspector to contain several binding motifs for Zinc finger 
proteins (loss of Zinc finger and BTB domain-containing protein 7A and Zinc finger protein 
GLIS2 binding sites). Another SNV allocated to a KLK15 splice region (rs3212852, 
ENST00000598239.5: c.481+5G>A) probably impairing normal mRNA processing (HSF 
and MaxEnt scores changes from 89.08 to 76.92 and 9.49 to 4.62, respectively). A latter 
SNV placed in EPPIN intron I (rs75681320, ENST00000354280.8: c.92-438C>T) in an 
insulator region containing several transcription binding factors (CTCF, SMC3, RAD21) as 
identified by ENCODE chromatin segmentation and Chip-seq data, respectively. 
Extended association study of male infertility 
To increase the statistic power of our study, we carried out an extended genotype 
analysis for the most promising candidate variants for male infertility. In this phase (phase 
III), we screened an additional panel of 95 cases (36 HV and 59 NV) and 138 controls (34 
individuals with normal semen parameters, 10 fertile men and 94 random Portuguese 
males), for 7 low-frequency SNVs and a common SNV (Supplementary Fig. S1). The 
selected low-frequency SNVs included: 3 nonsynonymous substitutions confirmed by 
Sanger sequencing and predicted as deleterious (KLK3 p.E220K - rs111901464; KLK12 
p.P34L - rs61742847 and KLK14 p.R138W - rs112658494; the splice donor site (KLK14: 
c.26+1G>A - rs117229324); and the 3 SNVs evaluated by SNaPshot (KLK8: rs74705037; 
EPPIN: rs75681320 and KLK15: rs3212852). The single common variant selected for the 
extended screening was the one located on KLK7 (rs1654526). 
The case-control analysis of the entire dataset comprising a total of 238 infertility 
cases (111 HV and 127 NV) and 217 controls (Table 3 and Supplementary Fig. S1) 
corroborated a trend toward increased MAFs in infertility cases for all low-frequency 
variants (Table 3). However, the sample size was not enough to reach statistical 
significance in most circumstances. Indeed, only the KLK12 p.P34L (rs61742847) 
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replacement showed a significant association for both HV+NV and HV group comparisons 
(P = 0.0388 and P = 0.0384, respectively), thus suggesting a possible contribution into the 
hyperviscosity phenotype. Nonetheless, the candidate variants identified in KLK3, KLK15 
and EPPIN, were found to present at least three times higher frequencies in the HV group 
than in controls. In contrary, the KLK14 splice variant showed an equivalent frequency 
increment in the NV group that could be connected to an asthenozoospermia phenotype, 
including in the single case identified among the HV group. Finally, the common KLK7 
(rs1654526) was confirmed as significantly associated with a reduced susceptibility to 
semen hyperviscosity (P = 0.0035) and male infertility (P =0.0258). 
SEMGs genetic screening 
The survey of SEMGs was centered in exon II, which covers nearly all protein 
coding sequence, except for a short N-region included in exon I. Similarly to the approach 
used in the high-throughput sequencing study, we started by analyzing the same cohort of 
143 cases and 79 controls by Sanger sequencing. In the first analysis of SEMGs variation, 
we identified 6 and 4 SNVs in SEMG1 and SEMG2, respectively (Supplementary Table 
S4). Among the SNVs found in SEMGs, only rs147894843 (ENST00000372781.3: 
c.1199G>A, p.G400D) in SEMG1, and rs2233903 (ENST00000372769.3: c.835C>T, 
p.H279Y), rs2071650 (ENST00000372769.3: c.1102G>C, p.G368R) and rs139977707 
(ENST00000372769.3: c.1654G>C, p.E552Q) in SEMG2 were predicted to affect protein 
function. In addition, in the SEMG1 we also covered the previously described CNV 
corresponding to the 5 or 6 repeat units (Jensen-Seaman and Li 2003; Lundwall et al. 
2003; Miyano et al. 2003). 
To investigate whether there was a higher burden of deleterious SNVs among 
SEMGs in cases than in controls, we applied again the C-alpha statistic (Neale et al. 
2011) (Supplementary Table S5). However, we did not observe any variant enrichment in 
all tests performed. In this initial phase, a single silent substitution located in SEMG1 and 
restricted to controls (p.T293T rs17850164) was found to displayed a significant 
association (P = 0.0423, in the HV+NV comparison). Nevertheless, 2 nonsynonymous 
substitutions were absent in controls (SEMG1 p.G400D and SEMG2 p.E552Q); 2 linked 
variants in SEMG2 (p.H279Yand p.G368R) were slightly increased in cases, and the 5 
repeat allele of SEMG1 showed a higher frequency in controls than in cases. Interestingly, 
the significantly associated p.T293T mutation had no predicted effect on mRNA 
secondary structure but it appeared as linked to the 5-repeat allele. Thus, in the extended 
study, we decided to genotype for SEMG1 the p.G400D replacement and the CNV; and 
for SEMG2 the p.H279Y and p.E552Q substitutions. 
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The analysis of the full case-controls datasets revealed a significant association of 
SEMG1 p.G400D (rs147894843) variant in HV+NV and NV groups (P = 0.0388 and P = 
0.04920, respectively) (Table 4). This variant creates a potential cleavage site (P1-P1’: DE 
search in MEROPS) for cathepsin D and metalloprotease 2, two proteases found at high 
and low abundances in semen, respectively and also for caspase-3,  a cysteine protease 
previously associated to male infertility and asthenozoospermia (Almeida et al. 2005; 
Rawlings et al. 2014). Consistently, in our study 4 out of 5 cases carrying the p.G400D 
had an asthenozoospermia phenotype, for which a significant association was also 
obtained (P = 0.0442, asthenozoospermia vs. controls). The SEMG2 variants did not 
reach significance in our group comparisons, nevertheless, we found a slighter increment 
on the p.H279Y (rs2233903) replacement in the NV group and a 7 times augmented 
frequency of p.E552Q (rs139977707) in the HV. Oddly, this SNV is likely to generate a 
novel cleavage site for KLK3 (P1-P1’: QS) in the SEMG2 sequence (Malm et al. 2000).  
The CNV maintained the tendency toward a lower frequency of the 5-repeat allele 
in infertile patients (P = 0.0667 for HV+NV cases vs. controls), as previously reported in 
Asians (Miyano et al. 2003). Notably, in our sample, we could detect a significant lowering 
of the 5-repeat allele in oligozoospermia patients (P = 0.02928) but not in 
asthenozoospermia as it has been previously hypothesized (Miyano et al. 2003). 
At last, in the extended survey of SEMGs we also discovered in a single individual 
exhibiting a combined phenotype of hyperviscosity and asthenozoospermia a novel 
SEMG1 variant (hg19 chr20: g.43837061T>C, p.Y315H), expected to abolish one of the 
KLK3 cleavage sites (Rawlings et al. 2014). 
Proteomic validation 
To assess a possible deleterious effect of the candidate variants that could result in 
the degradation of the mutant protein, we carried out a proteomic screening of KLK3 
p.E131K and p.S210W substitutions in the seminal plasma of individuals bearing these 
mutations. In both cases, it was possible to identify the mutant variant in comparable 
levels to those for the wild type (Fig. 4 for p.S210W; for p.E131K data is not shown), 
indicating that the mutant allele is secreted and not degraded by the cellular machinery. 
However, other deleterious functional effect of these variants in KLK3 function cannot be 
excluded: the p.S210W substitution by being placed in the binding pocket can still affect 
the interactions to substrates, and in the p.E131K the loss of glutamate residue could 
potentially affect the binding to ions like zinc, an important modulator of KLK activity in the 
seminal plasma.  
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Discussion 
We performed a comprehensive study of male infertility focused on the genetic 
variation of KLK and WFDC clusters, by applying a next-generation sequencing approach 
to the analysis of pooled DNA samples, allowing in a cost-effective manner to identify 
multiple susceptibility markers in cases with and without hyperviscosity. A follow-up 
genotype screening of selected locus regions confirmed the accuracy of the method, 
which permitted the variant calling and frequency inference of both common and rare 
alleles. 
Globally, an enrichment of potential candidate variants (high and low-frequency) 
was detected in KLKs in comparison to WFDCs, supporting a greater impact of the first 
cluster in human reproduction and fertility. Furthermore, in agreement with KLKs higher 
levels of sequence variation in infertility cases, other authors had reported a consistent 
downregulation of protein expression for most tested KLKs (KLK1-3, KLK5-10 and KLK13-
14) in the semen of individuals with abnormal viscosity and liquefaction parameters 
(Emami et al. 2009). 
Although, a greater emphasis was given in our study, in particular in the genotyping 
surveys, to nonsynonymous and splice variants, these may only explain a small fraction of 
KLK quantitative differences in semen through mechanisms of abnormal protein and 
mRNA degradation. Indeed, among validated variants only the p.P34L substitution in 
KLK12, which is located in a highly conserved residue across the entire family, as well as, 
in other far related serine proteases, and the mutated donor splice region of KLK15, could 
hypothetically be linked to hyperviscosity by those straightforward effects. However, 
neither KLK12 nor KLK15 were previously evaluated in the semen, and whereas the later 
protease is known to activate pro-KLK3 in-vitro, a role of KLK12 in male reproduction was 
not yet been elucidated (Takayama et al. 2001a). Worth to note, in this study two common 
variants in KLK12 region that did not surpass multiple testing were also associated to the 
hyperviscosity phenotype. 
On the other hand, SNVs positioned in regulatory regions may also cause 
significant differences in protein expression, if these disrupt a binding motif for an 
important transcription factor. Even though, this category of genetic variants of male 
infertility has been less explored in the genotyping phases of the study because of the 
less confident nature of bioinformatic predictions, several candidates are likely to have 
their link to hyperviscosity explained by such phenomena. This is likely to be the case of 
the low-frequency variant in the 5’ UTR of KLK8 (rs74705037), slightly augmented in 
hyperviscosity cases and the significantly associated variant, located in an intron of KLK7 
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(rs1654526), both placed in enhancer regions previously shown by ENCODE to interact 
with multiple regulatory elements. Interestingly, KLK7 besides being found in extremely 
reduced concentrations in hyperviscosity cases (Emami et al. 2009), its gene harbors 
three other common SNVs less strongly associated to this phenotype (rs1991820, 
rs1991819, and rs1991818). 
Another genotyped SNV possibly correlated to the hyperviscosity phenotype 
through gene downregulation is a low-frequency variant in KLK3 (rs111901464) 
positioned in a region identified by ENCODE chromatin segmentation as weaker 
enhancer, but that could also affect a shorter protein isoform lacking the catalytic triad 
(p.E220K). Up till now, a reduced expression of KLK3 has only been described in cases of 
delayed viscosity and displaying reduced spermatozoa number with abnormal morphology 
(Emami et al. 2009; Sharma et al. 2013). 
Two other nonsynonymous variants, predicted as deleterious, were found to be 
slightly increased in hyperviscosity (near two times higher), the KLK3 p.S210W 
(rs61729813) and the KLK14 p.R138W (rs112658494). However, these SNVs if truly 
linked to infertility are only expected to cause qualitative changes in protein interactions 
with other molecules. Specifically, the p.S210W variant of KLK3 was confirmed to not 
differentially affect the protein content in the semen and since it is located in a balcony 
region of the catalytic pocket (Ser210-Gly225) exposed to bulk solvents probably affects 
protease activity (Debela et al. 2006). Here, a substitution of a small polar residue (serine) 
by a large aromatic amino acid (tryptophan), where other KLK often present a glutamine 
(Q), is likely to restrain the substrate acceptance in the KLK3 catalytic pocket. 
Despite the limited number of SNVs identified in the WFDC cluster, two possible 
susceptibility variants were discovered to be more prevalent among the hyperviscosity 
cases, a SNV located in a regulatory region, specifically in an insulator of EPPIN, a 
smaller protease inhibitor reported to target KLK3, also implicated in antimicrobial 
activities (McCrudden et al. 2008) and a p.E552Q substitution in SEMG2. This later 
variant is likely to introduce a novel cleave site for KLK3 in the C-terminal region of the 
protein, but so far no specialized function has been attributed yet to such region (Robert et 
al. 1997; Robert and Gagnon 1999). 
Still, other susceptibility variants evaluated in the genotyping screening were 
overrepresented among infertility cases with normal viscosity. These included a 
nonsynonymous variant located in a critical structural region, p.Q42L in KLK4, and the 
disrupted donor splice of KLK14, all possible contributing to a lowering of the KLK content. 
Conversely, the remaining identified variants are mostly likely affecting molecular 
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interactions or protein activity, namely the KLK3 p.E131K, the KLK12 p.C196Y and the 
SEMG1 substitutions p.Y315H and p.G400D. Notably, both SEMG1 variants are expected 
to alter the protein proteolytic processing, but only the later substitution is in close 
proximity to a key sequence recognized as a thyrotropin-releasing hormone (TRH) like 
peptide (375-397 residues). Despite some controversy about the SEMG1 origin of the 
TRH-like peptides found in the human semen, these were demonstrated to increase the 
capacitation of spermatozoa (Khan and Smyth 1993; Huber et al. 1998; Robert and 
Gagnon 1999). More recently, nearly the same sequence of SEMG1 (376-388 residues) 
was found to bind to the CD52 glycosylphosphatidylinositol anchored antigen presented 
by spermatozoa, which also takes part in semen coagulation and its released during 
liquefaction (Flori et al. 2008). 
Most of these susceptibility SNVs found in normal viscosity cases were otherwise 
correlated in several instances to asthenozoospermia, a finding that may be still 
consistent with abnormal patterns of semen liquefaction. SEMGs and specially SEMG1 
are described to bound spermatozoa and to modulate their motility in a dose- and time 
dependent fashion (Robert and Gagnon 1996; Yoshida et al. 2008; Mitra et al. 2010). So 
far, the motility inhibitory peptides were correlated with N-terminal peptides released 
during semen liquefaction (-inhibin-92 and -inhibin-31) and containing cysteine 239 
residue, but the functional relevance of other SEMG1 regions should not be discarded 
(Silva et al. 2013). There is a growing body of evidence for the interaction of SEMG1 with 
other biomolecules, in most cases, with functional outcomes in spermatozoa motility. 
SEMG1 has been reported as a target for S-nitroso-glutathione, and for prolactin inducible 
protein, to bind zinc and while in EPPIN-complexes to interact with spermatozoa calcium 
channels (Lefievre et al. 2007; Yoshida et al. 2008; O'Rand and Widgren 2012; Tomar et 
al. 2013). Conversely, in asthenozoospermia patients SEMG1 was shown to remain 
bound to spermatozoa, to be increased in their semen, and its mRNA to be highly 
expressed by spermatozoa (Zhao et al. 2007; Martinez-Heredia et al. 2008; Terai et al. 
2010; Yu et al. 2014). 
 
In overview, all identified variants are expected to have a negative impact in fertility 
through modifications of semen liquefaction process, resulting from a deregulation of 
protein/peptide activity and concentration levels. Still, the consequences in the proteolytic 
cascade of each SNV might be difficult to disentangle, given that KLKs are known to have 
pervasive links with each other, often activating other members and overlapping in 
substrate affinity (Lawrence et al. 2010). Furthermore, low-frequency variants were always 
found in single heterozygosity cases, which indicate that in those individuals they are only 
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playing a part into the genetic background of male infertility. Moreover, candidate SNVs 
are only present in small fraction of cases and therefore, far from fully explaining KLK and 
SEMG association to hyperviscosity and asthenozoospermia phenotypes. This finding is 
concordant with a view of male infertility as a complex disease resulting from a complex 
network of genetic and non-genetic factors with a wide range of susceptibility effects. 
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Table 1 – Burden tests for KLK and WFDC low-frequency variants. 
  
Cases (HV+NV) 
vs. 
Controls 
HV Cases 
vs 
Controls 
NV Cases 
vs. 
Controls 
Nonsynonymous 
and splice region 
SNVs 
KLKs and 
WFDCs 
C-alpha = 50.9067 
(P-value = 0.0327) 
C-alpha = 30.7813 
(P-value = 0.0034) 
C-alpha = 22.9367 
(P-value = 0.0080) 
WFDCs  
C-alpha = 9.1536 
(P-value = 0.2872) 
C-alpha = -1.1391 
(P-value = 0.8730) 
C-alpha = 6.5306 
(P-value = 0.1536) 
KLKs  
C-alpha = 41.7530 
(P-value = 0.0106) 
C-alpha = 31.9205 
(P-value = 0.0001) 
C-alpha = 16.4061 
(P-value = 0.0066) 
UTR SNVs 
KLKs and 
WFDCs 
C-alpha = -11.0989 
(P-value = 0.5599) 
C-alpha = -2.0320 
(P-value = 0.8988) 
C-alpha = -9.2201 
(P-value = 0.5252) 
WFDCs 
C-alpha = 7.2740 
(P-value = 0.0696) 
C-alpha = 5.0348 
(P-value = 0.0654) 
C-alpha = 3.4013 
(P-value = 0.1822) 
KLKs 
C-alpha = -18.3729 
(P-value = 0.1808) 
C-alpha = -7.0668 
(P-value = 0.6191) 
C-alpha = -12.6214 
(P-value = 0.2766) 
     Significant P-values (P < 0.05) are underlined 
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Table 2 – Low-frequency variants surveyed in phase II. 
Gene SNP ID 
Genomic 
position 
(hg19) 
Consequence 
MAF 
(number of chromosome) 
    Control  
Cases 
(HV+NV) 
 
HV 
cases 
 
NV 
cases 
KLK3 rs182759459 51361469 p.E131K 0.000 
(0) 
 0.003   
(1) 
 0.000 
(0) 
 0.007 
(1) 
KLK3 rs61729813 51361850 p.S210W 0.013 
(2) 
 0.014   
(4) 
 0.020 
(3) 
 0.007 
(1) 
KLK3 rs111901464 51361879 intronic* 0.000 
(0) 
 0.010   
(3) 
 0.020 
(3) 
 0.000 
(0) 
KLK4 rs138071534 51412573 p.E53E 0.000 
(0) 
 0.003   
(1) 
 0.000 
(0) 
 0.007 
(1) 
KLK4 N/A 51412607 p.Q42L 0.000 
(0) 
 0.003   
(1) 
 0.000 
(0) 
 0.007 
(1) 
KLK4 N/A 51412717 intronic 0.000 
(0) 
 0.003   
(1) 
 0.007 
(1) 
 0.000 
(0) 
KLK4 N/A 51412740 intronic 0.000 
(0) 
 0.003   
(1) 
 0.007 
(1) 
 0.000 
(0) 
KLK6 rs77760094 51462454 p.T234M 0.000 
(0) 
 0.003   
(1) 
 0.007 
(1) 
 0.000 
(0) 
KLK6 N/A 51462508 p.I215N 0.013 
(2) 
 0.000   
(0) 
 0.000 
(0) 
 0.000 
(0) 
KLK8 rs74705037 51504808 5’UTR 0.006 
(1) 
 0.035 
(10) 
 0.033 
(5) 
 0.037 
(5) 
KLK12 rs140609488 51534048 p.C196Y 0.000 
(0) 
 0.003   
(1) 
 0.000 
(0) 
 0.007 
(1) 
KLK12 rs61742847 51537332 p.P34L 0.000 
(0) 
 0.010   
(3) 
 0.013 
(2) 
 0.007 
(1) 
KLK14 rs112658494 51582808 p.R138W 0.006 
(1) 
 0.028   
(8) 
 0.040 
(6) 
 0.015 
(2) 
KLK14 rs117229324 51585978 splice donor 0.006 
(1) 
 0.017   
(5) 
 0.007 
(1) 
 0.029 
(4) 
KLK15 rs3212852 51330129 splice region 0.013 
(2) 
 0.017   
(5) 
 0.027 
(4) 
 0.007 
(1) 
EPPIN rs75681320 44174847 intronic 0.013 
(2) 
 0.024   
(7) 
 0.040 
(6) 
 0.007 
(1) 
   * p.E220K predicted as damaging in a shorter isoform. N/A – Not applicable, novel variants without ID. 
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Figure 1 – Minor allele frequencies (MAFs) from 1000 Genomes data vs. controls from pooled 
sequencing. Allele frequency estimates for 277 SNVs based on pooled sequencing from the control group 
were compared with the described European average frequencies from 1000 Genomes project phase III 
samples. r2 - correlation coefficient (r2 = 0.826). 
 
 
 
Figure 2 – Minor allele frequencies (MAFs) from pooled sequencing vs. Sanger sequencing. Estimated 
MAFs based on pooled sequencing is plotted against the actual frequencies as determined by individual 
Sanger sequencing for the surveyed regions. r2 - correlation coefficients (HV: r2 = 0.9725; NV: r2 = 0.9695; 
controls: r2 = 0.9509). The data from HV cases, NV cases and controls are represented in orange, blue and 
green, respectively. 
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Figure 3 – Structural characterization of the KLK low-frequency variants. (A) Alignment of the amino acid 
sequences of the variant kallikreins. Variant sites are framed in red. Complete conservation is shown in dark 
blue background, whereas partial conservation is shown on a light blue background. The catalytic serine is 
highlighted with a red arrow. (B) Mapping of variant sites on a kallikrein structure. The overall structure is 
depicted as a green ribbon. Variant sites are shown as sticks. The catalytic triad and the second SS6 cysteine 
are shown as lines. 
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Figure 4 – Relative abundance of KLK3 p.S210W variant in seminal plasma. Spectral counts for p.S210W 
residue in two heterozygous (Het_1, Het_2) and of 33 homozygous (Hz) individuals. Total spectral counts are 
shown for Het_1 and Het_2 individuals, and the mean of spectral counts are displayed for Het_1+2 and Hz. 
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Natural selection is an important process by which populations adapt and evolve. 
Among the plethora of targets of natural selection, several classes of reproductive-related 
genes, including those encoding for seminal plasma proteins, were shown to be under 
positive selection and variable selective pressures within and between lineages (Jensen-
Seaman and Li 2003; Dorus et al. 2004; Clark and Swanson 2005; Hurle et al. 2007; 
Carnahan and Jensen-Seaman 2008; Ramm et al. 2008; Ferreira et al. 2013a; Ferreira et 
al. 2013b). Considering the importance of KLKs in many essential biological processes, 
especially in reproduction, this work aimed to elucidate the extent of natural selection on 
these genes, at inter and intra-specific level, and to uncover genetic variants with potential 
implications in health and disease. 
1. Evolutionary history of KLKs 
Gene duplication has long been recognized as a major source of raw genetic 
material for evolutionary innovation (Ohno 1970). According to the “birth-and-death” 
evolution hypothesis, new genes are generated by duplication and, while some are 
maintained in the genome by acquiring new and altered functions or differentiated spatial 
and temporal expression, others are deleted or become non-functional through disruptive 
mutations (Nei and Rooney 2005; Eirin-Lopez et al. 2012). This model is thought to be 
more common among genes underlying large variable physiological traits across species, 
such as those involved in sensory perception, immunity and reproduction. Indeed, the 
evolution of several reproductive-related genes was shown to be greatly marked by these 
processes (Tian et al. 2009). Two remarkable examples are found in genes encoding the 
zona pellucida (ZP) proteins, the extracellular matrix surrounding oocytes and in a 
transglutaminase (TGM4), which is recognized to be involved in the formation of semen 
coagulum and copulatory plugs in several primates and rodents species (Clark and 
Swanson 2005; Goudet et al. 2008; Tian et al. 2009). In both instances, several losses of 
ZP and TGM4 genes were found throughout the vertebrate evolution, whereas for ZP 
genes, it was hypothesized that these may be partially associated with the transition from 
an external to internal fertilization (from anamniotes to amniotes), for TGM4 these seemed 
to be related with lack of semen coagulation (opossum - Monodelphis domestica, cow- 
Bos Taurus, gibbon and gorilla).  
In the first part of this work, the evolution of KLK2 and KLK3, the most recent 
duplicates of the KLK cluster with known key roles in semen liquefaction, was addressed 
by analyzing a panel of 22 primate species (Paper I). Overall, the disclosed evolutionary 
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history of these two genes is consistent with the “birth-and-death” evolution model: (1) 
KLK3 was originated by a duplication of KLK2, an event that occurred after the Catarrhini 
split approximately 42 mya; (2) KLK3 functionally diverged from KLK2 mainly through the 
acquisition of a D207S substitution, which resulted in a change of the substrate affinity 
(trypsin- to chymotrypsin-like activity) and an extended spectrum of cleavage sites in 
SEMGs; and (3) KLK2 gene was inactivated in several species by different genomic 
mechanisms including gene deletion, pseudogenization and unequal crossing-over. The 
latter phenomenon was connected to independent events of KLK3-KLK2 gene fusion 
giving rise to chimeric KLKs (cKLK) in gorilla and northern white-cheeked gibbon 
(Nomascus leucogenys) (Paper I), which could be reconciled with previous reports of a 
partial KLK2 loss in gorilla and gibbon species (Clark and Swanson 2005). Given that, at 
protein level, these rearrangements account only for amino acid substitutions not 
predicted to affect KLK3 structure or function, it was advanced that these cKLKs were 
likely to be functionally active (Paper I). The analysis of the seminal plasma of these taxa 
could easily corroborate such hypothesis, however, the characterization of the ejaculate 
proteome of non-human primates is still restricted to a limited number of species, in which, 
unfortunately, gorilla and gibbon were not included (Claw 2013). Similarly, evidence of 
cKLK transcripts could indicate that, at least, these are transcribed, but the screening of 
KLK3 mRNA in prostate tissues from non-human primates also did not comprise the 
species in which these rearrangements occur (Mubiru et al. 2014). 
In the seminal proteins, adaptive evolution has been hypothesized to result from 
several major driving forces including sperm-egg recognition, male attempts to counteract 
the female immune response, host-pathogen interactions and post-copulatory selection 
(Clark and Swanson 2005; Ramm et al. 2008; Dorus et al. 2010; Findlay and Swanson 
2010). In the latter case, sperm competition has been recognized to affect several 
physiological and morphological traits in males, and its intensity to be highly correlated 
with mating behavior in primates (Harcourt et al. 1981; Dixson and Anderson 2002; 
Anderson et al. 2007; Dixson 2009). For example, multimale species exhibit larger testis 
relative to body size, higher sperm counts, bigger sperm midpiece volume, greater 
mitochondria load and prominent semen coagulation. Importantly, SEMGs have been 
previously identified as genes under adaptive evolution, in which their evolutionary rates 
and number of repeat units were found to correlate to different mating systems and to the 
rate of semen coagulation across several primate species (Jensen-Seaman and Li 2003; 
Dorus et al. 2004; Hurle et al. 2007). Notably, the number of functional KLKs was 
significantly associated with the content of SEMG repeats and primate mating systems 
(Paper I). On one hand, active KLK2 and KLK3 were correlated to higher SEMG repeat 
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numbers and a multimale mating behavior, whereas, on the other hand, the lack of one or 
both proteins was linked to lower repeat numbers and a unimale mating system, 
suggesting that the evolution of these two KLK genes might have been driven by 
reproductive biology, in a sperm competition manner and in a close relation to SEMGs. 
Consistently, a recent study centered in the evolution of 1170 seminal proteins detected 
an overrepresentation of pseudogenes within unimale lineages in comparison to multimale 
taxa (Claw 2013). In agreement with these findings, the loss of KLK2 in primates was 
more frequently observed in unimale than in multimale species (7 unimale and 2 
multimale) (Paper I). 
Recently, two studies aiming to estimate the evolutionary rates of seminal and non-
seminal proteins in hominoids, by the usage of comprehensive gene datasets, showed 
that the concept of reproductive genes as fast evolving genomic regions is indeed an 
oversimplification, since this broad category of genes tends to be under stronger selective 
pressures than those from non-reproductive tissues (Good et al. 2013; Carnahan-Craig 
and Jensen-Seaman 2014). Furthermore, the same authors also reported that in spite of 
some reproductive proteins being probable targets of adaptive evolution driven by sexual 
selection forces, in general, seminal proteins do not present faster evolutionary rates in 
species with strong sperm competition. Moreover, these authors also proposed that the 
evolutionary rates are more correlated to function and tissue specificity, rather than to the 
mating system (Good et al. 2013; Carnahan-Craig and Jensen-Seaman 2014). Still, the 
detection of post-copulatory selection may not be so straightforward due to the complexity 
of protein networks and proteolytic cascades, as illustrated by the results presented here 
for KLK2 and KLK3 (Paper I)(Fortelny et al. 2014). 
A possible role of KLKs in human adaptation is also plausible if one considers the 
coevolution of KLK2 and KLK3 with SEMGs in primates (Paper I) and a previously 
reported signature of natural selection for SEMG1 in Asian populations, which was 
correlated to an altered proteolytic profile and antimicrobial activities in semen (Ferreira et 
al. 2013b). Indeed, hallmarks of natural selection in the KLK2-KLK5 locus for East Asians 
were detected by three GWS of positive selection, based on distinct statistics and 
databases of human genetic variation, but those have remained unexplored (Voight et al. 
2006; Pickrell et al. 2009; Pybus et al. 2014). To better understand the evolutionary forces 
acting at the KLK3-KLK5 segment in East Asians, a comprehensive analysis of KLK 
genetic diversity in the region was carried out using mostly 1000G phase I data (Paper II). 
In general, the observed patterns of genetic diversity for KLK3-KLK5 region, as 
summarized by Tajima’s D, Fu and Li D* and Fay and Wu’s H statistics, suggested an 
excess of both low-frequency variants and high-frequency derived alleles in East Asians. 
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According to recent evidence, these results could simply be attributed to the explosive 
growth of human populations in the last 10,000 years, which is thought to have caused an 
increase of rare variants (Gravel et al. 2011; Keinan and Clark 2012). Nevertheless, the 
statistical significance obtained in the most updated models of Asian demography, already 
assuming a large population expansion, seems to favors a selective hypothesis (Laval et 
al. 2010; Gravel et al. 2011; Keinan and Clark 2012). 
Even though the KLK region could be associated to several statistical arguments for 
a non-neutral evolution, the selective footprints did not fit a standard selective sweep, as 
they were centered in a relatively short segment spanning from KLK2 to KLK5 (70 kb) 
and encompassing multiple recombination hotspots (Paper II). Such findings were not 
surprising given the current understanding of the field, which proposes classic selective 
sweeps as rare events in human evolution and the current patterns of human genetic 
diversity as an end product of milder selective events (soft sweeps or selection on 
standing variation) (Pritchard and Di Rienzo 2010; Pritchard et al. 2010; Hernandez et al. 
2011; Crisci and Jensen 2012; Granka et al. 2012). 
Moreover, recent investigations estimated that only ~0.5% of nonsynonymous 
substitutions have been targeted by natural selection in the last 250,000 years and many 
human adaptations are instead related to expression quantitative trait loci (eQTL) 
(Hernandez et al. 2011; Vernot et al. 2012; Grossman et al. 2013; Jha et al. 2015). In 
agreement with such assumption, none of the nonsynonymous SNPs at the KLK2-KLK5 
locus fitted a positive selection hypothesis and, likewise, the most promising candidate 
variants (rs1654556_G, rs198968_T and rs17800874_A) lay in putative regulatory regions 
in KLK4 and in the KLK4-KLK5 intergenic sequence (Paper II). These variants defined a 
common haplotype (GTA) in East Asians, which according to functional in vitro assays 
and in vivo data may downregulate KLK4 expression (Paper II)(GTEx-Consortium 2015). 
Remarkably, rs198968_T and rs17800874_A were shown to operate synergistically and to 
have a much higher effect than rs1654556_G in KLK4 expression, pointing out the former 
variants as the main KLK4 eQTLs where rs1654556_G might only play a minor 
contribution to gene downregulation.  
Although the GTA haplotype in other populations was only present at very low 
frequencies, or nearly absent, the three variants can be found outside Asia at intermediate 
haplotype configurations (GCA, GTG, GCG, ACA and ATG), which may suggests that the 
selected haplotype originated by recombination and then was swept to high frequencies 
only in East Asians (Figure 8). The recently released 1000G phase III data, which 
contains novel populations with South Asian, East Asian and African ancestries, as well 
as, more individual samples for the populations already screened in phase I, shows the 
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same discrepancies in allele and haplotype frequencies, further indicating the East Asian 
nature of the selective signature (Genomes Project et al. 2015). 
It is important to stress out that while rs1654556_G represents the ancestral allele 
state, variants rs198968_T and rs17800874_A are both derived alleles forms, and all of 
them might have been neutral before the emergence of the GTA haplotype, as indicated 
by their low frequencies in non-East Asian populations. Therefore, this may fit better a 
scenario of selection on standing variation (soft sweep), in which variants were already 
segregating in the population before the selective pressures had favored an increment in 
variant frequency (Hermisson and Pennings 2005; Przeworski et al. 2005; Pritchard and 
Di Rienzo 2010; Peter et al. 2012; Messer and Petrov 2013). 
 
 
 
Figure 8 – Worldwide estimated haplotype frequencies defined by rs1654556, rs198968 and 
rs17800874 according to 1000G phase III data for African, European, South Asia, East Asia and 
American populations. For each continental region the most common haplotypes are shown. In Africa the 
ancestral haplotype is also displayed. Ancestral and derived alleles are represented in blue and orange, 
respectively. 
 
 
As long as humans spread out of Africa they experienced a whole new set of 
climate variables and changes in food availability, which are likely to have dictated 
different subsistence strategies (Hancock et al. 2010a; Hancock et al. 2010b). In this 
regard, genetic variation already standing in populations may have played a prominent 
role in human evolutionary history since it would contribute to a faster adaptive response 
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to alterations in selective pressures. Indeed, such fast response patterns are observed in 
the case of artificial selection in maize (Innan and Kim 2004; Durand et al. 2010). 
A selective hypothesis associated with reproductive functions was considered at fist 
given that KLK4 has been also proposed to have a role in the proteolytic cascade of 
semen liquefaction and considering the reported importance of KLKs in the evolution of 
semen coagulation in primates (Paper I) (Takayama et al. 2001b). However, male 
physiological traits indicate that sperm competition is unlikely to have played a part in 
human evolution and these are rather consistent with a history of monogamy (unimale 
mating systems) (Dixson 2009). For example, in comparison with other mammals, 
humans have small testis relative to body size, longer spermatogenesis times, lower 
sperm cell counts and tinier spermatozoa midpieces. Furthermore, it was hypothesized 
that the reduced testis size observed in some modern Asian populations is not due to 
sperm competition, neither to changes in their mating system, but instead, are a by-
product of the selective forces acting on gonadal function in women to prevent multiple 
ovulation (Dixson 2009). Therefore, taking into account the traits known to have been 
targeted by natural selection in human populations and the possible implications of KLK4 
in these processes, two selective hypothesis related to tooth and epidermal features were 
advanced (Paper II). 
On one hand, the expression of KLK4 in some epidermal layers together with its 
ability to activate in vitro several molecules involved in important pathways of skin 
physiology, such as keratinization, melanosome transfer and skin desquamation, turned 
out to be an extremely attractive hypothesis (Seiberg et al. 2000; Komatsu et al. 2003; 
Babiarz-Magee et al. 2004; Komatsu et al. 2005; Matsumura et al. 2005; Becker-Pauly et 
al. 2007; Ramsay et al. 2008). Although, protein expression in skin is still a controversial 
issue and the KLK4 inactivation in amelogenesis imperfecta disease and mouse models 
does not seem to have major outcomes in epidermal phenotypes (Hart et al. 2004; 
Simmer et al. 2009; Wang et al. 2013). Nonetheless, it is important to note that skin as 
well as many human morphological traits, is thought to be polygenic, in which KLK4 may 
only contribute through a moderate effect and, hence, subtle changes in phenotypes 
might have remained undetected.  
On the other hand, KLK4 play an essential role in tooth maturation and accordingly, 
its disrupted activity result in enamel defects in humans and mice (Hart et al. 2004; 
Simmer et al. 2009; Wang et al. 2013). Additionally, KLK4 arose by a duplication of KLK5 
near the divergence of Boreoeutheria (e.g. primates, rodents and artiodactyls) and 
Afrotheria (e.g. elephant, hyrax and tenrec) lineages, where the latter taxonomic group 
presents a characteristic delayed in dental eruption (Kawasaki et al. 2014). Moreover, 
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KLK4 has been pseudogenized in toothless minke and bowhead whales (Balaenoptera 
acutorostrata and Balaena mysticetus, respectively), whereas in the toothed cetaceans 
(orca - Orcinus orca and bottlenose dolphin - Tursiops truncates) the gene remained intact 
(Kawasaki et al. 2014; Keane et al. 2015). In humans, and in East Asians in particular, it is 
possible to observe common dental variations, like upper central incisor shoveling, 
enamel extensions of the first maxillary molar and other dental traits, often designated as 
sinodonty, which can be partially associated with the genetic variation in EDAR, another 
gene showing footprints of positive selection in East Asians (Turner 1990; Hanihara and 
Ishida 2005; Sabeti et al. 2007; Hanihara 2008; Kimura et al. 2009; Kamberov et al. 
2013). 
For the reasons mentioned above, and bearing in mind that tooth morphologies are 
also likely a polygenic trait, KLK4 might represent yet another gene contributing to an 
adaptive tooth phenotype through a moderate effect. Still, the pervasive nature of KLK4, 
its wide pattern of tissue expression and the observed outcomes of selected variants in 
three different cellular systems, seem to suggest the existence of pleiotropic effects in 
other physiological functions, which may result in increased resistance or susceptibility to 
human disease. 
2. Implication of KLKs genetic variation in human health and disease 
Most, if not all, biological processes in humans comprise complex proteolytic 
networks, in which spatial and temporal alterations can lead to different disease states 
(Lopez-Otin and Bond 2008; Quesada et al. 2009). In this scope, the KLK gene family is 
no exception and despite the numerous studies performed already to understand the 
impact of KLKs in both normal and pathological conditions, significant pieces of 
information are still missing. For instance, from a clinical perspective, most of the literature 
has been focused on cancer risk, where KLK3 is by far the best studied member of the 
family, due to its early recognition as a biomarker for prostate cancer. Nevertheless, the 
recent development of diverse Klk mouse models (knockout, knock-in and transgenic) 
have shed light into the associations of each KLK with distinctive human disorders, such 
as amelogenesis imperfecta, atopic dermatitis, myocardial ischaemia, multiple sclerosis 
and schizophrenia (Ny and Egelrud 2004; Pons et al. 2008; Simmer et al. 2009; Smith et 
al. 2011; Tamura et al. 2012; Murakami et al. 2013; Furio et al. 2014). Nonetheless, the 
potential implications of KLK variation outside of malignancy remain largely unknown. 
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Hence, in-depth comprehensive surveys of the KLK locus within varied diseases, 
including male infertility, are fundamental. 
In a third work, the contribution of KLKs variability was explored in the framework of 
male infertility and three non-mutually exclusive phenotypes, hyperviscosity, 
asthenozoospermia and oligozoospermia, simultaneously with the study of their 
substrates and inhibitors, the SEMGs, EPPIN and EPPIN-like genes, all belonging to the 
WFDC family located at chromosome 20q13 (Paper III). 
Male infertility is considered a multifactorial disease with a strong genetic 
component, in which common variants may account with small increments into disease 
susceptibility (Carrell and Aston 2011). In this particular disorder, it is rather 
straightforward that strong deleterious alleles will be rapidly wipe out from extant human 
populations because of their negative impact in the reproductive fitness. Conversely, as 
mentioned earlier, as human populations have expanded many novel variants were 
originated and, due to their recent origins, they will still be segregating at low-frequencies 
in populations in spite of a possible influence in human fertility (codominant inheritance). 
Altogether, male infertility, or more precisely male subfertility, like other human complex 
disorders, can be considered as a consequence of a wide range of genetic variants with 
variable size effects into the different disease phenotypes (Aston and Carrell 2009; Aston 
et al. 2010; Carrell and Aston 2011; Lettre 2014). Specifically, in the case-control study of 
male infertility centered on the KLK and WFDC loci, the majority of identified candidate 
variants with potential serious effects in protein structure, activity and interactions, splicing 
processing and expression regulation were low-frequency variants, among which KLKs 
were overrepresented, suggesting a greater burden of these genes in male reproduction 
in comparison to WFDCs (Paper III). 
Among the recognized infertility phenotypes, delayed liquefaction, hyperviscosity 
and asthenozoospermia are the ones more probably correlated to a deregulated activity of 
KLKs and WFDCs in the semen, given that a small modification of the fine-tuned protein 
interactions in the semen might potentially interfere in its quality. Consistently, most KLKs 
have been previously described to be downregulated in individuals exhibiting the 
hyperviscosity phenotype (KLK1-2, KLK5-8, KLK10, KLK13-14) and a few KLKs were also 
found to display a significantly reduced protein expression in cases with delayed 
liquefaction (KLK2-3 and KLK13-14) (Emami et al. 2009). On the other hand, associations 
between abnormal sperm motility (asthenozoospermia) and KLK14 downregulation, 
SEMG1 augmented expression and the higher prevalence of EPPIN low-frequency 
variants were also reported (Martinez-Heredia et al. 2008; Emami et al. 2009; Ding et al. 
2010a; Ding et al. 2010b). In overview, the KLK and WFDC genetic variants identified in 
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Paper III comprised several SNVs possibly influencing the protein contents in the semen 
by mechanisms of abnormal protein and mRNA degradation (nonsynonymous 
substitutions and splice variants) or by gene misregulation (variants located in regulatory 
regions), which could in some instances relate to the reduced KLK levels already 
reported. Conversely, several other variants (nonsynonymous substitutions only) were 
found to likely affect important protein interactions in semen because of the insertion or 
removal of proteolysis cleavage sites, or even the substrate allowance in the protease 
catalytic pocket, all of them possibly connected to hyperviscosity and asthenozoospermia 
phenotypes. Furthermore, the distribution of these susceptibility markers across KLKs 
seems to suggest KLK3, KLK12 and KLK14 as the genes with greater impact in male 
fertility. 
Although a greater focus was given to nonsynonymous replacements and splice 
variants in the genotyping phases, mainly due to the reduced reliability of bioinformatics 
predictions for nucleotide substitutions located in transcription factor binding sites, the 
variants placed at coding regions may only explain a minor part of the genetic 
predisposition to male infertility (Paper III). Indeed, only a small fraction of the 456 
identified variants were nonsynonymous substitutions (12.7%; 9.6% low-frequency), which 
reinforces a possible contribution of gene regulation in the disease pathogenesis. This 
finding concurs with previous assumptions made for targets of natural selection, in which 
eQTLs are also thought to play a significant role in complex diseases by altering the gene 
expression timings and intensities (Epstein 2009; Nicolae et al. 2010; Bryois et al. 2014). 
In addition, it has been shown that common SNVs associated with complex traits are 
more likely to be eQTLs than nonsynonymous variants, in which the effect size is 
inversely correlated to allele frequency, in brief, the greater the allele frequency, the lower 
the contribution to the trait (Nicolae et al. 2010; Battle et al. 2014). 
Interestingly, for a common variant located KLK7 and a low-frequency CNV of 
SEMG1, both showing significant associations with male infertility, the ancestral alleles 
were the ones conferring an increased susceptibility to the disease. From an evolutionary 
perspective, this evidence fits well the “thrifty genotype” theory, which proposes alleles 
that were once beneficial in past human history, nowadays are less adapted to the 
environmental conditions of western societies (Neel 1962; Neel et al. 1998). Consistently, 
other complex disorders linked to this theory, like obesity and diabetes, are known to 
affect human fertility, as well as lifestyles habits such as smoking and alcohol 
consumption and tendency for parents having the first child at increased ages (Vine et al. 
1994; Sharpe and Franks 2002). 
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Finally, the semen is a complex body fluid known to be enriched in proteases and 
these have been established to have pervasive links with each other, their inhibitors and 
substrates (Pilch and Mann 2006; Batruch et al. 2011; Laflamme and Wolfner 2013; 
Fortelny et al. 2014). Therefore, it is attractive to speculate that some of these enzymes 
may have critical roles in the semen liquefaction profiling with possible functional 
repercussions in the spermatozoa abilities to fertilize the egg. Globally, these KLK and 
WFDC variants are far from explaining the genetic basis of male infertility, or even 
hyperviscosity or asthenozoospermia phenotypes, and only represent a minor proportion 
of its susceptibility and deleterious variation. In the near future, with the continuous 
decline of whole exome and genome sequencing costs, together with the advances in 
proteome technologies, new insights concerning the pathogenesis of male infertility will 
probably emerge with benefits in patient personalized medicine. 
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This work provides further support for an implication of proteolysis genes, 
specifically KLKs, as targets of adaptive evolution in primates through diverse biological 
functions including male reproduction and for a possible role of KLK sequence variation in 
both beneficial traits and disease phenotypes. 
 
1. It sustains the hypothesis that the evolution of KLK2 and KLK3 might have 
been driven by reproductive biology in a sperm competition manner. This study 
contributed not only to consolidate the origin of KLK3 in Catarrhini through an event of 
duplication and functional divergence from KLK2 towards a chymotrypsin-like activity and, 
consequently, an extended enzymatic spectrum over SEMG1 and SEMG2 cleavage, but 
also to unveil a complex dynamics of KLK2 and KLK3 evolution mediated by different 
genomic mechanisms of gene loss in a close correlation to SEMG gene structure, primate 
mating system and semen coagulation rates.  
 
2. It clarifies a signal of natural selection shaping the genetic diversity of the 
KLK cluster in Asian populations. A complex signature of positive selection was 
disclosed in East Asians favoring a haplotype defined by three variants (rs1654456_G, 
rs198968_T and rs17800874_A) acting synergistically to downregulate KLK4. A 
reasonable hypothesis is that this haplotype was driven to high frequencies in East Asians 
by offering a selective advantage into phenotypic traits characteristic of these populations, 
such as tooth shape and structure, and epidermal features. Still, due to the pervasive 
nature of KLK4, the possibility of pleiotropic effects in other physiological functions, 
including in reproductive biology, also exists and may result in an increased disease 
resistance or susceptibility. In a wider perspective, this study endorses the concept that 
soft sweeps and polygenic adaptation may actually be more common in human evolution 
than classic selective sweeps. 
 
3. It highlights several low-frequency variants at KLK and SEMG genes that 
may contribute to different male infertility phenotypes. An excess of low-frequency 
variants was observed for the KLK cluster but not for the WFDC locus and this burden 
was independent of the infertility phenotype considered. Among the most promising 
variants, two were found to overlap onto the protein structure in KLK3 (p.E131K) and in 
KLK14 (rs112658494, p.R138W). Furthermore, one variant in KLK12 (rs61742847, 
p.P34L) and another in SEMG1 (rs147894843, p.G400D) were significantly associated 
with semen hyperviscosity and asthenozoospermia, respectively. In addition, a common 
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intronic variant in KLK7 (rs1654526) and the copy number variation embracing one of the 
repeat units in SEMG1 were connected to a protective role against hyperviscosity and 
oligozoospermia, respectively. Nevertheless, the identified candidate variants are 
expected to only play a part in the genetic background of male infertility, given that they 
were always found in heterozygosity and that KLKs often overlap in substrate affinity. 
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Table S1 – General features of comparative sequence data set. 
Species Na Sequence Origin 
Homo sapiens (Hsa) 1 GRCh37 NM_005551 (KLK2)  
1 GRCh37 NM_001648 (KLK3)  
Pan troglodytes (Ptr) 1 CGSC 2.1.3/panTro3 
(chr19:55720749-56012427) 
Yerkes Primate Research 
Center in Atlanta, GA, USA 
2 ECACCb cell line EB176 (JC)  
Pan paniscus (Ppa) 1 AJFE01043435.1  
Gorilla gorilla (Ggo) 1 gorGor3.1/ gorGor3 
(chr19:48160184-48948382) 
Western Lowland 
2 ECACCb cell line EB (JC)  
4 Our study Lisbon Zoo 
Pongo pygmaeus (Ppy) 1 WUGSC 2.0.2/ponAbe2 
(chr19:52377104-52721866) 
Gladys Porter Zoo in Brownsville 
2 ECACCb cell line EB185 (JC)  
1 AC214871 BAC PAC resources 
bacpac.chori.org 
Macaca mulatta (Mmu) 1 MGSC Merged 1.0/rheMac2 
(chr19:57001913-57290885) 
 
Macaca fascicularis (Mfa) 2 ECACCb cell line CYNOM-K1  
Macaca fuscata (Mfu) 30 Our study Lisbon Zoo 
Saimiri boliviensis (Sbo) 1 AC199261 BAC PAC resources 
bacpac.chori.org 
Saguinus oedipus (Soe) 1 AY556462  
Callithrix jacchus (Cja) 1 WUGSC 3.2/calJac3 
(chr22:42634463-43227966) 
Southwestern National Primate 
Research Center in San 
Antonio, TX, USA 
Nomascus leucogenys (Nle) 1 AC198555 BAC PAC resources 
bacpac.chori.org 
Hylobates sp. 2 ECACCb cell line MLA144  
 8 Our study Lisbon Zoo 
Papio anubis (Pan) 1 AC157440 BAC PAC resources 
bacpac.chori.org 
Chlorocebus aethiops (Cae) 1 AC207140 BAC PAC resources 
bacpac.chori.org 
Colobus guereza (Cgu) 1 AC153315 BAC PAC resources 
bacpac.chori.org 
Aotus nancymaae (Ana) 1 AC153312 BAC PAC resources 
bacpac.chori.org 
Callicebus moloch (Cmo) 1 AC204813 BAC PAC resources 
bacpac.chori.org 
Ateles geoffroyi (Age) 1 AC225682 BAC PAC resources 
bacpac.chori.org 
Eulemur macaco (Ema) 1 AC198556 BAC PAC resources 
bacpac.chori.org 
Lemur catta (Lca) 1 AC153325 BAC PAC resources 
bacpac.chori.org 
Otolemur garnettii (Oga) 1 AC153738 BAC PAC resources 
bacpac.chori.org 
a N – sequence (chromosome) number 
b European Collection of Cell Cultures 
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Table S2 – KLKs, SEMGs and sperm competition. 
Species Functional 
KLK number 
Repeat Unitsa Mating 
Systemb 
Residual 
testis 
sizec 
Semen 
coagulation 
ratingd 
SEMG1 SEMG2 Total 
Hsa  2 6 8 14 UM -0.251 2 
Ptr  2 11 5 16 MM 0.326 4 
Ppa 2 9 8 17 MM 0.430 4 
Ggo 1 5 6 11 UM -0.622 2 
Ppy 2 13 8 21 MM -0.335 3 
Nle. 1 6 8 14 UM unknown 2 
Hylobates sp. 1 3 7 10 UM -0.471 2 
Mmu 1 4 10 14 MM 0.320 3 
Pan 1 11 4 15 MM 0.279 3 
Cae 2 7 14 21 MM 0.238  
Cgu 0 8 10 18 UM 0.272  
Cja 0 5 6 11 UM -0.366 2 
Saguinus sp. 0 9 - 9 amb -0.355 2 
Saimiri sp. 1 10 - 10 MM 0.204  
Aotus sp. 0 - 6 6 UM -1.066 2 
Lca 1 - 7 7 MM 0.222 4 
Callicebus sp. 0 7 6 13 UM -0.114  
a Expected repeat units number of SEMGs protein (Jensen-Seaman and Li 2003; Hurle et al. 2007). 
b Consensus mating system (Wlasiuk and Nachman 2010). 
c Combined data from adult males (Anderson et al. 2004; Dixson and Anderson 2004; Wlasiuk and 
Nachman 2010).  
d Semen coagulation is rated on a four-point scale (Dixson and Anderson 2002), with 1 reflecting no 
coagulation and 4 reflecting the production of a solid copulatory plug. 
UM – Unimale or monoandrous 
MM – Multimale or polyandrous 
Amb - ambiguous 
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Figure S1 - KLK3-KLK2 gene fusion event in Gorilla gorilla, Nomascus leucogenys and Hylobates sp. 
Schematic representation of G. gorilla (A) or N. leucogenys (B) genomic sequence alignments with the Homo 
sapiens reference sequence (KLK3 to KLK4). BlastN hits are represented as boxes joined with a line. Lighter 
lines indicate a non-optimal hit in one of the regions. Insertions and deletions cause a lack of correspondence 
between sequences. (C) Gene fusion event confirmed in G. gorilla and Hylobates sp. by PCR assay with 
gene- specific primers for KLK3 (exon 4) and for KLK2 (exon 5). The gene fusion product was confirmed in 
both species by sequencing of the resulting amplicons. 
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Figure S2 - Genomic sequence alignments of the orthologous genomic fragment spanning KLK1to KLK4 in 
Colobus guereza and Homo sapiens (green and red, respectively).  BlastN hits are represented as boxes 
joined with a line. Lighter lines indicate a non-optimal hit in one of the species. Insertions and deletions cause 
lack of correspondence between sequences. 
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Figure S3 – KLK2 protein alignment identifying deleterious mutations. ( ) Start codon; ( ) Catalytic triad 
residues; ( ) Activation site; ( ) Frameshift; ( ) Premature STOP codons; (?) Missing data. 
 
  
Hsa ------MWDL VLSIALSVGC TGAVPLIQSR IVGGWECEKH SQPWQVAVYS HGWAHCGGVL VHPQWVLTAA HCLK---KNS QVWLGRHNLF EPEDTGQRVP  [91]
Ptr ------.... .F........ .......... .......... .......... .......... .......... ....---... .......... ..........  
Ppa ------.... .F........ .......... .......... .......... ....Y..... .......... ....---... .......... ..........  
Ppy ------..V. ..F...P... ...A...... .......... .....A.... .......... .......... ....---... .......... ..........  
Mmu ------..V. ..F....... ...G....A. .......... .....A.... .......... .......... ....---... .....W.... ........A.  
Mfu ------..V. ..F....... ...G....A. .......... .....A.... .......... .......... ....---... .......... ........A.  
Mfa ------..V. ..F....... ...G....A. .......... .....A.... .......... .L........ ....---... .......... ........A.  
Pan ------..V. ..F....... .......... .......... .....A.... .......... .......... ....---... .......... .S......A.  
Cae ------..V. ..F....... .......... .......... .....A.... .......... .Y........ ....---... .....W.... ..........  
Soe MDTCVSIRF. ....T.C..S ...A...... .......... .......... .......... M......... ..R.---??? ?...R....S .......SI.  
Cja MDTCVSIRF. ....T....F ...E...... .......... F......... .E*....... .......... ..R.---E.. .F...W.... .......SI.  
Sbo ------.RL. I...T....S ...A...... .......... .......... .......... .......... ..R.---E.. .......... .......SI.  
Cmo MDTCVSLQF. ....T....S .......... T.......R. .......... .......... .........D ..R.---E.. .I........ .......SI.  
Age ------..F. ....T....S .......... .......... .......... .......... .......... ..I.---E.. .......... .T.....SI.  
Lca ------???? ?????????? ??.A...... V.......N. ........IR ..F.Q..... .......... ..IS---R.. .......S.R KH.....V.T  
Ema ------..F. .F.LT..LEW ..VA...... V.......N. ........TR ..FTQ..... .......... ..IS---R.. .....W...R KH.....V.T  
Oga ------.LF. .F.LT..M.W ....T.T... ........R. ....H.G.TQ ..F.Y...I. .......... ..SIYTGNTG .......M.S .D...A.VIK  
Hsa VSHSFPHPLY NMSLLKHQSL RPDEDSSHDL MLLRLSEPAK ITDVVKVLGL PTQEPALGTT CYASGWGSIE PEEFLRPRSL QCVSLHLLSN DMCARAYSEK  [191]
Ptr .......... .......R.. .......... .......... ...A...... .......... .......... .......K.. .......... ..........  
Ppa .......... .......R.. .......... ...H...... ...A...... .......... .......... .......K.. .......... ..........  
Ppy ......Y... ......RR.. .......... .......... ...A...... .......... .........Q .......K.. .......... ..........  
Mmu .......... ......R*.. .......... .......... ...A...... .......... .........Q .K.....K.. ...N...... ....G.....  
Mfu .......... ......RR.. .......... .......... ...A...... .......... .........Q .K.....K.. ...N...... .T..G.....  
Mfa .......... ......RR.. .......... .......... ...A...... .......... .........Q .K.....K.. ...N...... ....G.....  
Pan .......... ......RR.. .......... .....L.S.. ...A...... .......... .........Q .K.....K.. ...N...... G...G.....  
Cae .......... ......RR.. .......... .......... ...A...... ......P... .........Q .K.....K.. .......... ....G.....  
Soe .......... .......... S...N..C.. ...H.L.... ...T...... .A........ ..P......Q .K.L.H.K.. .Y..F..F.. ..........  
Cja .......... .......... S...N..L.. ...S.L.... ...T...... .......... ..P......Q .K.L.H.K.. .Y..F.---- --VCQSLL*E  
Sbo .......... .........F S...NY.... .....L.... ...A...... ..R....... ...A.....Q .K...H.K.. .......F.. ..........  
Cmo ..R.L...V. .......... S...N..... .Q...L...T ...A..I... .......... .........Q .....H.K.. .......F.. .V.QSLR*.S  
Age .......... .V.....R.. S...N..... .....L.... ...A..I... .......... .........Q .K...H.K.. .......F.. .V......K.  
Lca .NR.....H. .....GR.VF G..D.....I ...H..N... ...S....D. ..R..EV.S. .........Q .KK....EA. ...D.E.... .K.EE..Y..  
Ema .NR.....H. .....E..VF G..D.....I ...H..N... ...S....D. .....EV.S. .........Q .KK....ET. ...D.E.... .K.EE..Y..  
Oga INQT.L..R. .T.H...KT. EKS......I ...H.....N ...A...VD. .....EV.SI ..T......H .DN.V..... ...DII.... .R.KE..T.A  
Hsa VTEFMLCAGL WTGGKDTCGG DSGGPLVCNG VLQGITSWGP EPCALPEKPA VYTKVVHYRK WIKDTIAANP *--------- ---------- ---------- [262]
Ptr .......... .......... .......... .......... .......... .......... .......... .--------- ---------- ----------
Ppa .......... .......... .......... .......... .......... .......... .......... .--------- ---------- ----------
Ppy .......... .......... .......... .......... .......... ........Q. ......S... .--------- ---------- ----------
Mmu ..A....... .......... .......... .......... .......... ........W. ......T... RVPPSYPYL* ---------- ----------
Mfu ..A....... .......... .......... .......... .......... ........W. .......... RVPPSYPYL* ---------- ----------
Mfa ..A....... .......... .......... .......... .......... ........W. .......... RVPPSYPYL* ---------- ----------
Pan ..A....... .......... .......... .......... .......... .....SALPE VDQGHHRSQ. LSAPVLPLPL VDLSPPHVLA SLGLSGCWTP  
Cae ..A....... .......... .......... .......... .S........ .......... .......... .--------- ---------- ----------
Soe ....V..... ........?. .T........ .....S.... .........G ..I.....*. ......M..L .--------- ---------- ----------
Cja GDRVHVVCWA LDRR.RHLQ. *FW.STCL*W CASRYHVM.S *AMCPA*.AW CVHQGGALPE VDQQHHHGQ. L?-------- ---------- ----------
Sbo ....L..... ........K. .......... .......... D........G ......R... ......V..L RVPLSHPYLQ *--------- ----------
Cmo DRVHVV.WA. DRRKRHL*.* FW.STCL*WC ASRYHVMRP* AM.PA*KAWC .HQGGALPEV DQGHHHGQPL ?--------- ---------- ----------
Age .......... ...R....E. ......I... ..H....... K........G M......... ......V..L .--------- ---------- ----------
Lca .........H .D.K....S. ......I... M...L....T Q...K.Q... L...LWT.QE .......... .--------- ---------- ----------
Ema .........H .D.K....S. ......I... M...L....S Q...K.R... L...LWT.QE .......T.. .--------- ---------- ----------
Oga .........S .N......L. ......I... T........S K....RQ... L...LW..L. ..NE..T..L .--------- ---------- ----------
Hsa ---------- ---------- ---------- ---------- ------ [337]
Ptr ---------- ---------- ---------- ---------- ------
Ppa ---------- ---------- ---------- ---------- ------
Ppy ---------- ---------- ---------- ---------- ------
Mmu ---------- ---------- ---------- ---------- ------
Mfu ---------- ---------- ---------- ---------- ------
Mfa ---------- ---------- ---------- ---------- ------
Pan EAWNSPGQSL SLLSPTDLCS LVWIPGLLGK GMGRHRCRPV FLKFV* 
Cae ---------- ---------- ---------- ---------- ------
Soe ---------- ---------- ---------- ---------- ------
Cja ---------- ---------- ---------- ---------- ------
Sbo ---------- ---------- ---------- ---------- ------
Cmo ---------- ---------- ---------- ---------- ------
Age ---------- ---------- ---------- ---------- ------
Lca ---------- ---------- ---------- ---------- ------
Ema ---------- ---------- ---------- ---------- ------
Oga ---------- ---------- ---------- ---------- ------
Appendices | Appendix A 
 
152 
    A.               B. 
 
Figure S4 – Evolution of primate KLK2 and KLK3 related to reproductive traits. A) Correlation between the 
presence of functional KLK2 and KLK3 with semen coagulation rating. Semen coagulation is rated on a four-
point scale (Dixson and Anderson 2002), with 1 reflecting no coagulation and 4 reflecting the production of a 
solid copulatory plug. B) Correlation of residual testis size (Anderson et al. 2004; Dixson and Anderson 2004; 
Wlasiuk and Nachman 2010) with the presence of functional KLK2 and KLK3. 
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Supplementary Table S1 – Neutrality statistics data presented as –log10 of empirical ranked scores 
from 1000 Genomes Selection Browser (http://hsb.upf.edu/) for chr19:51353000-51461000 
(GRCh37/hg19) region. 
 
Due to the large size of the table this data is provided in digital format (Supplementary Tables – Paper II).  
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Supplementary Table S2 – Nonsynonymous and nonsense SNPs identified for the KLK3-KLK5 
segment in the 1000G data. 
SNP ID Protein Frequency Residue SIFT Polyphen 
    ASN CEU YRI       
rs61752561 
KLK3 
0 0.035 0 D102N Tolerated Benign 
rs61750343 0 0 0.006 R125C Deleterious Possibly damaging 
rs182759459 0 0.006 0 E131K Tolerated Benign 
rs2003783 0.094 0.106 0.136 L132I Tolerated Benign 
rs17632542 0 0.112 0 I179T Deleterious Benign 
rs61729813 0 0.035 0 S210W Deleterious Benign 
rs149376489 0.003 0 0 R250Q Tolerated Benign 
rs74478031 
KLK2 
0 0 0.011 Q22R Deleterious Possibly damaging 
rs139063242 0 0.006 0 G52D Deleterious Probably damaging 
rs181308768 0 0.006 0 S93R Tolerated Benign 
rs140321127 0.003 0 0 K245N Tolerated Possibly damaging 
rs198977 0.185 0.276 0.477 R250W Tolerated Benign 
rs60268688 0 0 0.091 D255A Deleterious Benign 
rs202006058 
KLK4 
0.003 0 0 G209E Deleterious Probably damaging 
rs2569527 0 0.006 0 Q197H Deleterious Benign 
rs34626614 0 0 0.074 G159D Tolerated Possibly damaging 
rs104894704 0 0 0.011 W153* - - 
rs182706497 0 0.012 0 R104Q Tolerated Benign 
rs145560168 0 0.006 0 G80R Tolerated Possibly damaging 
rs1654551 0.094 0.071 0.307 S22A Tolerated Benign 
rs146723372 
KLK5 
0 0 0.006 R268Q Tolerated Benign 
rs2232534 0 0.006 0 I172V Tolerated Benign 
rs200140569 0.003 0 0 R164H Tolerated Benign 
rs117067639 0 0.006 0 R117H Tolerated Probably damaging 
rs201524467 0.003 0 0 P79L Deleterious Probably damaging 
rs2232532 0 0.006 0 G55R Tolerated Benign 
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Supplementary Table S4 – Sanger sequenced regions and HapMap Phase I/II samples. 
Gene Region (GRCh37/hg19) 
KLK3 
chr19: 51358238-51358859 
chr19: 51359064-51359988 
chr19: 51360882-51361876 
chr19: 51362745-51363368 
KLK2 
chr19: 51376708-51376823 
chr19: 51377493-51378534 
chr19: 51379488-51380823 
chr19: 51381126-51381811 
KLKP1 
chr19: 51385330-51385955 
chr19: 51391176-51392415 
chr19: 51397905-51399140 
KLK4 
chr19: 51409600-51409874 
chr19: 51410019-51410450 
chr19: 51411434-51413535 
chr19: 51413604-51414080 
KLK5 
chr19: 51446559-51447226 
chr19: 51451645-51452580 
chr19: 51451427-5145770 
chr19: 51453387-51456344 
Population Sample ID 
CHB (15) 
NA18532, NA18537, NA18545, NA18547, NA18562, NA18563, NA18572, NA18573, 
NA18576, NA18577, NA18579, NA18593, NA18603, NA18611, NA18623 
JPT (15) 
NA18940, NA18943, NA18944, NA18947, NA18949, NA18951, NA18952, NA18956, 
NA18959, NA18968, NA18974, NA18978, NA18994, NA19000, NA19012 
CEU (10) 
NA11830, NA11995, NA12006, NA12144, NA12249, NA12716, NA12751, NA12812, 
NA12814, NA12873 
YRI (11) 
NA18522, NA18853, NA18861, NA18871, NA19102, NA19138, NA19160, NA19171, 
NA19209, NA19093, NA19207 
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Supplementary Table S5 – Variants not detected by the 1000G project phase I. 
Chromosome 
Chromosome Position 
(GRCh37/hg19) 
SNP ID Gene Population 
19 51380601  rs8105211  KLK2 ASN; CEU; YRI 
19 51380814 - KLK2 ASN 
19 51381276 - KLK2 ASN 
19 51391651 - KLKP1 ASN 
19 51409860 - KLK4 CEU 
19 51409977-51410044 esv1633192 KLK4 ASN; CEU; YRI 
19 51412263 - KLK4 YRI 
19 51412321 - KLK4 YRI 
19 51412418 - KLK4 ASN 
19 51412882 - KLK4 ASN 
19 51413871 - KLK4 YRI 
19 51455406 - KLK5 ASN 
19 51456172 rs79633852  KLK5 ASN; CEU; YRI 
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Supplementary Table S7 – iHS statistic for the 70 kb target region (chr19:51378273-51451045) in the 
ASN population. 
Chromosome 
Position 
(GRCh37/hg19) 
SNP ID Standardized |iHS|                       
19 51378725 rs1506685 0.760826 
19 51378986 rs198971 0.320343 
19 51379131 rs10403133 0.24359 
19 51379556 rs11549920 1.35274 
19 51379893 rs198972 1.32091 
19 51380110 rs6070 0.993009 
19 51380445 rs8105275 0.98984 
19 51380602 rs198974 0.473825 
19 51380815 rs198975 0.473825 
19 51381083 rs8108845 1.02074 
19 51381126 rs198976 0.473668 
19 51381777 rs198977 1.16083 
19 51383072 rs198978 0.604843 
19 51385253 rs16987929 1.2164 
19 51385402 rs8103659 1.21537 
19 51388878 rs198958 0.700013 
19 51389560 rs198957 0.495414 
19 51390353 rs198956 0.497751 
19 51390809 rs7256586 1.03071 
19 51393118 rs1354774 1.15457 
19 51393390 rs75380847 0.477157 
19 51394286 rs2739482 0.629016 
19 51396211 rs2739486 1.28641 
19 51396580 rs998771 0.749558 
19 51396922 rs61044983 1.31645 
19 51397182 rs2659112 0.750004 
19 51398071 rs8105985 1.38211 
19 51398841 rs59618192 1.3406 
19 51398888 rs1629856 0.880632 
19 51400676 rs2739493 0.996974 
19 51400812 rs2659107 1.55457 
19 51400836 rs1560719 0.867248 
19 51401807 rs3875143 1.50944 
19 51402682 rs1654513 1.23174 
19 51404513 rs2569536 2.18027 
19 51405475 rs2739496 1.2985 
19 51405982 rs806019 1.97009 
19 51406129 rs11881354 1.47197 
19 51406153 rs11881373 1.38777 
19 51406201 rs7507565 1.58032 
19 51406531 rs1090649 1.74605 
19 51406618 rs2569531 2.17343 
19 51407098 rs2739497 2.49244 
19 51407293 rs56352322 2.49459 
19 51407925 rs1701925 2.58113 
19 51408758 rs1701926 1.6866 
19 51408842 rs1701927 1.74944 
19 51409763 rs1139132 2.15163 
19 51409803 rs1654556 2.52879 
19 51409876 rs12150961 2.10599 
19 51410471 rs2235091 1.86394 
19 51410772 rs1654554 1.68539 
19 51411116 rs1654553 1.68134 
19 51411329 rs1701929 2.83352 
19 51411388 rs2979451 1.6505 
19 51412122 rs117475014 0.124992 
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19 51412315 rs2242670 1.00889 
19 51412326 rs2978643 2.0562 
19 51412666 rs1654552 0.903704 
19 51412668 rs1654551 1.06305 
19 51413328 rs198968 1.71822 
19 51413790 rs2242669 1.67238 
19 51413802 rs198969 1.17784 
19 51413906 rs2978642 1.69997 
19 51414965 rs2979452 1.65573 
19 51415150 rs2664152 1.54864 
19 51415252 rs2664153 1.7979 
19 51415515 rs118154507 1.08702 
19 51418250 rs55700942 1.50025 
19 51419062 rs2659077 0.918785 
19 51419546 rs1701930 1.55512 
19 51419669 rs1701931 1.55512 
19 51419694 rs1701932 1.46185 
19 51420025 rs1701933 1.46108 
19 51420119 rs34225434 1.46108 
19 51420319 rs78378001 1.00843 
19 51420820 rs2659078 0.886996 
19 51420996 rs62113140 1.46113 
19 51421056 rs56311033 1.46113 
19 51421096 rs10401284 1.42221 
19 51421172 rs10425823 1.51356 
19 51421255 rs55933733 1.61608 
19 51421491 rs2659079 1.5121 
19 51421833 rs62113142 1.5218 
19 51421883 rs10419776 0.412897 
19 51421979 rs10420003 0.987229 
19 51422216 rs268923 1.49214 
19 51422616 rs268922 1.25062 
19 51422658 rs73598979 1.00856 
19 51422691 rs268921 1.38611 
19 51422694 rs75883262 1.01105 
19 51422877 rs10427094 1.07727 
19 51423231 rs10401844 1.7027 
19 51423272 rs10403448 2.4497 
19 51423360 rs10403688 2.62828 
19 51423383 rs10402459 1.64671 
19 51423391 rs10402465 1.64671 
19 51423546 rs8100631 1.37185 
19 51423628 rs8101572 1.28299 
19 51424075 rs1532904 2.18817 
19 51424078 rs1532903 1.41785 
19 51424110 rs1532902 1.41785 
19 51424126 rs6509501 1.41001 
19 51424383 rs8104307 1.57298 
19 51424425 rs268919 0.812089 
19 51424448 rs8104644 1.38862 
19 51424484 rs8104329 2.16171 
19 51424607 rs138684768 0.0233301 
19 51424651 rs117837287 1.13183 
19 51424854 rs268917 1.43946 
19 51424890 rs870361 2.23027 
19 51425404 rs7254626 2.49066 
19 51425614 rs7255201 1.68072 
19 51426253 rs7258794 1.33302 
19 51427332 rs116958492 0.866571 
19 51427885 rs17727736 0.589067 
19 51428729 rs112561158 0.861658 
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19 51428793 rs113141458 0.590272 
19 51428914 rs113485158 0.0157743 
19 51429512 rs17800825 0.553558 
19 51429589 rs8111289 2.30832 
19 51429596 rs8110335 1.84862 
19 51429766 rs8111539 2.2872 
19 51429883 rs8113547 1.77494 
19 51429959 rs8100471 2.28275 
19 51430277 rs11665937 2.25353 
19 51430285 rs4802759 2.25353 
19 51430853 rs12461743 0.409778 
19 51431159 rs1865069 1.66187 
19 51431447 rs7250053 1.66187 
19 51431516 rs7250378 1.76855 
19 51431836 rs7255268 1.08365 
19 51431860 rs6509503 1.08365 
19 51431895 rs6509504 1.08365 
19 51431906 rs6509505 1.70436 
19 51432054 rs6509506 1.70436 
19 51432547 rs73600813 0.491551 
19 51432717 rs113870369 0.0829882 
19 51433003 rs2659081 0.466229 
19 51433046 rs2739400 0.571263 
19 51433048 rs2739401 0.571263 
19 51433092 rs2739402 0.00324212 
19 51433234 rs117145941 0.38612 
19 51433803 rs8099967 1.3272 
19 51433910 rs1654548 0.353653 
19 51433915 rs1701905 0.220944 
19 51434270 rs2472258 0.220755 
19 51434353 rs2456586 1.81066 
19 51434398 rs79966016 0.383806 
19 51434627 rs1654546 0.190778 
19 51434783 rs17800874 1.26907 
19 51435101 rs115458416 0.253172 
19 51435131 rs114406218 0.253172 
19 51435261 rs111504285 0.321438 
19 51435281 rs2569524 0.253172 
19 51435299 rs16988270 0.987032 
19 51435437 rs77202994 0.124606 
19 51436255 rs1701910 0.309952 
19 51436940 rs75024748 0.264681 
19 51437537 rs149622538 0.264681 
19 51437776 rs6509507 0.993766 
19 51438178 rs12459790 0.26041 
19 51439359 rs12460497 0.256661 
19 51439564 rs9304706 0.256661 
19 51439569 rs10164366 0.256661 
19 51440217 rs10401225 1.40799 
19 51440560 rs1701942 1.77283 
19 51440564 rs1701943 2.38079 
19 51440632 rs144230446 0.324326 
19 51440658 rs8113756 1.44562 
19 51440662 rs8113484 1.44562 
19 51441046 rs150986447 0.231681 
19 51441058 rs8102743 0.614044 
19 51441071 rs146825647 0.55102 
19 51441268 rs112062248 1.86888 
19 51441759 rs11084040 2.09146 
19 51441807 rs8104441 1.33381 
19 51441915 rs73932685 0.612944 
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19 51442108 rs6509508 1.60735 
19 51442397 rs77522061 0.653359 
19 51442699 rs268914 0.666325 
19 51443194 rs268913 0.676822 
19 51444467 rs1812619 1.5598 
19 51445723 rs62115181 1.53669 
19 51446123 rs2739408 1.46314 
19 51446246 rs2739409 0.875525 
19 51446273 rs145620611 0.875525 
19 51446327 rs2659090 1.70395 
19 51446660 rs2659092 0.30144 
19 51447065 rs1701949 1.74769 
19 51447954 rs1897604 2.36264 
19 51448182 rs12979210 1.69198 
19 51448185 rs4802761 0.944289 
19 51448685 rs12462803 0.826378 
19 51448904 rs12463293 2.20184 
19 51449566 rs55924070 1.55023 
19 51449664 rs268909 1.61505 
19 51449806 rs268908 1.00229 
19 51449901 rs268907 1.75459 
19 51449964 rs268906 1.50565 
19 51449969 rs12459543 0.974763 
19 51450534 rs10409028 1.03567 
19 51450929 rs268905 1.22115 
19 51451043 rs2411333 0.84265 
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Supplementary Table S8 – DIND statistic for the 70 kb target region (chr19:51378273-51451045) in the 
ASN population. 
DAF - derived allele frequency; iπA - ancestral intra-allelic nucleotide diversity; iπD - derived intra-allelic nucleotide diversity. 
Chromosome 
Position 
(GRCh37/hg19) 
SNP ID DAF iπA iπD iπA/iπD 
19 51378273 rs62113074 0.024 52.55 12.78 4.11 
19 51378725 rs1506685 0.129 52.33 46.60 1.12 
19 51378782 rs139053005 0.005 51.88 6.00 8.65 
19 51378821 rs2664158 0.035 52.46 25.82 2.03 
19 51378883 rs189213221 0.005 51.37 159.00 0.32 
19 51378884 rs2664159 0.027 52.28 27.07 1.93 
19 51378986 rs198971 0.591 56.44 47.53 1.19 
19 51379010 rs143718354 0.003 51.87 0.00 NA 
19 51379041 rs113183318 0.040 52.56 25.64 2.05 
19 51379042 rs111859906 0.046 51.55 53.22 0.97 
19 51379131 rs10403133 0.403 46.65 57.60 0.81 
19 51379255 rs138807230 0.003 51.27 0.00 NA 
19 51379257 rs78379394 0.003 51.86 0.00 NA 
19 51379556 rs11549920 0.073 50.35 55.58 0.91 
19 51379806 rs199554707 0.003 51.79 0.00 NA 
19 51379893 rs198972 0.288 33.91 73.01 0.46 
19 51380110 rs6070 0.215 33.61 74.19 0.45 
19 51380124 rs6071 0.013 52.14 11.40 4.57 
19 51380364 rs34964828 0.011 51.92 24.50 2.12 
19 51380445 rs8105275 0.212 34.90 70.33 0.50 
19 51380602 rs198974 0.780 74.37 32.69 2.28 
19 51380815 rs198975 0.780 74.37 32.69 2.28 
19 51380903 rs190951085 0.003 51.85 0.00 NA 
19 51381083 rs8108845 0.215 34.31 71.25 0.48 
19 51381126 rs198976 0.780 74.37 32.69 2.28 
19 51381392 rs145123696 0.003 51.88 0.00 NA 
19 51381764 rs140321127 0.003 51.84 0.00 NA 
19 51381777 rs198977 0.185 34.45 69.25 0.50 
19 51382351 rs141318172 0.005 51.89 26.00 2.00 
19 51382393 rs145052361 0.008 52.07 3.33 15.62 
19 51382797 rs183546409 0.003 51.52 0.00 NA 
19 51382882 rs143825608 0.003 51.85 0.00 NA 
19 51382949 rs148175263 0.011 52.03 14.17 3.67 
19 51383072 rs198978 0.806 73.73 32.30 2.28 
19 51383149 rs193241860 0.003 51.70 0.00 NA 
19 51383350 rs187930 0.005 50.72 119.00 0.43 
19 51383826 rs150678087 0.003 51.86 0.00 NA 
19 51384180 rs198979 0.995 119.00 50.72 2.35 
19 51384460 rs2664143 0.995 119.00 50.72 2.35 
19 51384500 rs185608 0.005 50.72 119.00 0.43 
19 51384556 rs2659119 0.005 50.72 119.00 0.43 
19 51384957 rs185255779 0.008 51.44 55.33 0.93 
19 51385134 rs146499870 0.003 51.78 0.00 NA 
19 51385253 rs16987929 0.191 33.50 71.67 0.47 
19 51385259 rs146805696 0.005 51.71 73.00 0.71 
19 51385402 rs8103659 0.191 33.50 71.67 0.47 
19 51385483 rs198964 0.005 50.72 119.00 0.43 
19 51385548 rs198963 0.005 50.72 119.00 0.43 
19 51385617 rs138142886 0.016 51.99 36.07 1.44 
19 51386494 rs139254001 0.003 51.67 0.00 NA 
19 51387089 rs193277178 0.003 51.75 0.00 NA 
19 51387248 rs116857887 0.008 51.93 9.33 5.56 
19 51387721 rs146721840 0.011 51.79 47.17 1.10 
19 51387899 rs142870280 0.003 51.84 0.00 NA 
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19 51387902 rs151037935 0.003 51.85 0.00 NA 
19 51388135 rs189211714 0.005 51.85 10.00 5.19 
19 51388158 rs181249001 0.003 51.86 0.00 NA 
19 51388220 rs185885795 0.005 51.85 10.00 5.19 
19 51388506 rs141834577 0.011 51.71 53.33 0.97 
19 51388863 rs186168236 0.003 51.82 0.00 NA 
19 51388878 rs198958 0.809 73.57 32.37 2.27 
19 51389560 rs198957 0.833 70.43 32.81 2.15 
19 51390171 rs111793246 0.005 50.72 119.00 0.43 
19 51390353 rs198956 0.833 70.43 32.81 2.15 
19 51390434 rs2659117 0.005 50.72 119.00 0.43 
19 51390508 rs198955 0.005 50.72 119.00 0.43 
19 51390636 rs67755001 0.005 50.72 119.00 0.43 
19 51390809 rs7256586 0.161 34.34 66.38 0.52 
19 51391121 rs66651444 0.005 50.72 119.00 0.43 
19 51391243 rs144646444 0.003 51.87 0.00 NA 
19 51391656 rs2664144 0.995 119.00 50.72 2.35 
19 51391710 rs67008636 0.005 50.72 119.00 0.43 
19 51391757 rs73054367 0.005 50.72 119.00 0.43 
19 51392135 rs187986221 0.011 52.15 7.17 7.28 
19 51392659 rs150327247 0.008 51.93 9.33 5.56 
19 51392728 rs137966185 0.027 51.45 57.22 0.90 
19 51392751 rs149477592 0.008 51.91 32.00 1.62 
19 51393118 rs1354774 0.167 32.81 70.43 0.47 
19 51393222 rs187508921 0.003 51.82 0.00 NA 
19 51393252 rs191966599 0.003 51.87 0.00 NA 
19 51393390 rs75380847 0.108 38.44 64.39 0.60 
19 51393757 rs181507414 0.003 51.75 0.00 NA 
19 51393831 rs10408670 0.005 50.72 119.00 0.43 
19 51393870 rs118189204 0.030 52.51 4.62 11.37 
19 51394286 rs2739482 0.836 69.33 33.37 2.08 
19 51394690 rs148459857 0.003 51.88 0.00 NA 
19 51394769 rs117402995 0.008 52.06 6.67 7.81 
19 51394787 rs186064740 0.003 51.83 0.00 NA 
19 51394808 rs2664146 0.005 50.72 119.00 0.43 
19 51395038 rs2659115 0.005 50.72 119.00 0.43 
19 51395122 rs2664147 0.995 119.00 50.72 2.35 
19 51395128 rs2659114 0.005 50.72 119.00 0.43 
19 51395183 rs2739483 0.995 119.00 50.72 2.35 
19 51395560 rs2664148 0.005 50.72 119.00 0.43 
19 51395790 rs79866735 0.005 51.48 44.00 1.17 
19 51395819 rs2739484 0.995 119.00 50.72 2.35 
19 51396201 rs145388082 0.003 51.87 0.00 NA 
19 51396211 rs2739486 0.164 33.37 69.33 0.48 
19 51396395 rs187725546 0.011 49.77 2.67 18.67 
19 51396580 rs998771 0.836 69.33 33.37 2.08 
19 51396922 rs61044983 0.159 34.88 65.12 0.54 
19 51397007 rs2739487 0.005 50.72 119.00 0.43 
19 51397101 rs2659113 0.005 50.72 119.00 0.43 
19 51397182 rs2659112 0.836 69.33 33.37 2.08 
19 51397212 rs56149619 0.005 50.72 119.00 0.43 
19 51397651 rs74554810 0.022 51.47 52.96 0.97 
19 51397897 rs147472492 0.008 52.00 12.67 4.11 
19 51398071 rs8105985 0.161 34.87 65.60 0.53 
19 51398191 rs1701939 0.995 119.00 50.72 2.35 
19 51398377 rs1654517 0.005 50.72 119.00 0.43 
19 51398569 rs55654965 0.005 50.72 119.00 0.43 
19 51398841 rs59618192 0.159 34.88 65.12 0.54 
19 51398864 rs117673213 0.003 51.86 0.00 NA 
19 51398878 rs56325314 0.005 50.72 119.00 0.43 
19 51398883 rs146687143 0.032 46.84 48.62 0.96 
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19 51398888 rs1629856 0.836 69.33 33.37 2.08 
19 51399049 rs2739491 0.995 119.00 50.72 2.35 
19 51399309 rs112035754 0.005 50.72 119.00 0.43 
19 51399496 rs2659110 0.005 50.72 119.00 0.43 
19 51399614 rs2659108 0.997 0.00 51.15 0.00 
19 51400676 rs2739493 0.820 72.66 33.78 2.15 
19 51400812 rs2659107 0.164 33.37 73.34 0.46 
19 51400836 rs1560719 0.836 73.34 33.37 2.20 
19 51400876 rs143903993 0.011 52.10 10.00 5.21 
19 51401528 rs150896065 0.019 51.95 39.14 1.33 
19 51401617 rs188115696 0.003 51.86 0.00 NA 
19 51401797 rs8104538 0.022 50.63 69.11 0.73 
19 51401807 rs3875143 0.161 32.69 72.57 0.45 
19 51402682 rs1654513 0.817 78.79 30.56 2.58 
19 51402706 rs183567117 0.003 51.87 0.00 NA 
19 51403072 rs188295377 0.003 51.87 0.00 NA 
19 51403390 rs149904243 0.005 51.94 5.00 10.39 
19 51403423 rs806024 0.040 49.43 65.70 0.75 
19 51403498 rs149022391 0.030 52.51 4.62 11.37 
19 51403543 rs188588201 0.011 51.69 61.33 0.84 
19 51403972 rs76720283 0.011 50.66 9.00 5.63 
19 51403995 rs146992379 0.008 51.93 9.33 5.56 
19 51404220 rs1701941 0.960 65.70 49.43 1.33 
19 51404513 rs2569536 0.196 29.17 83.39 0.35 
19 51404577 rs138731506 0.005 51.94 5.00 10.39 
19 51404753 rs187212182 0.003 51.45 0.00 NA 
19 51404955 rs192006428 0.011 52.13 6.17 8.45 
19 51405084 rs806023 0.032 50.20 52.38 0.96 
19 51405187 rs806022 0.960 65.70 49.43 1.33 
19 51405412 rs191624202 0.003 51.84 0.00 NA 
19 51405475 rs2739496 0.796 83.72 28.53 2.93 
19 51405673 rs806021 0.032 50.20 52.38 0.96 
19 51405808 rs806020 0.960 65.70 49.43 1.33 
19 51405982 rs806019 0.202 28.46 83.60 0.34 
19 51406129 rs11881354 0.161 32.69 72.57 0.45 
19 51406153 rs11881373 0.140 35.87 72.20 0.50 
19 51406201 rs7507565 0.132 49.96 60.54 0.83 
19 51406213 rs186644524 0.024 50.48 35.00 1.44 
19 51406241 rs192534387 0.005 51.94 5.00 10.39 
19 51406286 rs184386975 0.003 51.67 0.00 NA 
19 51406432 rs118100566 0.030 52.51 4.62 11.37 
19 51406531 rs1090649 0.798 83.60 28.46 2.94 
19 51406613 rs1090648 0.040 49.43 65.70 0.75 
19 51406618 rs2569531 0.161 32.69 72.57 0.45 
19 51406691 rs1090647 0.040 49.43 65.70 0.75 
19 51407098 rs2739497 0.177 31.76 77.18 0.41 
19 51407100 rs185221495 0.005 51.96 8.00 6.49 
19 51407293 rs56352322 0.177 31.76 77.18 0.41 
19 51407925 rs1701925 0.183 31.14 77.35 0.40 
19 51408243 rs145819982 0.032 50.49 18.52 2.73 
19 51408255 rs188706694 0.005 51.15 22.00 2.32 
19 51408269 rs180724848 0.005 51.55 106.00 0.49 
19 51408608 rs2569530 0.040 49.43 65.70 0.75 
19 51408758 rs1701926 0.798 83.60 28.46 2.94 
19 51408842 rs1701927 0.793 84.78 27.99 3.03 
19 51409387 rs182271026 0.997 0.00 51.50 0.00 
19 51409763 rs1139132 0.164 32.13 73.52 0.44 
19 51409803 rs1654556 0.210 27.64 84.40 0.33 
19 51409876 rs12150961 0.140 35.90 74.26 0.48 
19 51410171 rs73042387 0.005 51.75 10.00 5.18 
19 51410329 rs202006058 0.003 51.82 0.00 NA 
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19 51410398 rs198965 0.003 51.45 0.00 NA 
19 51410471 rs2235091 0.161 32.32 73.91 0.44 
19 51410772 rs1654554 0.806 84.50 29.97 2.82 
19 51411116 rs1654553 0.105 48.37 64.78 0.75 
19 51411263 rs7255024 0.008 51.04 113.33 0.45 
19 51411329 rs1701929 0.258 27.04 88.35 0.31 
19 51411356 rs75987180 0.040 51.62 39.94 1.29 
19 51411388 rs2979451 0.156 33.87 73.88 0.46 
19 51411392 rs117798052 0.011 51.90 39.33 1.32 
19 51411404 rs145306141 0.003 51.78 0.00 NA 
19 51411435 rs76655235 0.003 51.71 0.00 NA 
19 51411675 rs149728389 0.003 51.86 0.00 NA 
19 51412122 rs117475014 0.054 53.19 19.04 2.79 
19 51412315 rs2242670 0.806 93.62 33.20 2.82 
19 51412326 rs2978643 0.067 48.80 76.29 0.64 
19 51412416 rs73042402 0.011 51.00 97.17 0.52 
19 51412666 rs1654552 0.097 49.21 59.33 0.83 
19 51412668 rs1654551 0.094 37.88 70.69 0.54 
19 51412839 rs77569647 0.032 50.06 62.88 0.80 
19 51413328 rs198968 0.739 93.26 26.24 3.55 
19 51413395 rs141181534 0.003 51.86 0.00 NA 
19 51413790 rs2242669 0.172 36.43 90.11 0.40 
19 51413802 rs198969 0.124 48.23 64.47 0.75 
19 51413906 rs2978642 0.220 34.90 87.18 0.40 
19 51414522 rs116888134 0.048 43.34 44.09 0.98 
19 51414737 rs75873880 0.003 51.86 0.00 NA 
19 51414965 rs2979452 0.097 37.67 77.74 0.48 
19 51415150 rs2664152 0.145 46.88 67.91 0.69 
19 51415252 rs2664153 0.212 31.61 95.70 0.33 
19 51415450 rs184421915 0.005 51.22 4.00 12.81 
19 51415515 rs118154507 0.067 41.14 66.51 0.62 
19 51415705 rs148701654 0.008 50.90 3.33 15.27 
19 51415791 rs3760734 0.013 50.44 32.00 1.58 
19 51416042 rs115034065 0.013 50.74 47.60 1.07 
19 51416277 rs117319693 0.022 52.36 16.21 3.23 
19 51417294 rs191358802 0.003 51.46 0.00 NA 
19 51417736 rs10424317 0.992 100.67 50.84 1.98 
19 51417852 rs190593989 0.003 51.78 0.00 NA 
19 51417958 rs7246794 0.003 51.27 0.00 NA 
19 51418250 rs55700942 0.094 43.49 73.66 0.59 
19 51418978 rs188524307 0.003 51.86 0.00 NA 
19 51419016 rs150522181 0.003 51.87 0.00 NA 
19 51419062 rs2659077 0.906 73.66 43.49 1.69 
19 51419546 rs1701930 0.097 43.49 73.22 0.59 
19 51419669 rs1701931 0.097 43.49 73.22 0.59 
19 51419694 rs1701932 0.817 98.54 25.82 3.82 
19 51419812 rs184968554 0.005 51.82 46.00 1.13 
19 51420025 rs1701933 0.097 43.49 73.22 0.59 
19 51420119 rs34225434 0.097 43.49 73.22 0.59 
19 51420319 rs78378001 0.086 37.59 62.12 0.61 
19 51420820 rs2659078 0.903 73.22 43.49 1.68 
19 51420996 rs62113140 0.097 43.49 73.22 0.59 
19 51421056 rs56311033 0.097 43.49 73.22 0.59 
19 51421096 rs10401284 0.823 98.29 26.24 3.75 
19 51421172 rs10425823 0.817 98.54 25.82 3.82 
19 51421255 rs55933733 0.782 98.68 25.91 3.81 
19 51421316 rs186188017 0.008 51.51 57.33 0.90 
19 51421491 rs2659079 0.097 43.49 73.22 0.59 
19 51421833 rs62113142 0.817 98.54 25.82 3.82 
19 51421883 rs10419776 0.914 62.12 37.59 1.65 
19 51421979 rs10420003 0.086 37.59 62.12 0.61 
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19 51422216 rs268923 0.097 43.15 74.41 0.58 
19 51422616 rs268922 0.075 43.72 55.92 0.78 
19 51422658 rs73598979 0.089 37.22 62.63 0.59 
19 51422691 rs268921 0.836 93.95 26.06 3.60 
19 51422694 rs75883262 0.089 37.22 62.63 0.59 
19 51422877 rs10427094 0.091 36.90 65.14 0.57 
19 51422962 rs116947194 0.005 51.18 7.00 7.31 
19 51423231 rs10401844 0.785 95.13 24.79 3.84 
19 51423272 rs10403448 0.215 24.79 95.13 0.26 
19 51423360 rs10403688 0.226 24.42 95.51 0.26 
19 51423383 rs10402459 0.790 95.06 24.85 3.83 
19 51423391 rs10402465 0.790 95.06 24.85 3.83 
19 51423546 rs8100631 0.831 94.06 25.39 3.70 
19 51423603 rs150119603 0.011 52.13 6.17 8.45 
19 51423604 rs117343646 0.008 52.05 6.67 7.81 
19 51423628 rs8101572 0.078 43.56 55.86 0.78 
19 51423641 rs183548434 0.003 51.86 0.00 NA 
19 51423744 rs117098406 0.024 51.89 36.39 1.43 
19 51424075 rs1532904 0.172 25.36 94.53 0.27 
19 51424078 rs1532903 0.828 94.53 25.36 3.73 
19 51424110 rs1532902 0.828 94.53 25.36 3.73 
19 51424126 rs6509501 0.081 43.58 58.20 0.75 
19 51424383 rs8104307 0.828 93.62 30.10 3.11 
19 51424425 rs268919 0.946 50.57 47.06 1.07 
19 51424448 rs8104644 0.844 94.52 30.31 3.12 
19 51424484 rs8104329 0.156 30.08 93.44 0.32 
19 51424607 rs138684768 0.051 42.44 34.91 1.22 
19 51424619 rs141274704 0.027 48.86 29.09 1.68 
19 51424651 rs117837287 0.091 36.90 65.14 0.57 
19 51424854 rs268917 0.054 47.06 50.57 0.93 
19 51424890 rs870361 0.145 30.17 91.16 0.33 
19 51425251 rs117702669 0.003 51.88 0.00 NA 
19 51425404 rs7254626 0.175 24.85 94.70 0.26 
19 51425614 rs7255201 0.825 94.70 24.85 3.81 
19 51425748 rs187040616 0.003 51.84 0.00 NA 
19 51426253 rs7258794 0.054 46.92 48.37 0.97 
19 51426271 rs75111430 0.970 44.98 48.68 0.92 
19 51426285 rs114624700 0.030 48.68 44.98 1.08 
19 51426779 rs182320116 0.005 51.92 14.00 3.71 
19 51426813 rs187025895 0.003 51.69 0.00 NA 
19 51427076 rs192361415 0.003 51.86 0.00 NA 
19 51427332 rs116958492 0.051 47.08 69.25 0.68 
19 51427571 rs144574553 0.003 51.71 0.00 NA 
19 51427572 rs148021763 0.016 52.03 17.33 3.00 
19 51427885 rs17727736 0.070 38.97 40.59 0.96 
19 51428729 rs112561158 0.051 47.08 69.25 0.68 
19 51428793 rs113141458 0.070 38.97 40.59 0.96 
19 51428914 rs113485158 0.930 40.59 38.97 1.04 
19 51429232 rs150060784 0.005 51.94 9.00 5.77 
19 51429332 rs79735327 0.030 52.68 15.60 3.38 
19 51429512 rs17800825 0.070 38.97 40.59 0.96 
19 51429589 rs8111289 0.175 24.85 94.70 0.26 
19 51429596 rs8110335 0.785 95.25 24.28 3.92 
19 51429608 rs144627964 0.003 51.63 0.00 NA 
19 51429703 rs181276920 0.003 51.75 0.00 NA 
19 51429766 rs8111539 0.175 24.82 94.97 0.26 
19 51429883 rs8113547 0.815 96.10 24.99 3.85 
19 51429959 rs8100471 0.175 24.82 94.97 0.26 
19 51430006 rs139175576 0.005 50.79 2.00 25.39 
19 51430277 rs11665937 0.177 24.87 95.31 0.26 
19 51430285 rs4802759 0.177 24.87 95.31 0.26 
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19 51430436 rs17714545 0.024 49.78 52.50 0.95 
19 51430574 rs186172502 0.005 51.83 6.00 8.64 
19 51430853 rs12461743 0.070 38.97 40.59 0.96 
19 51431159 rs1865069 0.102 41.76 65.45 0.64 
19 51431447 rs7250053 0.102 41.76 65.45 0.64 
19 51431516 rs7250378 0.782 95.91 23.77 4.03 
19 51431836 rs7255268 0.898 65.45 41.76 1.57 
19 51431860 rs6509503 0.898 65.45 41.76 1.57 
19 51431895 rs6509504 0.898 65.45 41.76 1.57 
19 51431906 rs6509505 0.102 41.76 65.45 0.64 
19 51432054 rs6509506 0.102 41.76 65.45 0.64 
19 51432210 rs143614792 0.995 61.00 51.78 1.18 
19 51432547 rs73600813 0.070 38.97 40.59 0.96 
19 51432717 rs113870369 0.930 40.59 38.97 1.04 
19 51433002 rs150417602 0.022 52.37 18.64 2.81 
19 51433003 rs2659081 0.070 38.97 40.59 0.96 
19 51433046 rs2739400 0.073 39.03 47.64 0.82 
19 51433048 rs2739401 0.073 39.03 47.64 0.82 
19 51433092 rs2739402 0.927 47.64 39.03 1.22 
19 51433234 rs117145941 0.067 39.22 35.51 1.10 
19 51433803 rs8099967 0.825 95.28 26.13 3.65 
19 51433910 rs1654548 0.067 39.22 35.51 1.10 
19 51433915 rs1701905 0.933 35.51 39.22 0.91 
19 51434243 rs10409216 0.003 51.77 0.00 NA 
19 51434270 rs2472258 0.933 35.51 39.22 0.91 
19 51434353 rs2456586 0.113 42.37 70.45 0.60 
19 51434398 rs79966016 0.067 39.22 35.51 1.10 
19 51434627 rs1654546 0.933 35.51 39.22 0.91 
19 51434783 rs17800874 0.801 96.58 29.02 3.33 
19 51435101 rs115458416 0.930 41.32 39.09 1.06 
19 51435131 rs114406218 0.930 41.32 39.09 1.06 
19 51435261 rs111504285 0.070 39.09 41.32 0.95 
19 51435281 rs2569524 0.930 41.32 39.09 1.06 
19 51435299 rs16988270 0.836 94.79 33.94 2.79 
19 51435437 rs77202994 0.067 53.16 27.21 1.95 
19 51435606 rs67002911 0.032 48.51 37.80 1.28 
19 51435724 rs188570150 0.008 51.97 20.67 2.51 
19 51435736 rs1701906 0.008 51.67 61.33 0.84 
19 51435779 rs184266168 0.003 51.88 0.00 NA 
19 51435803 rs141297744 0.011 52.06 16.33 3.19 
19 51435978 rs35047583 0.032 48.51 37.80 1.28 
19 51436255 rs1701910 0.930 41.32 39.09 1.06 
19 51436940 rs75024748 0.070 39.09 41.32 0.95 
19 51437537 rs149622538 0.070 39.09 41.32 0.95 
19 51437776 rs6509507 0.844 95.48 28.88 3.31 
19 51438015 rs142560395 0.003 51.88 0.00 NA 
19 51438178 rs12459790 0.070 39.09 41.32 0.95 
19 51439205 rs192588396 0.003 51.75 0.00 NA 
19 51439359 rs12460497 0.070 39.09 41.32 0.95 
19 51439564 rs9304706 0.070 39.09 41.32 0.95 
19 51439569 rs10164366 0.070 39.09 41.32 0.95 
19 51440134 rs192681104 0.003 51.88 0.00 NA 
19 51440217 rs10401225 0.086 44.40 61.31 0.72 
19 51440237 rs140484129 0.005 50.78 2.00 25.39 
19 51440264 rs145628364 0.003 51.68 0.00 NA 
19 51440343 rs138496452 0.005 51.80 55.00 0.94 
19 51440420 rs150678688 0.003 51.28 0.00 NA 
19 51440560 rs1701942 0.124 49.34 54.92 0.90 
19 51440564 rs1701943 0.177 44.10 69.37 0.64 
19 51440632 rs144230446 0.070 39.09 41.32 0.95 
19 51440658 rs8113756 0.086 44.40 61.31 0.72 
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19 51440662 rs8113484 0.086 44.40 61.31 0.72 
19 51440753 rs1701945 0.048 48.14 48.49 0.99 
19 51441046 rs150986447 0.500 70.15 27.30 2.57 
19 51441058 rs8102743 0.484 66.39 31.78 2.09 
19 51441071 rs146825647 0.070 39.52 46.64 0.85 
19 51441268 rs112062248 0.879 69.28 44.08 1.57 
19 51441682 rs190414825 0.003 51.86 0.00 NA 
19 51441759 rs11084040 0.151 29.69 95.10 0.31 
19 51441807 rs8104441 0.849 95.10 29.69 3.20 
19 51441915 rs73932685 0.070 39.52 46.64 0.85 
19 51441934 rs191258507 0.003 51.82 0.00 NA 
19 51442108 rs6509508 0.852 94.69 29.70 3.19 
19 51442397 rs77522061 0.070 39.52 46.64 0.85 
19 51442534 rs148685704 0.013 51.34 84.20 0.61 
19 51442699 rs268914 0.070 39.52 46.64 0.85 
19 51443009 rs140916125 0.005 51.92 17.00 3.05 
19 51443194 rs268913 0.070 39.52 46.64 0.85 
19 51443488 rs80161131 0.003 51.51 0.00 NA 
19 51443922 rs117578550 0.011 51.10 24.17 2.11 
19 51443937 rs147098568 0.003 51.87 0.00 NA 
19 51444189 rs192759906 0.003 51.48 0.00 NA 
19 51444233 rs268911 0.970 33.05 48.58 0.68 
19 51444239 rs268910 0.970 33.05 48.58 0.68 
19 51444313 rs188302848 0.005 51.51 104.00 0.50 
19 51444467 rs1812619 0.108 36.59 89.01 0.41 
19 51444709 rs1812927 0.030 48.58 33.05 1.47 
19 51444761 rs965601 0.003 51.87 0.00 NA 
19 51444835 rs972921 0.030 48.58 33.05 1.47 
19 51444987 rs972920 0.030 48.58 33.05 1.47 
19 51445074 rs181668987 0.003 51.80 0.00 NA 
19 51445178 rs186869888 0.008 51.74 52.67 0.98 
19 51445424 rs36120506 0.032 48.51 37.80 1.28 
19 51445506 rs35418865 0.032 48.51 37.80 1.28 
19 51445543 rs146243744 0.011 52.14 7.33 7.11 
19 51445723 rs62115181 0.860 95.40 31.82 3.00 
19 51446123 rs2739408 0.911 54.53 50.12 1.09 
19 51446228 rs2569523 0.965 42.49 49.24 0.86 
19 51446246 rs2739409 0.070 39.84 50.90 0.78 
19 51446273 rs145620611 0.070 39.84 50.90 0.78 
19 51446327 rs2659090 0.105 35.68 89.17 0.40 
19 51446530 rs2659091 0.965 42.49 49.24 0.86 
19 51446660 rs2659092 0.930 50.90 39.84 1.28 
19 51447065 rs1701949 0.075 50.08 58.64 0.85 
19 51447270 rs141858477 0.005 51.97 3.00 17.32 
19 51447353 rs2253655 0.965 42.49 49.24 0.86 
19 51447954 rs1897604 0.142 31.78 95.63 0.33 
19 51448144 rs139835369 0.005 51.95 13.00 4.00 
19 51448182 rs12979210 0.858 95.63 31.78 3.01 
19 51448185 rs4802761 0.070 39.84 50.90 0.78 
19 51448685 rs12462803 0.067 40.31 50.99 0.79 
19 51448904 rs12463293 0.202 31.38 95.23 0.33 
19 51449038 rs142427219 0.003 51.86 0.00 NA 
19 51449566 rs55924070 0.831 97.37 30.56 3.19 
19 51449664 rs268909 0.105 36.64 90.96 0.40 
19 51449806 rs268908 0.895 90.96 36.64 2.48 
19 51449901 rs268907 0.113 36.11 93.62 0.39 
19 51449916 rs12979237 0.027 51.05 58.51 0.87 
19 51449964 rs268906 0.089 39.58 97.17 0.41 
19 51449969 rs12459543 0.073 39.95 87.46 0.46 
19 51450081 rs140217681 0.997 0.00 51.86 0.00 
19 51450150 rs181274545 0.003 51.50 0.00 NA 
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19 51450337 rs11666803 0.035 50.21 81.67 0.61 
19 51450351 rs62115183 0.038 50.28 78.62 0.64 
19 51450491 rs186064448 0.003 51.86 0.00 NA 
19 51450534 rs10409028 0.159 51.11 53.43 0.96 
19 51450661 rs73045911 0.038 51.85 45.30 1.14 
19 51450678 rs10409107 0.957 38.99 52.24 0.75 
19 51450694 rs148233985 0.003 51.82 0.00 NA 
19 51450835 rs141477292 0.003 51.87 0.00 NA 
19 51450929 rs268905 0.121 52.00 47.72 1.09 
19 51451043 rs2411333 0.194 51.82 49.92 1.04 
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Supplementary Table S9 – Candidate variants 
 
Due to the large size of the table this data is provided in digital format (Supplementary Tables – Paper II). 
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Supplementary Table S10 – CNV and rs1654556 genotypes for the ASN HapMap Phase I/II samples 
included in our Sanger sequencing study dataset. 
Sample ID 
Genotype 
CNV rs1654556 
NA18532 Ins/Del105 G/A 
NA18537 Ins/Ins G/G 
NA18545 Ins/Del67 G/A 
NA18547 Ins/Ins67 G/A 
NA18562 Ins/Ins G/G 
NA18563 Ins/Ins G/G 
NA18572 Ins/Ins G/G 
NA18573 Ins/Ins G/G 
NA18576 Ins/Ins G/G 
NA18577 Ins/Ins G/G 
NA18579 Ins/Del67 G/A 
NA18593 Ins/Ins G/G 
NA18603 Ins/Ins67 G/A 
NA18611 Ins/Ins G/G 
NA18623 Ins/Ins G/G 
NA18940 Ins/Ins G/G 
NA18943 Ins/Ins G/G 
NA18944 Ins/Ins G/G 
NA18947 Ins/Ins G/G 
NA18949 Ins/Ins67 G/A 
NA18951 Ins/Ins G/G 
NA18952 Ins67/Ins67 A/A 
NA18956 Ins/Ins G/G 
NA18959 Ins/Ins67 G/A 
NA18968 Ins/Ins G/G 
NA18974 Ins/Ins G/G 
NA18978 Ins/Ins G/G 
NA18994 Ins/Ins G/G 
NA19000 Ins/Ins67 G/A 
NA19012 Ins/Ins G/G 
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Supplementary Table S11 – Command lines used in the ms software. 
Gravel model (Gravel et al. 2011) with recombination for ASN population.  
ms N 100000  -s SEGSITES -r RECOMB_RATE BP -c 2 500 -G 142.30 -eN 0.0315 0.2546 -eN 0.06977 1.98 -eN 0.2025 1  
Gravel model (Gravel et al. 2011) with recombination for CEU population.  
ms N 100000 -s SEGSITES -r RECOMB_RATE BP -c 2 500 -G 112.674 -eN 0.0315 0.2546 -eN 0.06977 1.98 -eN 0.2025 1 
Laval model (Laval et al. 2010) with recombination for ASN population 
 ms N 100000 -s SEGSITES  -r RECOMB_RATE BP -c 2 500 -eG 0 39.7222 -eN 0.0414 0.9515 
Laval model (Laval et al. 2010) with recombination for CEU population 
ms N 100000 -s SEGSITES  -r RECOMB_RATE BP -c 2 500 -eG 0 126.884 -eN 0.019 0.442 
N = number of chromosomes 
SEGSITES = Segregating sites observed for each population and for each gene independently. 
RECOMB_RATE = recombination rate parameter as inferred from HapMap phase II data 
(http://hapmap.ncbi.nlm.nih.gov/downloads/recombination/latest/old_data/rates/) (McVean et al. 2004). 
BP = Total base pairs (bp) anayzed per gene. 
 
 
 
Supplementary Table S12 – Primers used for generation of luciferase reporter constructs for rs198968, 
rs17800874 and rs1654556. 
  Forward primer Reverse primer 
rs198968 AATCTGTGCCTGCTTCCTGG CCCGAGCAGAACAATTCGTT 
rs17800874 AGTCTTTCTGTTGAGGTGGT AGCATCTAATTGTTGGCTAC 
rs1654556 TCTGGAATGGGACTTCCAAC CCATGGAGGGAAAGCCATTT 
 
 
 
Supplementary Table S13 – Primers used for cDNA amplification of KLK3, KLK2, KLKP1, KLK4 and 
KLK5 transcripts. 
  Forward primer Reverse primer 
KLK3 GAATCGATTCCTCAGGCCAG CAATAGGGGGTTGATAGGGG 
KLK2 GCATCAAAGCCTTAGACCAG ATGCCAGAACGTGAGGTGGAC 
KLKP1 
GCTCTCAGAGCAAAGTCTCC GGGTGATGCAGTGAGCAGTA 
CTGGGGCATCTTAGAGCATC ACCCAGGATGTGAAAGTTGC 
KLK4 AACGAATTGTTCTGCTCGGG CACTGCGAAGCAATGCTGAT 
KLK5 AAAGTGCTTGGTGTCTGGCT TCAACATCTCTGGGAAGGAATG 
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Figure S1 – Selection statistics for KLK3-KLK5 locus. (A) Cross-Population Extended Haplotype 
Homozygosity (XP-EHH) plot from HGDP data for different continental populations as indicated by different 
color lines (http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/). East Asia is represented in green, South Asia 
in black, Europe in orange, Mideast in blue, Oceania in turquoise, America in yellow, Bantu in red and non-
Bantu African populations in pink and purple. (B) 1000 Genomes Selection Browser view. Statistic tracks for 
pairwise FST for CHB vs. CEU, YRI vs. CHB and CEU vs. YRI, FST Global (CHB, CEU and YRI), integrated 
haplotype score (iHS) for CHB, cross-population extended haplotype homozygosity (XP-EHH) for CHB vs. 
CEU and YRI vs. CHB, and cross-population composite likelihood ratio (XP-CLR) for CHB vs. CEU and YRI 
vs. CHB. The statistics are presented as –log10 of empirical ranked scores (http://hsb.upf.edu/). 
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Figure S2 – Genetic population differentiation (FST) analysis for KLK3-KLK5 locus of ASN vs. CEU, 
ASN vs. YRI and CEU vs. YRI populations. Genes’ location is delimited by open boxes. SNPs with 
significant FST P-values (upper P < 0.05) are displayed in blue, green and red for ASN vs. CEU, ASN vs. YRI 
and CEU vs. YRI comparisons, respectively. 
 
 
Figure S3 – Linkage disequilibrium plot of 1000G phase I data for KLK3-KLK5 region in Asians. The 
image was generated using Haploview 4.2 software. The triangular units represent haplotype blocks as 
defined by Gabriel et al. 2002. The degree of LD between pair of markers is indicated by the |D’| statistic (|D’| 
= 1, bright red; |D’| < 1, shades of red). The relative positions of KLK genes are depicted by open arrows, and 
the relative positions of the recombination hotspots are also shown. 
Appendices | Appendix B 
 
179 
 
  
F
ig
u
re
 S
4
 -
 S
c
h
e
m
a
ti
c
 r
e
p
re
s
e
n
ta
ti
o
n
 o
f 
K
L
K
3
-K
L
K
5
 l
a
n
d
s
c
a
p
e
 u
s
in
g
 U
C
S
C
 G
e
n
o
m
e
 B
ro
w
s
e
r.
 R
e
fe
re
n
c
e
 g
e
n
e
s
, 
D
N
a
s
e
 h
y
p
e
rs
e
n
s
it
iv
it
y
 a
n
d
 c
h
ro
m
a
ti
n
 s
ta
te
 
s
e
g
m
e
n
ta
ti
o
n
 f
ro
m
 E
N
C
O
D
E
 a
re
 s
h
o
w
n
 i
n
 t
h
e
 u
p
p
e
r 
im
a
g
e
. 
T
h
e
 i
n
s
e
ts
 d
is
p
la
y
 i
n
 d
e
ta
il 
th
e
 K
L
K
4
 l
o
c
u
s
 a
n
d
 t
h
e
 p
u
ta
ti
v
e
 e
n
h
a
n
c
e
r 
w
it
h
in
 t
h
e
 i
n
te
rg
e
n
ic
 r
e
g
io
n
 b
e
tw
e
e
n
 
K
L
K
4
 a
n
d
 K
L
K
5
. 
T
h
e
 S
N
P
s
 r
s
1
6
5
4
5
5
6
, 
rs
1
9
8
9
6
8
 a
n
d
 r
s
1
7
8
0
0
8
7
4
 a
re
 h
ig
h
lig
h
te
d
 b
y
 r
e
d
 c
ir
c
le
s
. 
Appendices | Appendix B 
 
180 
 
Figure S5 – Worldwide allele frequencies from HGDP data for rs198968 and 17800874 SNPs as inferred 
by fastPHASE (adapted from http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/). (A) Frequencies of rs198968 
located in intron I of KLK4. (B) Frequencies of rs17800874 located in a putative enhancer in the intergenic 
region between KLK4 and KLK5. 
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Figure S6 – Extended haplotype homozygosity (EHH) statistic for ASN (CHB+JPT) sample using 1000G 
data. Plots of EHH over genetic distance for the largest non-overlapping cores encompassing rs1654556 (A), 
rs198968 (B) or rs17800874 (C) variants. Core haplotype sequences are indicated below EHH plots and 
candidate variants underlined. 
 
 
Figure S7 – Plots of KLK4 expression for rs198968 (A) and rs17800874 (B) quantitative trait loci (eQTL) 
in prostate tissues from GTEx data (http://www.gtexportal.org/home/). The corresponding genotypes are 
indicated in parenthesis and the number of samples and P-values are shown.  
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Figure S8 – Tissue expression of KLK2, KLK3, KLK4, KLK5 genes and KLKP1 pseudogene. Multiplex 
PCRs carried out in a cDNA panel from human healthy organs, each one including a minimum of three 
donor’s pool. GAPDH or SERPINA1 fragments were used as internal controls. 
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Table S1 – Primers used for amplicon generation in pooled NGS sequencing. 
Amplicon 
Genomic 
Position 
(GRCh37) 
Amplicon 
Size (bp) 
Forward Primer Sequence Reverse Primer Sequence 
KLK1_1 
19:51326900-
51327089 
189 GTGAGGCCAGCAAGAGAATC TCTGAGGGGATAAGGGCTTT 
KLK1_2 
19:51324763-
51325199 
436 AGCAGAACCAGATCCCAAGAG CTCCCTCTCCTAGCCTTGTCC 
KLK1_2b 
19:51326087-
51326287 
200 CAATGCAGGACCCACTTGAC ACCACATGCTCCTTTCCTTG 
KLK1_3 
19:51323336-
51323830 
494 TTCCCTGGCCCTTTCTCC TTCCTCTGTCTCCGCCCA 
KLK1_4 
19:51323064-
51323400 
336 AAGCAGATGCCTGGTTAGCTC GGCAGACTGTGTAGCCCAAG 
KLK1_5 
19:51322376-
51322718 
342 TAGGTGATGGCAGAACGTGAC CACCTTCCTCTGGGAGTGG 
KLK10_1 
19:51521652-
51522148 
496 AAGCGGTAAGGCAAGACTCA AGCTGGGCCCTTCTTCTG 
KLK10_1c 
19:51522225-
51522560 
335 GTGACGGGAACACATTCTCC CTGTTCCAGCCCGAATCTC 
KLK10_1b 
19:51522862-
51523454 
592 GTGGGGTGCAGGTAGCTT GGCTCTTTTAGCCTTGGTTTG 
KLK10_2 
19:51520262-
51520679 
417 ACCTCCAGCTGTGGGAGTTC ATATTTCCCTACCACCCTCGC 
KLK10_3 
19:51518996-
51519504 
508 ACAGACCCAGGCATCTAGGAC ACTCTTCCTATCTCCAGGCCC 
KLK10_4 
19:51518499-
51519011 
512 GGATGGAAATGGGATTGAGG AGATGCCTGGGTCTGTGAGTC 
KLK10_5 
19:51517931-
51518318 
387 TTTGAACAGTGCAGACAAGGG TCGTCTTTATCCCAACCCAAC 
KLK11_1 
19:51530588-
51530907 
319 AAGGGAACAGAGCCCTTGG CTGTCAGAACCTAGGCCCTCC 
KLK11_2 
19:51528768-
51529183 
415 TCACTGTCCAGACACAGAGGG CCAACGACTTCCACATGGTT 
KLK11_3 
19:51527819-
51528247 
428 ATCCCTGAGCTTCTCTCCATC GCCACTGCATTTGACCTTATG 
KLK11_4 
19:51527197-
51527646 
449 CACATCGTCACTGTGAACCG TCCTCAAAGGTGTCACTCACC 
KLK11_5 
19:51526194-
51526555 
361 TTTGTGCTGAGGTCAGAAACG TCACAGCAAGCACTGCATTAG 
KLK11_6 
19:51525706-
51526066 
360 AGGGTCTTGGCTTAGGGTTTC AGTGCCTACCCATCCTGTCTC 
KLK12_1 
19:51537661-
51537967 
306 GAGACCGAGGTGAGCAGTACC AGAGAAGCAGAGAGGGCAGAG 
KLK12_1b 
19:51538006-
51538534 
528 CTACCTGCTCCCCTGTGTGT AACCCAGCTCCCTAGTCACC 
KLK12_2 
19:51537159-
51537576 
417 CACCCTCCCTTGTGATCCTAC CCTGGGTGTCTTTGATGTTTC 
KLK12_4 
19:51533947-
51534272 
325 TTCCCTGATTCATCCTCCATC GTATTGACATGGATGGGCCAC 
KLK12_6 
19:51532333-
51532826 
493 AAATGGACAGACATGGCCC TAATGACCAGACTTGGAGCCC 
KLK13_1 
19:51567997-
51568430 
433 CAGCTTTCCAGAGAGGACAGG GAGCAGAGAGGTTTCAGACGC 
KLK13_2 
19:51563600-
51563974 
374 TCCAACTCCATCCTCAAATCC GCAATAATCCGACCCTTACCC 
KLK13_2b 
19:51566690-
51567310 
620 TTTTCAGAGCCTCAAGTCCA GTTCTCTGGAAACCCCGTTC 
Appendices | Appendix C 
 
188 
KLK13_3 
19:51563005-
51563454 
449 AGACCTTCCCTCCCATCTCTG GGATGGAGAAGAAGTTAGGTTGG 
KLK13_4 
19:51561616-
51562002 
386 GAATTATTCCTGCCATCCCTG TCGCCTATTTCACCTTCATCC 
KLK13_5 
19:51559725-
51560128 
403 TTTCAGGACATGGATCACTGG TCTCCATCTTTCACTCTCTCCC 
KLK14_1 
19:51585668-
51586143 
475 AGGAATTTAGGCCTCCAGCAC AGAGACACCTCCCCTCCTTC 
KLK14_1b 
19:51587364-
51587653 
289 ATACCTGGACCTGGAGCAGA TTCCAACCCCGTCTGTTAAG 
KLK14_2 
19:51584672-
51585120 
448 AACCAGGAGCCAGCCACTAC AATATTGGGCATGTCTCACCC 
KLK14_3 
19:51582504-
51583087 
583 TCAGACGTATGAGTCCAGGC TGCAGTTAGTGAGAAGCAGGC 
KLK14_5 
19:51581193-
51581509 
316 GGACTCCTGGGTCCTGAGTA CTGTCTCCCTGTGTCTGCTTC 
KLK15_1 
19:51334542-
51334898 
356 ACCTGACGGTAAGGGCTTAGG GGGATACCGGTGGTCAGAAG 
KLK15_1c 
19:51335999-
51336505 
506 TATTCCTCCCACCGCATATC CACGGGTTCAAGTCAGTTCA 
KLK15_1b 
19:51340287-
51340546 
259 TTCTGGAACCAGACAAGCTG TCCCGTCTGCTCATGTGTTA 
KLK15_2 
19:51330807-
51331153 
346 TCGTCTTTCAGAACCCAGGAG GTAGTTAGGGCAGGGTGCAAG 
KLK15_3 
19:51330044-
51330489 
445 CATAAATTCCGGCCCTTGTC TCTTTCTGTCCTCTACTTGCGG 
KLK15_4 
19:51329759-
51330100 
341 TCCAAGCCTAACCCTAGCATC CAAGGAATCCTATGCTCCAGG 
KLK15_5 
19:51328912-
51329337 
425 TGGGACAAGTCCTTGGCTAAC ATTGAGTTGAGTTGGGTTGGG 
KLK2_1 
19:51364665-
51365253 
588 TAGGGGAAGGTTGAGGAAGG CCTCACCCCCTGTACAGAAA 
KLK2_1b 
19:51376610-
51376917 
307 TCAGCATCTAGGTGCCAACAG TTGCAATGTGGAAGAGTCAGG 
KLK2_1c 
19:51378707-
51379223 
516 GCTGTAGCTGGGTGCACAAT GAGGAGGAGAGGCATGAGG 
KLK2_2 
19:51377818-
51378341 
523 TAGCTACAGAATTGCCAGCCC CGAGATCAGACACAGAGAGAAA 
KLK2_3 
19:51379646-
51380135 
489 TGGAGTCTCCCTTATCCTCCC GCGCAAGACTATGGGTCAGAG 
KLK2_3c 
19:51380421-
51381106 
685 TTCCCTGACTCCCTCAACAC CAGGTCATCCTCATCGTCAC 
KLK2_4 
19:51380027-
51380360 
333 CAGATGGTGTAGCTGGGAGC GGGAGGCAGATGTCTGGTTAG 
KLK2_5 
19:51381548-
51381890 
342 AGAGCTGGGAATTGCTCTCAG ATCCAGAAAGGCCAAGTGATG 
KLK3_1 
19:51358007-
51358329 
322 GCAAGTGCTAGCTCTCCCTCC GGGAAAGAGCCTCAGCTTGAC 
KLK3_2 
19:51359371-
51359744 
373 GACTCCCAGCCTTGGTTCTC GGCCTTAGAGGTTATCCTGGG 
KLK3_3 
19:51361204-
51361670 
466 GAGCCTCCTCCTTGCTCC GTTCCTTGGCCCTCCTCC 
KLK3_4 
19:51361552-
51361998 
446 CAGCATTGAACCAGAGGAGTG AGGGAATGAGATGAGACACGG 
KLK3_5 
19:51363154-
51363496 
342 GGTCTGAAAGATAGGATTGCCC ACCCTGGACCTCACACCTAAG 
KLK3_5b 
19:51362765-
51363091 
326 CCATTCTCCACCTACCCACA CCGACTTCCAGAAGAAGGTG 
Appendices | Appendix C 
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KLK4_1 
19:51413768-
51414071 
303 CACGATACAAGGAGTTGCAGG GAGAGGGATGGAGAGACTTGG 
KLK4_2 
19:51409576-
51410163 
587 GGGAAGCAAGGAGGACACTA TGACCCCCAAATACATCCTG 
KLK4_2b 
19:51412404-
51412768 
364 AGAGCCTTCACCGCTGTTTC CTCCTGAACCTCTGACCACG 
KLK4_3 
19:51411022-
51411567 
545 CACTGTTTCCCTCTGGGTACA AAGGGGGAGACAGAGACACA 
KLK4_3b 
19:51411761-
51412422 
661 AGAGCTCTGGGTCAGCCC AAACAGCGGTGAAGGCTCT 
KLK4_4 
19:51411514-
51411823 
309 TCTCTCCATCTCTGCATCTCG GGTGTGTGTCTGCCCTCTTC 
KLK4_5 
19:51410044-
51410500 
456 GGGATCTGTACCCTTGGTTTG ATCTGGAATGGGACTTCCAAC 
KLK5_1 
19:51455688-
51456387 
699 GATCGCACAACCACAAGTACA GCTATTGCTAAGGCCCGATA 
KLK5_2 
19:51452869-
51453482 
613 CAACCTCATCCTCCCACCTT TCAGCATGTCAGACACCCAC 
KLK5_4 
19:51451819-
51452504 
685 CTCAGAATTTGGCAACGCTC GAGGGAGTTGAGGATGGTTTG 
KLK5_5 
19:51446793-
51447129 
336 TCAACATCTCTGGGAAGGAATG CTATGGGCATCTCTGGGTCTC 
KLK6_1 
19:51471244-
51471553 
309 CCCAATACCAGCCTCTTCTCC GGGATCCTCTGATGGAAGATG 
KLK6_E2 
19:51471710-
51472089 
379 AGCCAGTCTCCTGGCTCAGG ATGGGAGTTTTCCTCGGAGC 
KLK6_1b 
19:51472706-
51473027 
321 AGCCTGCCCAGGTTCAGT GGACAAAAGGAAGCCATTGA 
KLK6_2 
19:51470337-
51470659 
322 GGGATGCCTATGTCACCTCC TTGACTGGAGTTCATGTTGAGG 
KLK6_3 
19:51466444-
51466886 
442 CTCACCATTAGCCCATCTTCC ATTCATGACTTCCCAGCCCTC 
KLK6_4 
19:51464861-
51465166 
305 GGGTTCTCCCTCAGCCTGT GCTGAGTCTGGCCCATCTCT 
KLK6_5 
19:51462288-
51462771 
483 CACGTCGCTGCGTTTATTAAG CTGTGCCTTTGTGTGTCTTACTG 
KLK7_1 
19:51485315-
51485741 
426 AGACAGACAGAAGGAGCCCAC CTGGGCCTGAATGCTTTCTC 
KLK7_1b 
19:51486996-
51487408 
412 TCAGGACCGGGAGTCTAGG GGACTGTGGGACCAGAATGT 
KLK7_2 
19:51484926-
51485262 
336 GAGAATAGAGCCGTAGGCACAG CTGTCCATCTCTGACTCTGGG 
KLK7_3 
19:51483232-
51483772 
540 CCAGAAGGGCTGTTGTTCAG TCTGAATCTGTGAATGTCACTCC 
KLK7_4 
19:51482961-
51483262 
301 CAGTCACTCGGGTCAAGCTC GAACCAGGAGCCTGAACAAC 
KLK7_5 
19:51480716-
51481057 
341 ACTTCATAGGTCATCGGCGTC TGGTGGAAGTCCATAATCTGC 
KLK8_1 
19:51504766-
51505458 
692 TCTGAGTACCTCTGCACCTCA TTCTTCGGTTCCCGGTTACT 
KLK9_1b 
19:51504228-
51504595 
367 CCGTATCGCACTCTTCACATC CCTCCCTTGGAATGTAGGAATC 
KLK9_2 
19:51503604-
51503946 
342 TCTCCTTCCTGAGTCGAAACC GTTGTATGCGGAGAACTTGCC 
KLK9_2II 
19:51512357-
51512986 
629 ACTTCTGGCCTAAAGCACCC GCACTTACCTCCTCTCCCAAG 
KLK9_3 
19:51503178-
51503608 
430 CTTTGCCAATAGCTTGGGTTC GGAGAGAGCTGAGGACTGGAC 
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KLK9_3I 
19:51509588-
51510089 
501 
TCGATTGGCAGATAGATAGACTG
AC 
GTGTGGCTTGCAGAGGGTC 
KLK9_4 
19:51500783-
51501212 
429 AACAGCAGCAGCAATTCAATG GGGTTAGATCCAGACAGGGATG 
KLK9_5 
19:51499160-
51499568 
408 CCATGAGAACTTGGTTTCTGC ACCAATCATGCCAAAGAACTG 
KLK9_5I 
19:51506182-
51506643 
461 ACTGTGTCTTGCTTGACCTCG GAGATGGAGGACTCTCGGATG 
KLKP1_1 
19:51399490-
51399948 
458 TCCCTCCGATACCTCCTCTT TAGTCATGCCCTGCTCACTG 
KLKP1_2 
19:51398587-
51399086 
499 GGAAGGTGTGGGTTGTATTGA ATACCCTGCCCATGTTTTCC 
KLKP1_3 
19:51398300-
51398561 
261 AGACCCACCCAGCACTCA TGAACCCCTCCACTTTGTGT 
KLKP1_4 
19:51390924-
51391588 
664 TATTCCTGTGGGGCACAGAC CCCTGATCTGGGTGTAGCAT 
KLK-prom51323816 
19:51323816-
51324326 
510 GCGGAGACAGAGGAAGAAAG CCTCGACCTTGGACTTCAGG 
KLK-prom51324011 
19:51324011-
51324670 
659 AAGACAGGGACAGCGAGAAA AGTCTCTCTGCGGCATCTCT 
KLK-prom51326564 
19:51326564-
51327093 
529 CAGGAGGGGATGATCAGAGT GGGCTCTGAGGGGATAAGG 
KLK-prom51339854 
19:51339854-
51340550 
696 CCCCAGCCTTGTCCCTTC GCACTCCCGTCTGCTCAT 
KLK-prom51361995 
19:51361995-
51362670 
675 CCCTCCTTCCCTCTTCTTTG CCATCATCACTCCCTCCACA 
KLK-prom51373385 
19:51373385-
51373812 
427 AGGAGGAATGTGGGTTCTGA TGCTGAATGATGAGTGGATGA 
KLK-prom51373661 
19:51373661-
51374136 
475 GTTGCCCATGCTTTGATCTT TGCCTCGTATCTGGGAGACT 
KLK-prom51376037 
19:51376037-
51376736 
699 GGCACATGAGACTTTGTATTGAA CCCACATGCTGACACAGG 
KLK-prom51393934 
19:51393934-
51394591 
657 CACACATGTGAGCCATGTCC GTAGCCCCTCCAAAAGCAAT 
KLK-prom51398232 
19:51398232-
51398523 
291 GCCTGGGACTCTCCTTCACT AGCTGTGATTCCCCCTGAAG 
KLK-prom51412383 
19:51412383-
51413066 
683 GGCTCATTCCGTCCTCCT CTACCCTGAATCCCTGACCA 
KLK-prom51424940 
19:51424940-
51425412 
472 TGGCTCCTCTGGTTATGGAG CCTTTTGTGGTGTTGTTTCG 
KLK-prom51425335 
19:51425335-
51425815 
480 CATGGACACACAGAGACATGG TTCCTGCCACCTCTGCTC 
KLK-prom51456150 
19:51456150-
51456555 
405 GCACAGACACCTCTCCTTCC TGACCCAGAGTTGGTGAGAA 
KLK-prom51471042 
19:51471042-
51471502 
460 GGCTCTCTCCAACTTTCCAA GATGGGAAGGACAGAGGTCA 
KLK-prom51472627 
19:51472627-
51473027 
400 CACCCCCAGCACTCTCTG GGACAAAAGGAAGCCATTGA 
KLK-prom51482248 
19:51482248-
51482852 
604 AAGGGAGGGAGAGCAAGCTA CCTGGGGATGAGACAGAGAG 
KLK-prom51495240 
19:51495240-
51495641 
401 CCTGGCACCTGTTGCTAAGT CCCAAAAGAAATGGGGTTCT 
KLK-prom51495933 
19:51495933-
51496293 
360 CCCCAAGTCTTTTCAGGCTTA 
AAAGAGACTCGTTTTAAACATAACC
AA 
KLK-prom51504253 
19:51504253-
51504749 
496 CACACGCACCCACATAACC CGGACCCTCCTTCTCCAG 
KLK-prom51505824 
19:51505824-
51506294 
470 CAGACCCTCCCTCAATTTCC GTCCCAGCCTCAATGGTTC 
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KLK-prom51522289 
19:51522289-
51522745 
456 CCGACCTTACCCCAGAGTTG TGAGAAAGAGGCTCCCACTG 
KLK-prom51522567 
19:51522567-
51523264 
697 TGGGCACAATTACCCTAATGA CTTGCTGGGGACGTGAAC 
KLK-prom51529766 
19:51529766-
51530361 
595 GGCAGCTTCCCTTTCCTC GAGGGATTTCAAGACAAATTGC 
KLK-prom51530756 
19:51530756-
51531088 
332 CCACCTCAACCTCTGCATCT CTTTCCAAGTGGACCCTCCT 
KLK-prom51569993 
19:51569993-
51570442 
449 GGGCTCACATGGAAACTTGT TGTCGCCAATGCAAAGTTAG 
WFDC5 
20:43738985-
43739464 
479 ATTAGAGCTGGGCTCGGAGA ATAACCGTGAGCTTCCTCCA 
WFDC5-I 
20:43743619-
43743832 
213 AGAGGGATTTCCCGCACT GTCACTCCACACCCCCTCT 
WFDC12 
20:43752727-
43753154 
427 CTGGGAGGCAGGTCTCCTTA ATGCCCAGCAGGAACACTAT 
WFDC12_3 
20:43752037-
43752609 
572 
GTCTGAACATCTCCATTGTCCAAA
G 
GCTGCTATAACAAATTACCATAGAC
TGG 
PI3 
20:43803421-
43803692 
271 CCCAGAATGGGGTGGATATT AGGGTCTCCCCTTAGTCCAA 
PI3-I 
20:43804476-
43804801 
325 TGTGGGCTCGTTTCTTCTTT CCTCGTTCTCCAGCTAGTGC 
PI3-II 
20:43804954-
43805220 
266 TGCCTCTGAGTGCTTTGATG CCAGGAGCCCAGAAGTCATA 
SEMG1 
20:43835618-
43835803 
185 CACCCATGGCACACTCACT CAGCTTTCCCCAAGGCTTAC 
SEMG1_E2_1 
20:43835886-
43836527 
641 
GGAGAACATAACTGCTTTGGGAT
CC 
GATTTTCTCCACCCAAAGCTTCAG 
SEMG1_E2_2 
20:43836371-
43837103 
732 GGATTTGAGACTTGCCTGCTA GATCAGGGGAATAGCCCATC 
SEMG1-I 
20:43838184-
43838456 
272 ATCCCCACCCTTCACTTTTT CCCCTTGAGCCACTAGGAAT 
SEMG2 
20:43849891-
43850127 
236 GGTGAGGAAGCTGGCATTTA AGGCTTACCCTCTCCACTCA 
SEMG2-I 
20:43850295-
43850958 
663 TTGCAAGAGAGCTTTGGAGA CCTCTCTCACGTCAACCACA 
SEMG2-II 
20:43850835-
43851528 
693 GGTGGATCCCAAAGCAGTTA TGAGACGTCTTTCTTCTGTACTCG 
SEMG2_E2_1 
20:43851192-
43851925 
733 
CTGGATTCCTGTTTGTATCTGCCT
T 
AAAGATGTATCCAAAGGCAGCATT
T 
SEMG2_E2_2 
20:43851683-
43852219 
536 
TCTACTCGCCAGGAAATGGTGTT
CA 
TTCAAGTACAGAAGAAAGACGACT
C 
SEMG2-IIII 
20:43852881-
43853120 
239 ACCCCCACTCTCCACTATCC ATCACTGGAGCCAAAAGCAG 
SLPI_1 
20:43882078-
43882825 
747 TCTTCACCTGTCTGCGACTCT GCTACCTTCCTGCTTAGGGC 
SLPI_2 
20:43881536-
43882286 
750 
AGGGAAGAAGAGATGTTGTCCTG
AC 
TGCTTGGAGTAGGGTTCAGG 
SLPI_3 
20:43880699-
43881240 
541 
GCTTTGAGTTTAGAGTTTTACGGT
G 
AAATCACTTGTCCCAAATCACAG 
WFDC2-I 
20:44098945-
44099303 
358 GGTTAAGGTTTGGAGCAGGA TTTCAACCGCCTTGACTTTC 
WFDC2-II 
20:44099770-
44100098 
328 AGGGTTCAGCTTTTGCCTTT CACAGGGGCTGTATTCTGGA 
WFDC2-III 
20:44109941-
44110192 
251 GCTGCAGGTACTCCTGCCTA GGGGAGACAGAGACAGAACG 
SPINT3 
20:44141031-
44141518 
487 TTGCTCTAAATTTCCCCAGTG GGTTTGGTCTCCTTCAACCA 
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SPINT3-I 
20:44144124-
44144307 
183 CCAGCCTGATTCCCAGTCTA TTGGTCCCTTTTCTCCCTAAA 
WFDC6 
20:44162813-
44163181 
368 GAATTATTCAGCCTCGGAGAG GTCCAAGCATCTCACCCTTT 
WFDC6-I 
20:44163762-
44164007 
245 CTTGGTGAGCACAGGAGACC CAGGCACCCAAACAGCTCTA 
WFDC6-II 
20:44167931-
44168167 
236 CAAGGACGGAGTTCCCAATA TGTCTCCAGGGCTGTCTCTT 
EPPIN-WFDC6 
20:44165605-
44166266 
661 ACAGATGCCTGGCTGGAA TGCCAACATTGTGTCAGGTT 
EPPIN-WFDC6-I 
20:44166557-
44166786 
229 GATAGGAGGTGAGGGCACTG GGGAGCACTGGCTCCTTTA 
EPPIN-WFDC6-II 
20:44170519-
44171204 
685 TGACACAGGTATAAACTGGGAGT AAGAATGCACCTGGCAAAAG 
EPPIN-WFDC6-III 
20:44175884-
44176435 
551 AAGGGCTGAGGCCAATACTT CCAAGAGACCGACAGAGACA 
EPPIN_E2 
20:44174141-
44174883 
742 ATTCCTCAACAAGGCCAAAAAGA TAAATCGCAGGTCTCCCAAGTC 
EPPIN_E3 
20:44171201-
44171700 
499 AGGGATGCAGATGCCCACTC TCTTACCTCCTGATCAGAGCTGG 
WFDC8 
20:44181751-
44181982 
231 GGGAGGTATATCCCCAATCC AAGGCTCTTTGAAGGGTGGT 
WFDC8-I 
20:44184309-
44184529 
220 GACCCTCAGATTTCCAGGAT TTTCCTTGCTTCCTGACCTC 
WFDC8-II 
20:44187453-
44187668 
215 AAGTGGGGAACCTCTGTCCT CCGAAAGAATGTGAGTTTGGA 
WFDC8-III 
20:44190678-
44190883 
205 GGCCTCATGTCTAACCCTCA CCCACCTCTCTTCTCATCCA 
WFDC8-IIII 
20:44207815-
44208012 
197 AGACCCTCCATGTCTGGCTA GGGCAGACTGGCATAGAATG 
WFDC8_E6 
20:44180310-
44180901 
591 
GAATAAAACCTTGTTTGAGATTCC
C 
TGCAATAAAACTTATGTATTCCAAA 
WFDC9 
20:44236511-
44236818 
307 CTGCTGAGGATTGCAATGAG CCCAGGATTCTTGACTTTTGA 
WFDC9-I 
20:44237241-
44237477 
236 TCGGTAAGGACCAGTGATGA CGGACCCTGCTAACTTCTTC 
WFDC9-II 
20:44238707-
44238915 
208 CCGTCCCTTTTCACACCAC ACCCTGTTCTCCTCAATCCA 
WFDC9-III 
20:44243211-
44243406 
195 AATCCAAGCAAGCCACAAAT AAGTTCCTGGCCTTTGAACA 
WFDC10A 
20:44258078-
44258562 
484 TGCAATGAAACATCAGTTAATTCT CCAGCAGCCCATCACCTAC 
WFDC10A-I 
20:44259437-
44259927 
490 GAGGAGGCTTCAGCTTGAGA ATTGAACACCAGGACGCAAG 
WFDC11 
20:44277155-
44277451 
296 AAGGGTACTCATGGGTGGTG TTAAGCAGGGGGAATGAATG 
WFDC11-I 
20:44277868-
44278072 
204 ACACCCAAGCAAACATCTCC CCATCAACCTTTGACCATCTC 
WFDC11-II 
20:44279118-
44279335 
217 CTAATCCAGCCTCACCACCT TTGCTTCACACCTCTCTTTCC 
WFDC11-III 
20:44295650-
44295844 
194 AACCCATCCAAGCAAGACAA TTGACTGGTTTTGCTCACCA 
WFDC10B 
20:44313261-
44313619 
358 CACCTGTAGTGGCAGCAAAA CTGCTCCTGCATCATTTCAG 
WFDC10B-I 
20:44314506-
44314715 
209 ACTCTCCATCACCCATCCAG ATTTCCTTCCCTCTCCACAG 
WFDC13 
20:44330630-
44330869 
239 TTGGAGTACACGGTGAAAGG GCCCAGATCCAGCACCTAC 
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WFDC13-I 
20:44333046-
44333680 
634 TTGGTGAGGCCCTTCTCTTA ACTTCCTTTGGGCTGGATCT 
WFDC13-II 
20:44334363-
44334590 
227 TTGAGGTTCTGCCTTCCCTA GCGAGACCAAATCCCTGTACT 
WFDC13-III 
20:44336383-
44337027 
644 GCCTGACAACAGACAGTTCAA GCACCTTATTGCAGCCTCTT 
WFDC13-IIII 
20:44336940-
44337566 
626 GCCATATCATGAACCCAGGA TGGAAGGAATGGAGGCAAG 
SPINT4 
20:44350923-
44351157 
234 GGTGAGCTCAACCGTCTCA TGACCTTTGGATTTATTTTCTGC 
SPINT4-I 
20:44352497-
44352727 
230 TCAATGGGAACCTCTCATGC CAAGGACCAAGGACAGGATT 
SPINT4-II 
20:44354240-
44354542 
302 TGGGTTTTTCTTTCCTTTGC GATGGGACCAGCTGACATTT 
WFDC3 
20:44386959-
44387160 
201 ATTGCCCTGCTACATGCTTC GGGCCTGAGAGTTCTCACCT 
WFDC3-I 
20:44402824-
44403163 
339 TGAGCCCTCAAATAGCACAA TCCTAGGGTGGAGGGAAAAC 
WFDC3-II 
20:44404022-
44404269 
247 TCTGTTATTGTTGATGACAATGGA CCTTTTCCTGTGCCTGTTGT 
WFDC3-III 
20:44405690-
44405873 
183 TTCTTCCCAAAAGAGCCAAC GGGCTCCAATGCTTTGATTA 
WFDC3-IIII 
20:44408377-
44408577 
200 CGTCCCAGATTTCACCATTT GTGTCAGACTGGGTGGCATT 
WFDC3-IIIII 
20:44416429-
44416645 
216 CAAGCAGACCAAACAGACCA TTGCTGTCTCCCTTTTTGCT 
WFDC3-IIIIII 
20:44416626-
44417321 
695 AGCAAAAAGGGAGACAGCAA AGGCTGGAGGGAAGAGTTGT 
WFDC3-IIIIIII 
20:44417045-
44417736 
691 CCTCTCAACCCTGGTGCTAA TGGCTAGTTACCCCAAACTCA 
WFDC3-IIIIIIII 
20:44418509-
44418733 
224 CAGGGATCCCAAATGATAGC AAGGTTTTGGGACTGGGTTT 
WFDC3-IIIIIIIII 
20:44419466-
44419660 
194 GTCCCTCTAACCCACACAGG GCCAGTGGACACCATTAGGT 
WFDC3-IIIIIIIIII 
20:44420406-
44420624 
218 AACACCCACACTGCACAATC ACTCCGCTGGACTCTGTCAC 
promWFDC43740354 
20:43740354-
43740863 
509 TGCACAAAGCTGGAAATCAG AGGGCTAAACCTTGGACCTC 
promWFDC43743055 
20:43743055-
43743675 
620 AGAGCTTCCTCCCCACAAA GTCAGCTGCCTGCTGTCTTT 
promWFDC43743631 
20:43743631-
43744251 
620 CGCACTCACCTCCCTTCTT GCTGGCCTCACTCATTATGC 
promWFDC43756560 
20:43756560-
43757240 
680 GGTAAAATTGCAGGGGACAA TGGTTCAAGGCTTTCCACTT 
promWFDC43767320 
20:43767320-
43767859 
539 AGAAAGATGCCACAGGGTGA TGATACAAGCCTGGGGAAAG 
promWFDC43803065 
20:43803065-
43803761 
696 CAGGACCAGGGAAGAAGGA CTGAAATCTGGGCTCCAGTG 
promWFDC43805135 
20:43805135-
43805514 
379 CTGGAGCTGCCTCTCTCATC AGGACTGATGGTGGATTGGA 
promWFDC43810346 
20:43810346-
43810687 
341 GGCAACTTTTGGGAGGAAGT GGCATGAGAAGTGGCTTGAT 
promWFDC43835443 
20:43835443-
43835710 
267 TGGCATGATGATCTAAAAGGA TGATGTTGGGCTTCATCTTG 
promWFDC43838631 
20:43838631-
43838893 
262 AGGCTTTCATGACCCTGGTA CTTTCCATCCACAGGTGACA 
promWFDC43847932 
20:43847932-
43848286 
354 TGCATTTTCCTGCTTTGTTTT TGAAGCATGTGAGCTATGTGG 
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promWFDC43880574 
20:43880574-
43880886 
312 TGCATAAACTCGTCTCAGGAAA CTTTGCACATCCTGCTTCTG 
promWFDC43881954 
20:43881954-
43882216 
262 GCACCTGGCTCTCCTAGAAC AGTAAGCAGGTCGGGGAACT 
promWFDC43882809 
20:43882809-
43883391 
582 TCGCAGACAGGTGAAGAAGA GTTGCTGTGTTGGCCTCATA 
promWFDC43883326 
20:43883326-
43883925 
599 TCCTGACACCAAGGAGATTG TCCCTTCATGCCCTTAATTTC 
promWFDC44096513 
20:44096513-
44096955 
442 TGATGCCATTGACTGATGAAA GCCACTGTCCCCAAAATG 
promWFDC44118145 
20:44118145-
44118600 
455 GGGTGAGGGAGAAGGAGAAT GGTAGTCACACACCGAGTTCC 
promWFDC44126775 
20:44126775-
44127304 
529 TCCCTGGATGAACAATCCATA CTATCATGAGGCTGCAGAGC 
promWFDC44144077 
20:44144077-
44144479 
402 AAATGGGCTCTGTTTGTGCT GCTTCCACCCTGAAGTGGTA 
promWFDC44146706 
20:44146706-
44147345 
639 GGAAGTGAGAAGCTGCCTTT TGATTTTTCACATACATGCACA 
promWFDC44166833 
20:44166833-
44167497 
664 CCACTTCACCTATCCCCAGA CAGCTAACTGTACTGGGCACTG 
promWFDC44217442 
20:44217442-
44217785 
343 CCAGGAGGGTGTTTCTCACT GTGGAGAGGTGAAGGTGGAA 
promWFDC44239700 
20:44239700-
44240140 
440 GAACTGCAAATGGCCAGAC TTCCTTGCTTCTTCAGGAAA 
promWFDC44258078 
20:44258078-
44258756 
678 TGCAATGAAACATCAGTTAATTCT TGCAGGTTTCTTCTTCATTCC 
promWFDC44314543 
20:44314543-
44315008 
465 TGCATCCTCATCTTGTCACG TGGGTTAATTCTAAGCACCTTTT 
promWFDC44333893 
20:44333893-
44334284 
391 TTGCAAGGCCCATATGAAAT GCAAGGGCTAGTCTCTTCAAA 
promWFDC44386629 
20:44386629-
44387010 
381 GCCAGAGACAGGTAAGCAGAA CCCTGAGGGTTTCCTTCTTT 
promWFDC44407439 
20:44407439-
44408065 
626 TGTGGCATCTAACCATCGTC CCTGGGTTGTTTAGCTGCAT 
promWFDC44409920 
20:44409920-
44410617 
697 CATCATGATCCCCTACACTGC GGCTGACCCTTTTCTAAAACC 
promWFDC44420732 
20:44420732-
44421329 
597 GGCAGCTGGTTCTTACGG ATGTTCCAAGGGTTCTGTGG 
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Table S2 – Variants identified in phase I. 
 
Due to the large size of the table this data is provided in digital format (Supplementary Tables – Paper III).  
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Table S3 – List of common SNVs identified in phase I and presenting significant nominal P-values for 
case-control association analysis by Fisher’s exact test. 
Gene SNV ID Consequence 
Control vs. Cases 
(HV+NV)  
Controls vs.  
HV Cases 
Controls  vs.  
NV Cases 
P-value P-value P-value 
upstream WFDC12 
rs6104024 
 
0.0010 0.0278 0.0027 
upstream WFDC12 
rs6017495 
 
0.0251 0.0441 0.0851 
intergenic rs6073760 
 
0.0468 0.0630 0.1475 
WFDC6 rs41304411 p.I122I 0.4500 0.0002* 0.0516 
intergenic rs6073789 
 
0.1218 0.6906 0.0493 
intergenic rs6065839 
 
0.0840 0.1988 0.0338 
upstream KLK15 rs266851 
 
0.0781 0.2009 0.0305 
KLK3 rs2271095 intronic 0.0391 0.2129 0.0349 
KLK3 rs266875 intronic 0.0189 0.2012 0.0346 
KLK3 rs11084034 intronic 0.0410 0.3432 0.0415 
KLKP1 rs2739491 
 
0.0813 0.1762 0.0386 
KLK4 rs2979451 intronic 0.0863 0.0246 0.1346 
KLK6 rs28384475 5'UTR 0.0607 0.1204 0.0386 
KLK7 rs1654526 intronic 0.0006 0.0003* 0.0066 
KLK7 rs1722558 intronic 0.2688 0.0780 0.0090 
KLK7 rs1991820 intronic 0.1548 0.0120 0.2560 
KLK7 rs1991819 intronic 0.2781 0.0255 0.4339 
KLK7 rs1991818 intronic 0.3778 0.0470 0.4756 
KLK10 rs2075691 intronic 0.0461 0.1990 0.0896 
KLK10 rs2075690 p.L149P 0.0320 0.1408 0.0729 
KLK10 rs2075687 intronic 0.0306 0.2756 0.0468 
KLK10 rs77303625 intronic 0.1544 0.0278 0.3547 
KLK10 rs10425377 intronic 0.0623 0.0073 0.1895 
KLK10 rs7259651 5'UTR 0.1139 0.0152 0.2616 
KLK12 rs75565227 intronic 0.1336 0.0398 0.2717 
upstream KLK12 rs8104577 
 
0.0230 0.0294 0.1234 
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KLK13 rs2736433 intronic 0.0487 0.2756 0.1532 
KLK14 rs11671800 intronic 0.0188 0.0269 0.0826 
KLK14 rs6509518 intronic 0.0031 0.0225 0.0157 
Significant nominal P-values (P < 0.05) are underlined. 
*Significant P- value after adjustment for multiple testing (Bonferroni correction). 
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Table S4 – Identified SNVs in SEMG1 and SEMG2 in the pilot study. 
Gene SNP ID Consequence Control    Cases (HV+NV)   HV cases   NV cases 
      MAF   MAF P-value   MAF P-value   MAF P-value 
SEMG1 rs17850164 T293T 0.019 
 
0.000 0.0423 
 
0.000 0.1287   0.000 0.1484 
SEMG1 rs2233887 R372L  0.013 
 
0.003 0.2893 
 
0.007 0.5195 
 
0.000 0.2880 
SMEG1 rs147894843 G400D* 0.000 
 
0.010 0.2663 
 
0.013 0.2364 
 
0.007 0.4626 
SEMG1 rs7270676 N402N 0.051 
 
0.024 0.7107 
 
0.027 0.2152 
 
0.022 0.1642 
SEMG1 rs79500955 R447H 0.006 
 
0.007 0.7120 
 
0.007 0.7377 
 
0.007 0.7120 
SEMG1 rs2233889 N455N 0.019 
 
0.028 0.4077 
 
0.020 0.6330 
 
0.037 0.2823 
SEMG1 5 repeat units 
 
0.051 
 
0.024 0.1190 
 
0.027 0.2152 
 
0.022 0.1642 
SEMG2 rs2233901 S274N 0.139 
 
0.178 0.1765 
 
0.193 0.1307 
 
0.162 0.3528 
SEMG2 rs2233903 H279Y*† 0.019 
 
0.028 0.4077 
 
0.020 0.6330 
 
0.037 0.2823 
SEMG2 rs2071650 G368R*† 0.019 
 
0.028 0.4077 
 
0.020 0.6330 
 
0.037 0.2823 
SEMG2 rs139977707 E552Q* 0.000   0.010 0.2663   0.020 0.1143   0.000 N/A 
*Predicted as damaging by SIFT or Polyphen. 
†Variants in linkage disequilibrium 
N/A - Non-applicable 
Significant nominal P-values (P < 0.05) are underlined. 
 
Table S5 – Low-frequency burden analysis of SEMGs predicted functional variants. 
    
Cases (HV+NV) 
vs.  
Controls 
HV Cases  
vs. 
 Controls 
NV Cases  
vs.  
Controls 
Nonsynonymous 
Total 
C-alpha = -2.9879 C-alpha = -1.8499 C-alpha = -0.6938 
(P-value = 0.6566) (P-value =0.6180) (P-value = 0.8992) 
SEMG1 
C-alpha = -0.0493 C-alpha = -0.4830 C-alpha = -0.0926 
(P-value = 0.8195) (P-value = 0.6813) (P-value = 0.8670) 
SEMG2 
C-alpha = -2.9186 C-alpha = -1.3669 C-alpha = -0.6011 
(P-value = 0.6933) (P-value = 0.6738) (P-value = 0.8194) 
Damaging 
substitutions 
Total 
C-alpha = -2.4665 C-alpha = -0.8140 C-alpha = -0.5609 
(P-value = 0.7788) (P-value =0.8282) (P-value = 0.9173) 
SEMG2 
C-alpha = -2.9186 C-alpha = -1.3669 C-alpha = -0.6011 
(P-value = 0.6935) (P-value = 0.6823) (P-value = 0.8197) 
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Figure S1 – Flow-chart of the strategy used to detect rare and common variants on KLK and WFDC 
clusters associated with male infertility. Using a DNA pooled sample approach and a high-throughput 
sequencing strategy, we detected in phase I 456 SNVs based on stringent filtering criteria. We then performed 
genotyping validation of 3 SNVs and 7 gene regions in phase II, using the same samples as in phase I. In 
phase III, we extended the analysis of the most promising SNVs to a further 138 controls and 95 infertility 
cases to allow a combined analysis of 217 controls and 238 cases. 
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Figure S3 – WFDCs minor allele frequencies (MAFs) from 1000 Genomes data and control pooled 
sequencing in repetitive regions. Allele frequency estimates obtained in pooled sequencing for the control 
group (black) and the described frequencies from the combined European populations from 1000 Genomes 
project phase III (orange). 
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Figure S4 – KLKs minor allele frequencies (MAFs) from 1000 Genomes data and control pooled 
sequencing in repetitive regions. Allele frequency estimates obtained in pooled sequencing for the control 
group (black) and the described frequencies from the combined European populations from 1000 Genomes 
project phase III (orange). 
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